🎙️ Episode 3 of The Psych Consult: Second Opinion is here!
Host Claire Brandon, MD, and critical care physician Lakshman Swamy, MD, discuss why quiet, hypoactive ICU delirium is often missed.
🔗 www.psychiatrictimes.com/view/podcast-hypoactive-delirium…
Psychiatric Times
Psychiatric Times is a peer-reviewed medical trade publication written for an audience involved in the profession of psychiatry. It is published monthly by MJH Associates and is distributed to about 50,000 psychiatrists monthly. The download of the journal is free of charge. More on Wikipedia
-
PsychiatryLive
@Psychiatry_Live
-
PsychiatryLive
@Psychiatry_Live
In the phase 3 APPROACH study, HLP003 as an adjunctive treatment for adults with MDD achieved statistically significant and clinically meaningful results on the primary and key secondary endpoints starting as early as day 2. www.psychiatrictimes.com/view/positive-phase-3-results-hl…
-
PsychiatryLive
@Psychiatry_Live
The FDA has approved @TevaUSA's dexmedetomidine (Igalmi) sublingual film for the at-home treatment of agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults. www.psychiatrictimes.com/view/fda-approves-igalmi-for-agi…
-
PsychiatryLive
@Psychiatry_Live
Explore the types of scams encountered in psychiatric practice in order to help identify those at risk. www.psychiatrictimes.com/view/scams-what-psychiatrists-ne…
-
PsychiatryLive
@Psychiatry_Live
According to internal documents and close sources, the FDA has shelved the fast-track drug review initiative. What does this mean for psychiatric treatments that received vouchers, like #psilocybin for treatment-resistant depression? ⬇️
PsychiatryLive
@Psychiatry_Live
Read more here: www.psychiatrictimes.com/view/fda-shelves-fast-track-drug…
-
PsychiatryLive
@Psychiatry_Live
How is schizophrenia management evolving? Attend our live national broadcast to explore real-world strategies to manage side effects, support treatment persistence, and optimize long-term functional
outcomes in schizophrenia. Register Today! studio.mjhassoc.com/reach/rethinking_schizophrenia_manage… -
PsychiatryLive
@Psychiatry_Live
Oveporexton (Orzeyful) is now available in the US by prescription for the treatment of narcolepsy type 1 in adults. This is the first and only orexin agonist for this indication. www.psychiatrictimes.com/view/oveporexton-now-available-f…
-
PsychiatryLive
@Psychiatry_Live
Where do OCD and schizophrenia overlap, complicating diagnosis and care? www.psychiatrictimes.com/view/schizo-obsessed-untangling-…
-
PsychiatryLive
@Psychiatry_Live
The first participant has been dosed in the Brexanolone Lifting Outcomes of Moms (BLOOM) study, @LipocineInc's phase 3 trial evaluating LPCN 1154 for postpartum depression. www.psychiatrictimes.com/view/first-participant-in-phase-…
-
PsychiatryLive
@Psychiatry_Live
🚨 @COMPASSPathway have completed their submission of an NDA for COMP360 psilocybin for treatment-resistant depression.
If approved, COMP360 would become the first classic psychedelic medicine ever approved by the FDA. www.psychiatrictimes.com/view/nda-submission-complete-com… -
PsychiatryLive
@Psychiatry_Live
Our November theme: Emergency Psychiatry.
If you are interested in being featured in a future Special Report/print issue, submit to our content series! www.psychiatrictimes.com/view/presenting-our-november-202… -
PsychiatryLive
@Psychiatry_Live
Big news: Psychiatric Times is now PsychiatryLive! 🧠
After 40+ years of psychiatric coverage, we're building on that legacy with more real-time news, video, live events, and expert perspectives.
Same team. Same commitment. A new name for what's next.
www.psychiatrictimes.com/psychiatry-live-faq -
PsychiatryLive
@Psychiatry_Live
The November issue of Psychiatric Times is now live! This month, we examine the uses of GLP-1s in psychiatry.
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6/psychtimes/31349b60f7178da46… -
PsychiatryLive
@Psychiatry_Live
We're excited to welcome Lumin Health as a new Strategic Alliance Partner of PsychiatryLive!
Together, we're bringing clinicians more insights, resources, and support to advance mental health care.
Learn more: www.psychiatrictimes.com/sap-partner/lumin-health
#psychiatry #mentalhealth #sap -
PsychiatryLive
@Psychiatry_Live
November is Alzheimer’s Awareness Month. Explore the latest clinical insights, research, and perspectives on Alzheimer disease and dementia from Psychiatric Times.
🔗www.psychiatrictimes.com/topics/alzheimer-disease -
PsychiatryLive
@Psychiatry_Live
How is schizophrenia management evolving? Attend our live national broadcast to explore real-world strategies to manage side effects, support treatment persistence, and optimize long-term functional outcomes in schizophrenia. Register Today! studio.mjhassoc.com/reach/rethinking_schizophrenia_manage…
-
PsychiatryLive
@Psychiatry_Live
Is your adult ADHD patient covered from morning to night? Our expert panel talks treatment selection, all-day symptom control, adherence, and when to add a non-stimulant. www.psychiatrictimes.com/peer-exchange/managing-adult-adh… #adhd #psychiatry
-
PsychiatryLive
@Psychiatry_Live
In this week's episode of "Psyched Perspectives," host @tapkidmd and guest Diego Regalado, MD, discuss immigrant mental health and the importance of cultural humility. www.psychiatrictimes.com/view/podcast-diego-regalado-md-o…
-
PsychiatryLive
@Psychiatry_Live
🧠 Today is #internationalstutteringawarenessday.
This year, we shared the first ever interdisciplinary consensus guidelines on stuttering.
🔗 Read them here: www.psychiatrictimes.com/view/interdisciplinary-consensus… -
PsychiatryLive
@Psychiatry_Live
🎃 The entire October issue of Psychiatric Times is now live on our website. Read it here: www.psychiatrictimes.com/journals/psychiatric-times/vol-4…
-
PsychiatryLive
@Psychiatry_Live
In our latest CME article, learn how to recognize historical and persistent barriers to the ethical use of long-acting injectable antipsychotics. www.psychiatrictimes.com/view/evidence-based-ethical-prin…
-
PsychiatryLive
@Psychiatry_Live
Adult ADHD is more common than many clinicians think, and symptoms often look nothing like the childhood picture. Drs. Lentzsch-Parcells, Patel, and Feld break down diagnosis, comorbidities, and burden in our new Peer Exchange. www.psychiatrictimes.com/peer-exchange/managing-adult-adh… #adhd
-
PsychiatryLive
@Psychiatry_Live
According to a new review, ADHD medications may help improve brain fog in perimenopausal women. www.psychiatrictimes.com/view/adhd-medications-for-managi…
-
PsychiatryLive
@Psychiatry_Live
🎙️ Episode 2 of The Psych Consult: Second Opinion is here!
Claire Brandon, MD, and endocrinologist Caroline Messer, MD, discuss where thyroid disease and psychiatric illness overlap.
🔗 www.psychiatrictimes.com/view/podcast-thyroid-pitfalls-in… -
PsychiatryLive
@Psychiatry_Live
🦠 Phase 2 signal-finding trial of bezisterim for the treatment of long COVID shows safety and symptom gains, with strongest benefits for severe fatigue, post-exertional malaise, and cognitive issues. www.psychiatrictimes.com/view/new-phase-2-data-on-beziste…
-
PsychiatryLive
@Psychiatry_Live
How is schizophrenia management evolving? Attend our live national broadcast to explore real-world strategies to manage side effects, support treatment persistence, and optimize long-term functional outcomes in schizophrenia. Register Today! studio.mjhassoc.com/reach/rethinking_schizophrenia_manage…
-
PsychiatryLive
@Psychiatry_Live
🏃 Athletes can feel the relief a substance gives them long before they can see what it costs.
Check out this composite case of cannabis use in a track athlete to learn more about how to assess. www.psychiatrictimes.com/view/relief-is-not-free-a-case-s… -
PsychiatryLive
@Psychiatry_Live
A psychiatric nurse practitioner shares mentorship lessons, training fixes, and practical tips to close prescriber gaps and improve team-based care in this week's episode of "Psyched Perspectives."
www.psychiatrictimes.com/view/podcast-lindsey-hill-dnp-pm… -
PsychiatryLive
@Psychiatry_Live
Today marks the first-ever Treatment-Resistant Depression Awareness Day in the US. www.psychiatrictimes.com/view/the-first-ever-treatment-re…
-
PsychiatryLive
@Psychiatry_Live
Routine symptom measures can sharpen psychiatric diagnosis.
Learn how to gather consistent, evidence-based measurements from the initial evaluation and throughout patient treatment from John Rush, MD, in our October cover: www.psychiatrictimes.com/view/measurement-informed-psychi… -
PsychiatryLive
@Psychiatry_Live
Mental health care changes lives—and so do the clinicians behind it. 💚🌍
On #worldmentalhealthday, we’re reminded that progress in psychiatry means progress for every patient, family, and community. #mentalhealthawareness #mentalhealth -
PsychiatryLive
@Psychiatry_Live
🚨 The FDA has approved olanzapine (Weltruza) extended-release injectable suspension, a once-monthly subcutaneous long-acting injectable, for adults with schizophrenia. www.psychiatrictimes.com/view/olanzapine-lai-weltruza-rec…
-
PsychiatryLive
@Psychiatry_Live
Check out the latest episode of "Psychopharm Today"! This month, host Jessica Gannon, MD, interviews Andrew A. Nierenberg, MD, about how a learning health network can transform bipolar disorder care.
Watch it here: www.psychiatrictimes.com/view/how-a-learning-health-netwo…
Listen here: www.psychiatrictimes.com/view/podcast-a-learning-health-n… -
PsychiatryLive
@Psychiatry_Live
The October issue of Psychiatric Times is now live! This month, we're rethinking treatment resistance and measurement-based care.
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6/psychtimes/91d31cd84a8c1ad6a… -
PsychiatryLive
@Psychiatry_Live
The FDA has cleared Motivista, a prescription digital therapeutic indicated for the negative symptoms of schizophrenia, as an adjunct to outpatient care. This is the first authorized treatment for negative symptoms of schizophrenia in the United States. www.psychiatrictimes.com/view/fda-grants-clearance-to-mot…
-
PsychiatryLive
@Psychiatry_Live
A recent study found that vortioxetine was consistently associated with improvements in depressive symptoms, though improvements in cognitive symptoms were inconsistent, with neutral-to-positive, predominantly domain-specific effects. www.psychiatrictimes.com/view/vortioxetines-effect-on-cog…
-
PsychiatryLive
@Psychiatry_Live
🌴 Join leading psychiatry experts in Aventura, FL, Dec. 4–5 for the 2026 Southern Florida Psychiatry Conference!
Gain practical insights and strategies to enhance patient care.
🔗Register now: registration.gotoper.com/southern-florida-psychiatry-conf…
#soflopsych #psychiatry #mentalhealth #cme -
PsychiatryLive
@Psychiatry_Live
Our October theme: PTSD.
If you are interested in being featured in a future Special Report/print issue, submit to our content series! www.psychiatrictimes.com/view/presenting-our-october-2026… -
PsychiatryLive
@Psychiatry_Live
Q3 2026 has come to an end. What were the highlights from the psychopharmacology pipeline and FDA this quarter? Find out here: www.psychiatrictimes.com/view/the-psychiatric-pipeline-in…
-
PsychiatryLive
@Psychiatry_Live
🍂💊 Check out all the psychopharmacology pipeline & FDA updates from September: www.psychiatrictimes.com/view/september-2026-in-review-up…
-
PsychiatryLive
@Psychiatry_Live
A new cross-sectional study found that 49.0% of US adults who used both alcohol and cannabis in the past month reported using them simultaneously, despite potential compounded risks, including impaired judgment, injury, and intoxication effects. www.psychiatrictimes.com/view/how-prevalent-is-simultaneo…
-
PsychiatryLive
@Psychiatry_Live
Pharmacologic interventions are a critical component of comprehensive suicide prevention. Among currently available interventions, lithium and clozapine have the strongest evidence for reducing suicidal behavior over time: www.psychiatrictimes.com/view/evidence-based-pharmacologi…
-
PsychiatryLive reposted
Nicolas Badre
@BadreNicolas
Are we adults at 18?
Courts are repeatedly told by colleagues of mine that people under 25 are impulsive and cannot make decisions for themselves.
The claim is dressed up as neuroscience. What is usually missing is an examination of the actual person. A few years ago I wrote about the same problem with PTSD. This is the next one.
My latest in @PsychTimes:
www.psychiatrictimes.com/view/exploring-a-misuse-of-neuro… -
PsychiatryLive
@Psychiatry_Live
Whether you are a psychiatrist, a therapist, or someone who's ever Googled "is my anxiety actually my heart," this conversation is the curbside consult you wish you'd had sooner: www.psychiatrictimes.com/view/podcast-not-always-panic-a-…
-
PsychiatryLive
@Psychiatry_Live
Survey data show that nearly 34% of women and 17% of men have experienced contact sexual violence, physical violence, or stalking by an intimate partner during their lifetime. www.psychiatrictimes.com/view/breaking-the-cycle-of-intim…
-
PsychiatryLive
@Psychiatry_Live
🚨 The FDA has granted Breakthrough Device Designation to NET Recovery for its NET Device as an aid in reducing psychostimulant use in adults 18 and older diagnosed with stimulant use disorder. www.psychiatrictimes.com/view/fda-grants-breakthrough-dev…
-
PsychiatryLive
@Psychiatry_Live
Explore evolving perspectives on the diagnosis, management and treatment considerations in major depressive disorder and bipolar I disorder. Read more: www.psychiatrictimes.com/view/what-low-doses-of-vraylar-c… #sponsored
-
PsychiatryLive
@Psychiatry_Live
🎙️ The Psych Consult: Second Opinion is here!
Claire Brandon, MD, and cardiologist Lara Oboler, MD, explore how SVT and POTS can mimic panic attacks, the clues that can help distinguish them, and why cardiac and psychiatric care can go hand in hand.
🔗 www.psychiatrictimes.com/view/podcast-not-always-panic-a-… -
PsychiatryLive
@Psychiatry_Live
How can body-based technologies help target 2 of the most challenging symptoms to treat in psychiatry, dissociation and anhedonia?
@schoeller_felix, the founder of ReWire Neurotechnologies, shares more in our September issue: www.psychiatrictimes.com/view/embodied-technologies-for-m… -
PsychiatryLive
@Psychiatry_Live
Denial of suicidal intent in adolescents after firearm injury can coexist with high-risk behaviors, necessitating assessment beyond self-report, particularly when affect appears constricted or emotionally numb. www.psychiatrictimes.com/view/the-silence-between-the-que…
-
PsychiatryLive
@Psychiatry_Live
Last chance to register for Jersey City Psychiatry 2026! 🧠
Join fellow mental health professionals October 2–3 in Jersey City, NJ, for 2 days of education, connection & conversations on the latest in psychiatric care.
Register: registration.gotoper.com/jcpsych-26/home #jcpsych2026 -
PsychiatryLive
@Psychiatry_Live
Two grief experts expose the hidden health, social, and economic toll of bereavement—and the policy gaps leaving millions of grieving Americans unsupported.
www.psychiatrictimes.com/view/podcast-griefs-impact-on-pu… -
PsychiatryLive
@Psychiatry_Live
Back in August 2026, @APSARD announced that its US Adult ADHD Guidelines have entered stage 3, the final review stage before publication.
Ahead of the release of the guidelines, we spoke with APSARD president Brooke Molina, PhD: www.psychiatrictimes.com/view/insights-on-the-new-adult-a… -
PsychiatryLive
@Psychiatry_Live
Lipocine has announced the initiation of the phase 3 Brexanolone Lifting Outcomes of Moms (BLOOM) study evaluating LPCN 1154 for postpartum depression. The first participant is expected to be dosed in early Q4 2026. www.psychiatrictimes.com/view/initiation-of-bloom-phase-3…
-
PsychiatryLive
@Psychiatry_Live
🎙️ One week to go!
The Psych Consult: Second Opinion, hosted by Claire Brandon, MD, launches September 21.
Get a first look at the new video-podcast series with our teaser: www.psychiatrictimes.com/view/get-ready-for-the-psych-con…
Stay tuned!
#psychiatry #thepsychconsult -
PsychiatryLive
@Psychiatry_Live
The September issue of Psychiatric Times is now live! This month, we're debunking the top misleading claims about antidepressants.
Check out our exclusive digital issue now and follow along as articles are shared throughout the month. www.psychiatrictimes.com/view/vol-43-issue-9-interactive -
PsychiatryLive
@Psychiatry_Live
New positive topline results from the second phase 3 study of DT120 (lysergide) ODT in adults with generalized anxiety disorder: a single dose delivered rapid, sustained anxiety relief. www.psychiatrictimes.com/view/positive-topline-results-fr…
-
PsychiatryLive
@Psychiatry_Live
Today, we remember September 11, 2001, and the nearly 3,000 lives lost. We honor the first responders, families, and communities forever changed.
Read more about the lasting mental health impact of 9/11 and lessons from disaster psychiatry.
🔗www.psychiatrictimes.com/view/disaster-psychiatry-lessons… -
PsychiatryLive
@Psychiatry_Live
Check out the latest episode of "Psychopharm Today"! This month, host Michael E. Henry, MD, interviews Maurizio Fava, MD, about his decades-long work on treatment-resistant depression.
Watch it here: www.psychiatrictimes.com/view/the-instincts-behind-a-care…
Listen here: www.psychiatrictimes.com/view/podcast-treatment-resistanc… -
PsychiatryLive
@Psychiatry_Live
Newly published results from 2 phase 3 studies evaluating oveporexton in individuals with narcolepsy type 1 show that treatment with oveporexton led to statistically significant improvements over placebo on all measures. www.psychiatrictimes.com/view/new-phase-3-data-on-ovepore…
-
PsychiatryLive
@Psychiatry_Live
According to new 52-week topline data, COMP360 for the management of treatment-resistant depression has demonstrated rapid onset, substantial effect, and sustained durability through 1 year with just a few doses. www.psychiatrictimes.com/view/new-52-week-topline-open-la…
-
PsychiatryLive
@Psychiatry_Live
🎙️ Something new is coming!
The Psych Consult: Second Opinion, hosted by Claire Brandon, MD, explores the intersection of psychiatry and other areas of medicine.
Launching September 21.
Stay tuned for conversations with experts across the collaborative care team! -
PsychiatryLive
@Psychiatry_Live
🚨The FDA has granted Breakthrough Therapy designation to Definium Therapeutics for DT120 (lysergide) orally disintegrating tablet (ODT) for the treatment of major depressive disorder. www.psychiatrictimes.com/view/dt120-lysergide-odt-receive…
-
PsychiatryLive
@Psychiatry_Live
Today, we’re celebrating the psychiatrists, mental health professionals, researchers, and advocates whose work continues to advance mental health care and improve lives.
Wishing you a safe and happy Labor Day from Psychiatric Times! 💙 -
PsychiatryLive
@Psychiatry_Live
🧠💊 The latest "Brain Trust" episode is now live! Joseph Goldberg, and guest Anita Clayton discuss how to spot and treat sexual dysfunction in psychiatric care: www.psychiatrictimes.com/view/podcast-tips-for-treating-s…
-
PsychiatryLive
@Psychiatry_Live
Pramipexole was associated with improvement in anhedonia and apathy, and with increased physical activity in patients with mood disorders, in a placebo-controlled trial that measured both behavioral and neurophysiologic change. www.psychiatrictimes.com/view/repurposing-dopamine-agonis…
-
PsychiatryLive
@Psychiatry_Live
Our September theme: Depressive Disorders.
If you are interested in being featured in a future Special Report/print issue, submit to our content series! www.psychiatrictimes.com/view/presenting-our-september-20… -
PsychiatryLive
@Psychiatry_Live
Today is International Overdose Awareness Day 💜
For #ioad2026, we've taken a look at the current overdose statistics and what we can do to prevent overdose deaths: www.psychiatrictimes.com/view/international-overdose-awar… -
PsychiatryLive
@Psychiatry_Live
As August comes to a close, be sure to check out all the updates on psychopharmacology from this month: www.psychiatrictimes.com/view/august-2026-in-review-updat…
-
PsychiatryLive
@Psychiatry_Live
Let's get vulnerable.
In our latest "Psyched Perspectives" podcast episode, explore how vulnerability works as a tool to strengthen your connection with patients. www.psychiatrictimes.com/view/podcast-vulernability-as-a-… -
PsychiatryLive
@Psychiatry_Live
The Lindsay Clancy trial may be setting a dangerous precedent for psychiatry. Can the mental health system be responsible for a patient’s criminal behavior? www.psychiatrictimes.com/view/psychiatry-on-trial-are-psy…
-
PsychiatryLive
@Psychiatry_Live
In our latest CME article, learn how to identify the diagnostic features of migraine and recognize common psychiatric comorbidities that may complicate assessment, prognosis, and treatment. www.psychiatrictimes.com/view/migraine-and-psychiatric-co…
-
PsychiatryLive
@Psychiatry_Live
Bipolar depression does not have a single face. Understanding this altered experience requires more than symptom recognition—it also requires a treatment approach that extends beyond pharmacotherapy. www.psychiatrictimes.com/view/the-5-faces-of-bipolar-depr…
-
PsychiatryLive
@Psychiatry_Live
❓🧠 EPISODE 2: NOW LIVE!
Learn what's on the mind of guest Laura Melaro, DNP, APRN, FNP-BC, PMHNP-BC: www.psychiatrictimes.com/view/podcast-the-case-for-integr… -
PsychiatryLive
@Psychiatry_Live
🚨The FDA has cleared Roche’s Elecsys pTau217 blood test, a single blood-based option to aid in identifying amyloid pathology associated with Alzheimer disease in patients aged 55+ and older with signs and symptoms of cognitive decline. www.psychiatrictimes.com/view/fda-clears-first-and-only-s…
-
PsychiatryLive
@Psychiatry_Live
🌟Happy Monday! The entire August issue of Psychiatric Times is now live on our website. Read it here: www.psychiatrictimes.com/journals/psychiatric-times/vol-4…
-
PsychiatryLive
@Psychiatry_Live
New patent published for novel combination of MDMA and N-acylethanolamines for the treatment of PTSD, anxiety, and eating disorders: www.psychiatrictimes.com/view/patent-application-publishe…
-
PsychiatryLive
@Psychiatry_Live
Join leading experts at the 2026 Southern Florida Psychiatry Conference for 2 days of practical insights on emerging treatments and challenging psychiatric conditions.
📅 Dec. 4–5 | Aventura, FL
⏰ Early-bird registration ends Aug. 31!
🔗registration.gotoper.com/southern-florida-psychiatry-conf… -
PsychiatryLive
@Psychiatry_Live
Much of psychiatry's caseload involves co-managing chronic pain.
In our latest "Psyched Perspectives" podcast episode, learn more about integrative chronic pain care. www.psychiatrictimes.com/view/podcast-integrative-approac… -
PsychiatryLive
@Psychiatry_Live
The FDA signals clear IND path for @protagenic's PT00114, a first-in-class neuropeptide aiming to reset stress responses in patients with generalized anxiety disorder. www.psychiatrictimes.com/view/fda-feedback-paves-way-for-…
-
PsychiatryLive
@Psychiatry_Live
Urine drug screenings are often misordered and misread, risking stigma and harm. Let's discuss when testing truly helps. www.psychiatrictimes.com/view/lets-talk-about-drug-testing
-
PsychiatryLive
@Psychiatry_Live
🧠 Neuropsych in the News: Today, the FDA has moved forward 2 different potential treatments for Parkinson's and Tourette syndrome, respectively.
Read the news here: www.psychiatrictimes.com/view/neuropsychiatry-in-the-news… -
PsychiatryLive
@Psychiatry_Live
Check out the latest episode of "Psychopharm Today"!
In this conversation, learn more about entactogenic therapeutics for the treatment of mood and anxiety disorders. www.psychiatrictimes.com/view/podcast-exploring-entactoge… -
PsychiatryLive
@Psychiatry_Live
Psychiatry is evolving. Are you keeping up?
Join leading experts at Jersey City Psych 2026 for practical insights and discussions on the latest approaches to complex psychiatric care.
📍 Jersey City, NJ | Oct. 2–3
🔗 Register today: registration.gotoper.com/jcpsych-26/home -
PsychiatryLive
@Psychiatry_Live
A new study sought to explore the possibility of major depressive disorder treatment with tDCS outside of the traditional clinical setting, which could improve access to care, particularly for patients who face barriers to frequent in-person visits. www.psychiatrictimes.com/view/home-based-tdcs-for-depress…
-
PsychiatryLive
@Psychiatry_Live
Recognize postpartum psychosis fast: learn more about early signs and key risk factors in our new FAQ: www.psychiatrictimes.com/view/faq-what-clinicians-need-to…
-
PsychiatryLive
@Psychiatry_Live
Before our August issue drops, be sure to check out our interactive digital July issue for the latest updates in deprescribing: www.psychiatrictimes.com/view/vol-43-issue-7-interactive
PsychiatryLive
@Psychiatry_Live
And, if you enjoyed our July interactive digital issue, be sure to check out our very first digital issue from February: www.psychiatrictimes.com/view/vol-43-issue-2-interactive
-
PsychiatryLive
@Psychiatry_Live
Our August theme: Suicide.
If you are interested in being featured in a future Special Report/print issue, submit to our content series! www.psychiatrictimes.com/view/presenting-our-august-2026-… -
PsychiatryLive
@Psychiatry_Live
🚨BREAKING NEWS: The FDA has approved @TakedaPharma's Orzeyful (oveporexton) for treatment of narcolepsy type 1 in adults. www.psychiatrictimes.com/view/fda-approves-oveporexton-fo…
-
PsychiatryLive
@Psychiatry_Live
This week's episode of "Psyched Perspectives," hosted by @tapkidmd, is now available to stream. Let's unpack clinician trauma and how discomfort becomes a tool for patient connection.
Listen here: www.psychiatrictimes.com/view/podcast-navigating-trauma-t… -
PsychiatryLive reposted
PsychiatryLive
@Psychiatry_Live
As July comes to a close, be sure to check out all the updates on psychopharmacology from this month: www.psychiatrictimes.com/view/july-2026-in-review-updates…
-
PsychiatryLive
@Psychiatry_Live
Tech & Psychiatry Update: @amaehealth today announced a collaboration with Google Health Enterprise to incorporate wearable-derived behavioral data into its precision psychiatry care model. www.psychiatrictimes.com/view/bringing-wearable-data-into…
-
PsychiatryLive
@Psychiatry_Live
Learn about unmet needs in effectively treating patients with MDD, and explore the latest research in digital therapeutics for depression symptoms. Watch now: www.psychiatrictimes.com/view/a-digital-therapeutic-ct-15… #sponsored
-
PsychiatryLive
@Psychiatry_Live
As the Lindsay Clancy trial continues, sensational media linkage of mental illness with violence risks conflating postpartum psychosis with dangerousness. www.psychiatrictimes.com/view/postpartum-psychosis-on-tri…
-
PsychiatryLive
@Psychiatry_Live
As July comes to a close, be sure to check out all the updates on psychopharmacology from this month: www.psychiatrictimes.com/view/july-2026-in-review-updates…
-
PsychiatryLive
@Psychiatry_Live
Traditional eating-disorder models centered on thinness miss male-pattern pathology focused on muscularity, physique optimization, and performance, including bulking/cutting cycles and supplement misuse. www.psychiatrictimes.com/view/the-weight-of-performance-a…
-
PsychiatryLive
@Psychiatry_Live
This week's episode of "Psyched Perspectives," hosted by @tapkidmd, is now available to stream on Apple Music, Spotify, and psychiatrictimes.com!
Listen here: www.psychiatrictimes.com/view/podcast-exploring-the-inter… -
PsychiatryLive
@Psychiatry_Live
Substance use disorders among adolescents pose a profound global public health concern, with epidemiological data indicating that approximately 5% to 8% of youth aged 12 to 17 engage in regular substance misuse. www.psychiatrictimes.com/view/attachment-based-therapy-in…
-
PsychiatryLive
@Psychiatry_Live
Join us October 2–3 in Jersey City for #jerseycitypsych2026!
Hear from leading experts, explore the latest advances in psychiatric care, and gain practical insights you can apply in clinical practice.
Register today: registration.gotoper.com/jcpsych-26/home -
PsychiatryLive
@Psychiatry_Live
A new preclinical study offers evidence that soluble tumor necrosis factor is related to head injury and the amyloid pathology, neuronal loss, and functional deficits characteristic of Alzheimer disease. www.psychiatrictimes.com/view/preventing-alzheimer-diseas…
-
PsychiatryLive
@Psychiatry_Live
Centanafadine (Simtriyo) has been approved by the FDA for treatment of ADHD in adults and children aged 6 and older (>20 kg). @OtsukaUS www.psychiatrictimes.com/view/fda-approves-centanafadine-…
-
PsychiatryLive
@Psychiatry_Live
Discover how innovative digital therapies can help reshape the landscape of MDD treatment. Learn more now: www.psychiatrictimes.com/view/a-digital-therapeutic-ct-15… #sponsored
-
PsychiatryLive
@Psychiatry_Live
🧠💊 This week's "Brain Trust" episode is now live!
Joseph Goldberg, and guest Walter A. Brown discuss how placebo and nocebo effects shape psychiatric care, as well as how expectations and framing boost medication benefit and reduce side effects: www.psychiatrictimes.com/view/podcast-the-power-of-the-pl… -
PsychiatryLive
@Psychiatry_Live
Culture is the shifting set of norms/expectations that can push an intervention off course.
A good clinician does not fight the wind; they trim the sail, keeping the same destination (recovery, dignity, participation), while adjusting how they get there. www.psychiatrictimes.com/view/the-wind-check-how-to-adapt… -
PsychiatryLive
@Psychiatry_Live
A recent meta-analysis ranked add-on atypical antipsychotics for major depressive disorder, comparing symptom response and dropout risks to guide smarter next-step treatment. www.psychiatrictimes.com/view/assessing-antipsychotics-as…
-
PsychiatryLive
@Psychiatry_Live
New data show APOE4 worsens early sleep disruption in Alzheimer models.
Tri Doan, MD, PhD, shares more about a new therapeutic strategy in treating Alzheimer disease in our latest Q&A: www.psychiatrictimes.com/view/targeting-apoe4-a-promising… -
PsychiatryLive
@Psychiatry_Live
The FDA has granted Fast Track designation to remlifanserin, an investigational, highly selective, 5-HT2A receptor inverse agonist for the treatment of hallucinations and delusions associated with Alzheimer disease psychosis. @AcadiaPharma www.psychiatrictimes.com/view/remlifanserin-for-the-treat…
-
PsychiatryLive
@Psychiatry_Live
🧠💊 This week's "Brain Trust" episode is now live!
Joseph Goldberg, and guest Michael Ostacher discuss comorbid mood and substance use disorders: www.psychiatrictimes.com/view/podcast-managing-co-occurri… -
PsychiatryLive
@Psychiatry_Live
Postpartum depression affects ~12.5% of mothers in the US and is associated with impaired bonding, adverse infant neurodevelopmental outcomes, increased suicidality, and relationship disruption when untreated.
www.psychiatrictimes.com/view/zuranolone-in-the-room-clos… -
PsychiatryLive
@Psychiatry_Live
The FDA has accepted the New Drug Application for reboxetine (AXS-12) for the treatment of cataplexy in narcolepsy. @axsome www.psychiatrictimes.com/view/fda-accepts-nda-for-axs-12-…
-
PsychiatryLive
@Psychiatry_Live
☀️ Psychiatry meets paradise this December. Join us in Aventura for the 2026 Southern Florida Psychiatry Conference and explore the latest advances shaping mental health care. 🧠
⏳ Early bird savings end Aug. 31: registration.gotoper.com/southern-florida-psychiatry-conf…
#soflopsych #psychiatry #cme -
PsychiatryLive
@Psychiatry_Live
New 6-month toxicology data for intravenous VY1706 to treat Alzheimer disease, showing sustained tau protein reduction and favorable tolerability. @VoyagerTx www.psychiatrictimes.com/view/vy1706-for-treatment-of-alz…
-
PsychiatryLive
@Psychiatry_Live
The July issue of Psychiatric Times is now live! This month, we take share insights from top experts on the controversial topic of deprescribing.
Check out our exclusive digital issue now and follow along as articles are shared throughout the month. www.psychiatrictimes.com/view/vol-43-issue-7-interactive -
PsychiatryLive
@Psychiatry_Live
🧠💊 This week's "Brain Trust" episode is now live!
Joseph Goldberg, and guest Roy Perlis explore the challenges of integrating AI tools into everyday psychiatric practice: www.psychiatrictimes.com/view/podcast-how-ai-can-help-in-… -
PsychiatryLive
@Psychiatry_Live
The first episode of podcast "Psyched Perspectives" is now available to stream on Apple Music, Spotify, and psychiatrictimes.com!
Listen here: www.psychiatrictimes.com/view/podcast-discussing-parental… -
PsychiatryLive
@Psychiatry_Live
New 6-month data from the phase 3 COMP006 trial show that COMP360 psilocybin delivers rapid, lasting relief in treatment-resistant depression. www.psychiatrictimes.com/view/new-6-month-data-from-secon…
-
PsychiatryLive
@Psychiatry_Live
Our July theme: Substance Use.
If you are interested in being featured in a future Special Report/print issue, submit to our content series! www.psychiatrictimes.com/view/presenting-our-july-2026-th… -
PsychiatryLive
@Psychiatry_Live
🔐 Don't miss any of the psychiatric pipeline news from quarter 2! Check out our exclusive recap here: www.psychiatrictimes.com/view/the-psychiatric-pipeline-in…
-
PsychiatryLive
@Psychiatry_Live
⚔️🧠 How is tribalism harming the field of psychiatry?
The very first episode of "On Your Mind With Erin Crown" is now posted: www.psychiatrictimes.com/view/tribalism-in-psychiatry-on-… -
PsychiatryLive
@Psychiatry_Live
Positive data from the largest real-world analysis of Deep TMS in Comorbidity PTSD and MDD shows meaningful improvements in both PTSD and depression symptoms across a large and diverse patient population. www.psychiatrictimes.com/view/new-positive-data-from-larg…
-
PsychiatryLive
@Psychiatry_Live
🧠💊 This week's "Brain Trust" episode is now live!
Joseph Goldberg, MD, and guest David Dunner, MD, FACPsych, discuss the evolving treatment of bipolar disorder: www.psychiatrictimes.com/view/podcast-practical-insights-… -
PsychiatryLive
@Psychiatry_Live
Schizophrenia affects women differently than men, as estrogen is considered neuroprotective in schizophrenia.
www.psychiatrictimes.com/view/preventing-relapse-in-schiz… -
PsychiatryLive reposted
NJ Psychiatric Association
@NJ_Psychiatry
@fda has announced initiatives to promote utilizing psychedelic-based treatments for serious mental illness (SMI), showing a new acceleration in attention towards treatments of SMI. Learn more via @psychtimes at www.psychiatrictimes.com/view/fda-fast-tracks-psychedelic…
#njpa #psychiatry #mentalhealth -
PsychiatryLive
@Psychiatry_Live
⏰ Early bird pricing for the Jersey City Psychiatry Conference ends June 30th.
Lock in your spot at the best rate before it's gone. CME credits, expert sessions, and a room full of your peers.
Register now → registration.gotoper.com/jcpsych-26/home
#psychiatry #mentalhealth #cme -
PsychiatryLive
@Psychiatry_Live
Learn about unmet needs in effectively treating patients with MDD, and explore the latest research in digital therapeutics for depression symptoms. Watch now: www.psychiatrictimes.com/view/a-digital-therapeutic-ct-15… #sponsored
-
PsychiatryLive
@Psychiatry_Live
Cognitive impairment represents one of the main determinants of functional impairment in schizophrenia, and is directly responsible for negative outcomes in several real-world contexts. www.psychiatrictimes.com/view/evidence-based-nonpharmacol…
-
PsychiatryLive
@Psychiatry_Live
Need something to read this week? The entire June issue of Psychiatric Times is now live on our website. Read it here: www.psychiatrictimes.com/journals/psychiatric-times/vol-4…
-
PsychiatryLive
@Psychiatry_Live
Once-nightly regular-release lithium cuts kidney risk, maintains bipolar control, improves adherence, and guides safer serum levels in bipolar disorder. www.psychiatrictimes.com/view/dose-lithium-once-a-day-at-…
-
PsychiatryLive
@Psychiatry_Live
Key steps for treatment of first-episode psychosis: team-based care, low-dose meds, relapse planning, family support, and cannabis harm reduction. www.psychiatrictimes.com/view/treating-patients-with-firs…
-
PsychiatryLive
@Psychiatry_Live
The FDA has issued a Complete Response Letter (CRL) for cytisinicline for smoking cessation in adults, citing manufacturing concerns, with no deficiency in clinical safety or efficacy of the drug. www.psychiatrictimes.com/view/fda-issues-crl-for-cytisini…
-
PsychiatryLive
@Psychiatry_Live
Psychiatry is evolving fast. Stay ahead of it.
🌊 SoCal Psych 2026 | July 10–11 | Huntington Beach, CA
Expert sessions on MDD, schizophrenia, substance use disorders & more. CME credits available.
Register → registration.gotoper.com/scpsych-26/home
#psychiatry #cme #socalpsych2026 -
PsychiatryLive
@Psychiatry_Live
New positive topline results from phase 3 study Emerge evaluating a single dose of DT120 ODT 100 µg in adults with major depressive disorder: DT120 delivers rapid, lasting relief with mild, transient adverse effects. www.psychiatrictimes.com/view/positive-topline-results-fr…
-
PsychiatryLive
@Psychiatry_Live
Psychiatrists should be talking to patients about sex: sexual dysfunction can exacerbate comorbid psychiatric disorders and contribute to medication nonadherence. www.psychiatrictimes.com/view/addressing-sexual-wellness-…
-
PsychiatryLive reposted
Alto Neuroscience
@AltoNeuro
Ph2 findings for ALTO-203 showed improvements in attention, alertness, & EEG biomarkers in patients with depression. In a recent @PsychTimes interview, Amit Etkin, MD, PhD, discusses how these findings may help identify patients most likely to benefit.
www.psychiatrictimes.com/view/alto-203-an-h3-inverse-agon… -
PsychiatryLive
@Psychiatry_Live
🧠💊 This week's "Brain Trust" episode is now live!
Joseph Goldberg and guest Henry Nasrallah, discuss off-label prescribing and polypharmacy: www.psychiatrictimes.com/view/podcast-how-to-prescribe-of… -
PsychiatryLive
@Psychiatry_Live
We are so excited to share that our collaborative podcast with @ASCPorg is now available on Apple Music, Spotify, and psychiatrictimes.com!
Tune in here: www.psychiatrictimes.com/view/podcast-limitations-of-curr… -
PsychiatryLive
@Psychiatry_Live
Learn more about bretisilocin, a potential best-in-class compound for the treatment of major depressive disorder from @abbvie, and the evolving psychedelic landscape here: www.psychiatrictimes.com/view/developing-next-generation-…
-
PsychiatryLive
@Psychiatry_Live
Social media disorder remains noticeably absent from psychiatric diagnostic frameworks. However, 83% of readers believe social media is addictive. What's the verdict?
Read our June cover story here: www.psychiatrictimes.com/view/engineered-addiction-redefi… -
PsychiatryLive
@Psychiatry_Live
Discover how innovative digital therapies can help reshape the landscape of MDD treatment. Learn more now: www.psychiatrictimes.com/view/a-digital-therapeutic-ct-15… #sponsored
-
PsychiatryLive
@Psychiatry_Live
The June issue of Psychiatric Times is now live! This month, we examine the dangers of social media for our youth, highlighting the recent legal battles between teens and social media giants.
Download the issue now and follow along as articles are shared throughout the month.
PsychiatryLive
@Psychiatry_Live
Download here: cdn.sanity.io/files/0vv8moc6/psychtimes/6f45cece92a357757…
-
PsychiatryLive
@Psychiatry_Live
📣 Mark your calendars!
The Jersey City Psychiatry Conference is October 2–3, 2026.
Two days of clinical education, emerging research, and real talk about where psychiatry is headed.
Early bird pricing is open now — but only through June 30. 🔗registration.gotoper.com/jcpsych-26/home -
PsychiatryLive
@Psychiatry_Live
🎙️🧐💊 This week's "Brain Trust" episode is now live!
Joseph Goldberg and guest Robert M. Post, MD, discuss evolving perspectives on bipolar disorder and treatment, emphasizing early intervention and the underutilization of lithium: www.psychiatrictimes.com/view/podcast-early-intervention-… -
PsychiatryLive
@Psychiatry_Live
Phase 2 topline data show that elunetirom for the treatment of bipolar depression achieved statistical significance across the primary and all key secondary depression endpoints. www.psychiatrictimes.com/view/new-positive-phase-2-toplin…
-
PsychiatryLive
@Psychiatry_Live
The FDA has issued a Complete Response Letter for CTx-1301, a novel formulation of dexmethylphenidate for treatment of ADHD. www.psychiatrictimes.com/view/fda-issues-crl-for-ctx-1301…
-
PsychiatryLive
@Psychiatry_Live
Our June theme: Special Populations.
We want to hear your clinical insights! Submit to our content series ⬇️ www.psychiatrictimes.com/view/presenting-our-june-2026-th… -
PsychiatryLive
@Psychiatry_Live
This Memorial Day, Psychiatric Times honors the brave individuals who made the ultimate sacrifice in service to our country. We remember their courage, reflect on their legacy, and express gratitude to all who have served.
-
PsychiatryLive
@Psychiatry_Live
🎙️🧐💊 This week's "Brain Trust" episode is now live!
Guest Michael Gitlin, MD, shares insights on the complex psychopharmacology of personality disorders: www.psychiatrictimes.com/view/podcast-the-complex-psychop… -
PsychiatryLive
@Psychiatry_Live
Antipsychotic medications remain the most effective intervention for reducing psychotic symptoms and preventing relapse. Yet medication alone is often insufficient. Psychotherapy can play an important role in relapse prevention and long-term recovery. www.psychiatrictimes.com/view/psychotherapy-and-the-preve…
-
PsychiatryLive
@Psychiatry_Live
The HHS has released the Surgeon General’s “Warning on the Harms of Screen Use," which aims to raise national awareness about the growing risks associated with excessive and harmful screen use among youth. www.psychiatrictimes.com/view/the-new-plan-to-protect-you…
-
PsychiatryLive
@Psychiatry_Live
Need new reading material? The entire May 2026 issue of Psychiatric Times is now live on our website. Read it here: www.psychiatrictimes.com/journals/psychiatric-times/vol-4…
-
PsychiatryLive
@Psychiatry_Live
The latest focus on psychedelic use for mood disorders and continued research into neuromodulation holds much potential. #apaam26 www.psychiatrictimes.com/shorts/future-of-psychedelics-an…
-
PsychiatryLive
@Psychiatry_Live
Ketamine-assisted psychotherapy may have a practical advantage over psilocybin, MDMA, and LSD-assisted protocols, which typically require 6 to 10 hours per session, compared with approximately 2 hours for ketamine-assisted psychotherapy. #apaam26 www.psychiatrictimes.com/view/advances-in-ketamine-assist…
-
PsychiatryLive
@Psychiatry_Live
Behavioral addictions extend beyond traditional internet overuse and may include compulsive gaming, extreme online gambling, and even maladaptive exercise behaviors shaped by social media culture, shared Hector Colon-Rivera, MD. #apaam26 www.psychiatrictimes.com/view/assessing-and-treating-digi…
-
PsychiatryLive
@Psychiatry_Live
Christoph Correll, MD, presented efficacy and real-world data on olanzapine-samidorphan for schizophrenia and bipolar disorder at #apaam26. He found that it keeps olanzapine efficacy yet limits weight gain, improves negative symptoms, and cuts ER visits. www.psychiatrictimes.com/view/olanzapine-samidorphan-for-…
-
PsychiatryLive
@Psychiatry_Live
Synendos Therapeutics has initiated dosing in a phase 2 trial of SYT-510, a first-in-class endocannabinoid modulator, aiming to ease generalized anxiety disorder symptoms with improved safety and adherence. @synendos
www.psychiatrictimes.com/view/syt-510-for-generalized-anx… -
PsychiatryLive
@Psychiatry_Live
Adult patients with ADHD rarely self-identify their core symptoms. Instead, they typically present with anxiety, depression, and general distress—requiring the clinician to actively probe for ADHD features beyond the presenting complaint. #apaam26
www.psychiatrictimes.com/view/approaching-adult-adhd-diag… -
PsychiatryLive
@Psychiatry_Live
Patients with preexisting severe mental illness, including schizophrenia and bipolar disorder, who subsequently develop cancer face significant disparities in cancer screening and access to care, shared Michelle Riba, MD, MS. #apaam26
www.psychiatrictimes.com/view/psycho-oncology-the-relatio… -
PsychiatryLive
@Psychiatry_Live
Childbirth-related PTSD: frequently overlooked and underdiagnosed in postpartum care. Amanda Koire shares more on the clinical pattern she noticed. #apaam26
www.psychiatrictimes.com/view/childbirth-related-ptsd-rec… -
PsychiatryLive
@Psychiatry_Live
How can we spot digital behavioral addiction?
Watch this short video to learn more and keep your eyes peeled for our upcoming June cover story 👀
#apaam26
www.psychiatrictimes.com/shorts/spotting-digital-behavior… -
PsychiatryLive
@Psychiatry_Live
When having conversations with older adult patients about their sexual wellness, Anita Clayton shared that it's critical to:
1. Have an open dialogue.
2. Do not make assumptions about their preferences or activity.
#apaam26
www.psychiatrictimes.com/shorts/talking-about-sexual-well… -
PsychiatryLive
@Psychiatry_Live
Join us this December for the 2026 Southern Florida Psychiatry Conference in Aventura, Florida, where experts will tackle today’s most pressing challenges in mental health care.
⏳ Early bird savings end August 31—secure your spot now: registration.gotoper.com/southern-florida-psychiatry-conf… -
PsychiatryLive
@Psychiatry_Live
New data from the largest tardive dyskinesia (TD) study to date highlights a significant gap in diagnosing TD in patients with comorbid mood disorders: young adults with mood disorders face high TD burden yet low diagnosis rates. www.psychiatrictimes.com/view/new-data-from-impact-td-reg…
-
PsychiatryLive
@Psychiatry_Live
XPro1595 showed directionally consistent benefit across cognitive, global, functional, behavioral, and biomarker endpoints over 24 weeks in an Alzheimer disease with inflammation subgroup, with no amyloid-related imaging abnormalities. www.psychiatrictimes.com/view/phase-2-mindful-trial-resul…
-
PsychiatryLive
@Psychiatry_Live
Can digital tools help reduce depression symptoms? Watch the latest Between the Lines series to explore new research in treating patients with major depressive disorder. Watch here: www.psychiatrictimes.com/view/a-digital-therapeutic-ct-15… #sponsored
-
PsychiatryLive
@Psychiatry_Live
🎙️🧬 This week's "Brain Trust" episode is now live!
Guest and Psychiatric Times Editor in Chief, John J. Miller, MD, explores pharmacogenetic testing in psychiatry: www.psychiatrictimes.com/view/podcast-pharmacogenetic-tes… -
PsychiatryLive
@Psychiatry_Live
According to a new systematic review and meta-analysis, there is no causal link between the use of nearly all antidepressants during pregnancy and an increased risk of autism/ADHD. www.psychiatrictimes.com/view/antidepressant-use-in-pregn…
-
PsychiatryLive
@Psychiatry_Live
Our Schizophrenia Special Report starts releasing today.
Read the introduction by Special Report Chair Peter F. Buckley, MD, now: www.psychiatrictimes.com/view/understanding-schizophrenia… -
PsychiatryLive
@Psychiatry_Live
An estimated 77,000 individuals with psychotic disorders are in US jails and prisons at any given time.
This could, in part, be driven by the neurological deficit anosognosia, in which an affected individual is unable to perceive their own illness. www.psychiatrictimes.com/view/anosognosia-and-the-crimina… -
PsychiatryLive
@Psychiatry_Live
What does cannabis legalization mean for psychosis risk? www.psychiatrictimes.com/view/cannabis-and-psychosis-risk…
-
PsychiatryLive
@Psychiatry_Live
Should we create a new term for borderline personality disorder?
Renaming borderline personality disorder fails to address the condition's complexity. www.psychiatrictimes.com/view/borderline-personality-diso… -
PsychiatryLive
@Psychiatry_Live
Join us July 10–11 in Huntington Beach for the Southern California Psychiatry Conference. Explore emerging therapies, real-world case discussions, and expert insights on MDD, SUD, schizophrenia, and more.
Register now: registration.gotoper.com/scpsych-26/home -
PsychiatryLive
@Psychiatry_Live
A large meta-analysis found that GLP-1 drugs don’t raise depression or suicidality and modestly boost quality of life and eating control in diabetes/obesity. Read the research here: www.psychiatrictimes.com/view/evaluating-glucagon-like-pe…
-
PsychiatryLive
@Psychiatry_Live
The HHS is targeting psychiatric overprescribing.
Joseph F. Goldberg, MD, urges careful deprescribing: stop ineffective medications and replace them with evidence-based treatments. www.psychiatrictimes.com/view/what-clinicians-need-to-kno… -
PsychiatryLive
@Psychiatry_Live
The May issue of Psychiatric Times is now live! This month, we take closer look at the psychopharmacology pipeline.
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6/psychtimes/9bff843d1d39fbdf5… -
PsychiatryLive
@Psychiatry_Live
The FDA has cleared @NRxPharma to initiate a clinical trial of NRX-101 vs placebo in patients with depression and suicidality who are being treated with either robotic-assisted or sham TMS. www.psychiatrictimes.com/view/fda-clears-clinical-trial-o…
-
PsychiatryLive
@Psychiatry_Live
💊 🧠 Our May cover story by Editor in Chief John J. Miller, M.D. is now live! Read about the psychopharmacology pipeline and the potential treatments you need to have your eyes on here: www.psychiatrictimes.com/view/psychiatrys-medication-pipe…
-
PsychiatryLive
@Psychiatry_Live
The HHS has rolled out a plan to curb psychiatric overprescribing, pushing deprescribing guidance while major psychiatric organizations like the @APApsychiatric and @afspnational urge caution and access to care. www.psychiatrictimes.com/view/hhs-launches-action-plan-to…
-
PsychiatryLive
@Psychiatry_Live
"Brain Trust: Conversations in Psychopharmacology" is now available on Apple Music, Spotify, and psychiatrictimes.com!
Tune in for discussions on the most important and interesting topics in psychiatric pharmacology and clinical practice: www.psychiatrictimes.com/series/brain-trust -
PsychiatryLive reposted
Mount Sinai Psychiatry
@MountSinaiPsych
Thalia Robakis, MD, PhD, discusses the randomized clinical trial happening at Mount Sinai, examining the efficacy and tolerability of the SAINT transcranial magnetic stimulation (TMS) protocol in women with postpartum depression. @PsychTimes www.psychiatrictimes.com/view/the-saint-trial-expanding-r…
-
PsychiatryLive
@Psychiatry_Live
According to new network meta-analysis findings, lumateperone (Caplyta) ranked highest across 4 key efficacy measures and demonstrated a favorable tolerability profile, particularly with respect to weight, when compared with the other agents evaluated. www.psychiatrictimes.com/view/lumateperone-ranks-highest-…
-
PsychiatryLive
@Psychiatry_Live
ICYMI: Auvelity for the treatment of Alzheimer disease dementia is now FDA approved. Read the news here ⬇️
PsychiatryLive
@Psychiatry_Live
🚨 BREAKING NEWS: The FDA has approved @axsome's oral dextromethorphan-bupropion (Auvelity, formerly known as AXS-05) for the treatment of agitation associated with Alzheimer disease. www.psychiatrictimes.com/view/fda-approves-auvelity-for-t…
-
PsychiatryLive
@Psychiatry_Live
Learn about unmet needs in effectively treating patients with MDD, and explore the latest research in digital therapeutics for depression symptoms. Watch now: www.psychiatrictimes.com/view/a-digital-therapeutic-ct-15… #sponsored
-
PsychiatryLive
@Psychiatry_Live
New survey data from the @SczPolicyAction show that despite growing recognition of serious mental illness as a treatable medical condition, access to consistent, evidence-based care remains limited. www.psychiatrictimes.com/view/new-span-survey-highlights-…
-
PsychiatryLive
@Psychiatry_Live
Our May theme: Psychedelics.
We want to hear your clinical insights! Submit to our content series ⬇️
www.psychiatrictimes.com/view/presenting-our-may-2026-the… -
PsychiatryLive
@Psychiatry_Live
Approximately 50% to 70% of individuals with ADHD have comorbid sleep disturbances. www.psychiatrictimes.com/view/adhd-and-sleep-disorders-wa…
-
PsychiatryLive reposted
American Foundation for Suicide Prevention
@afspnational
AFSP and JED intend to merge to form the nation’s largest nonprofit dedicated to suicide prevention across the lifespan. John MacPhee of @jedfoundation and Bob Gebbia of AFSP spoke with @PsychTimes to discuss the important work that lies ahead. Read: www.psychiatrictimes.com/view/afsp-jeds-mission-to-preven…
-
PsychiatryLive
@Psychiatry_Live
🚨 BREAKING NEWS: The FDA has approved @axsome's oral dextromethorphan-bupropion (Auvelity, formerly known as AXS-05) for the treatment of agitation associated with Alzheimer disease. www.psychiatrictimes.com/view/fda-approves-auvelity-for-t…
-
PsychiatryLive
@Psychiatry_Live
TDScreen, a video-based AI screening tool from @Videra_Health, was able to identify symptoms of tardive dyskinesia and prompt patients to seek clinical evaluation. www.psychiatrictimes.com/view/ai-screening-tool-for-tardi…
-
PsychiatryLive
@Psychiatry_Live
Spot delirium in the ICU early with MD‑MOSAIC: an exam for ventilated patients that sharpens diagnosis, prevents harm, and improves outcomes. www.psychiatrictimes.com/view/md-mosaic-a-proposed-psychi…
-
PsychiatryLive
@Psychiatry_Live
Narcolepsy is more than excessive sleepiness. Dr. Doghramji, Dr. Strunc, Ellen Wermter, FNP-BC, and Dr. Winter break down recognition, diagnosis, and treatment strategies for optimizing narcolepsy care.
Watch here: www.psychiatrictimes.com/peer-exchange/multidisciplinary-…
#narcolepsy #sleepmedicine -
PsychiatryLive
@Psychiatry_Live
An application for @AdialPharma's AD04 has been submitted to the FDA's Commissioner’s National Priority Voucher Pilot Program, which could lead to expedited FDA review. www.psychiatrictimes.com/view/ad04-application-submitted-…
-
PsychiatryLive
@Psychiatry_Live
The FDA has approved the sNDA based on long-term data evaluating the safety and efficacy of @JNJInnovMed's Caplyta for the prevention of relapse in schizophrenia.
Caplyta demonstrated a 63% lower risk of relapse compared with placebo. www.psychiatrictimes.com/view/fda-approves-snda-of-caplyt… -
PsychiatryLive
@Psychiatry_Live
Need something to read this weekend? The entire April issue is now live on our website. Read it here: www.psychiatrictimes.com/journals/psychiatric-times/volum…
-
PsychiatryLive
@Psychiatry_Live
Medical illnesses can impact the way in which depression presents, and cultivating an awareness of how depression can manifest is an essential skill in psychiatry. Learn more in our latest CME: www.psychiatrictimes.com/view/shared-pathways-distinct-co…
-
PsychiatryLive
@Psychiatry_Live
Read the whole story here: www.psychiatrictimes.com/view/sex-hormones-and-eating-dis…
Dr Erik Messamore
@ErikMessamoreMD
"Research into sex hormones and eating disorders reveals a compelling neuroendocrine narrative. Estrogens and androgens are not merely reproductive hormones but active participants in brain organization and function, particularly in critical developmental windows." - @PsychTimes
-
PsychiatryLive
@Psychiatry_Live
The @afspnational and @jedfoundation have shared their intent to combine and become the AFSP/JED, which would be the nation’s largest nonprofit dedicated to suicide prevention across the lifespan. www.psychiatrictimes.com/view/afsp-and-jed-announce-inten…
-
PsychiatryLive
@Psychiatry_Live
Expanded phase 2a results for EMP-01 in adults with social anxiety disorder demonstrate clinically meaningful and consistent improvements across clinician-rated symptoms, patient-reported experience, and real-world behavioral outcomes. @ataibeckley www.psychiatrictimes.com/view/emp-01-for-social-anxiety-d…
-
PsychiatryLive
@Psychiatry_Live
Participants with narcolepsy type 1 taking once-daily alixorexton demonstrated clinically meaningful improvements in patient-reported disease severity, cognitive impairment, and fatigue, with improvements sustained through 12 to 13 weeks. www.psychiatrictimes.com/view/new-aan-poster-presentation…
-
PsychiatryLive
@Psychiatry_Live
New youth substance use disorder criteria help clinicians deliver developmentally tailored, prevention-first care with coordinated family and community supports. www.psychiatrictimes.com/view/empathetic-curiosity-better…
-
PsychiatryLive reposted
Shrinks In Sneakers @AndPsychiatry
High-potency cannabis is not a niche issue anymore. It is a psychiatric one
In my new @PsychTimes piece, I argue that modern cannabis has evolved far beyond the low-potency marijuana of the old days
www.psychiatrictimes.com/view/high-potency-cannabis-ameri…
#psychiatry #cannabis #mentalhealth #psychosis -
PsychiatryLive
@Psychiatry_Live
New evidence shows lithium adds minimal weight in bipolar disorder. www.psychiatrictimes.com/view/management-of-lithiums-adve…
-
PsychiatryLive
@Psychiatry_Live
Explore how an individualized, partner-based approach can inform treatment decisions in schizophrenia care, including assessment, treatment history, and tolerability considerations. Read the article: www.psychiatrictimes.com/view/integrating-a-different-kin…
#sponsored -
PsychiatryLive reposted
Roger S. McIntyre, MD, FRCPC
@rogersmcintyre
The Sigma 1 receptor has been an enigma the Sigma enigma ! The target of many important drugs eg ketamine,dextromethorphan
my very good friend Dr John Miller has provided a wonderful concise summary of this receptor and the pharmacological opportunity
www.psychiatrictimes.com/view/the-curious-story-of-sigma-… -
PsychiatryLive
@Psychiatry_Live
📣 Registration is open for SoCal Psych 2026!
Join us July 10–11, 2026 in Huntington Beach, CA for SoCal Psych — a clinical education experience where experts present on managing complex psychiatric conditions and emerging treatments.
Register today: registration.gotoper.com/scpsych-26/home -
PsychiatryLive
@Psychiatry_Live
A new 56-week post hoc analysis from @Alkermes found that treatment with Lybalvi was associated with significant and durable improvement in negative symptoms of schizophrenia. www.psychiatrictimes.com/view/lybalvi-associated-with-imp…
-
PsychiatryLive
@Psychiatry_Live
Almost 40% of American adults regularly watch reality TV.
These shows put therapy on camera, reducing stigma but raising ethical, privacy, and misinformation risks—and affecting both the viewers and cast. www.psychiatrictimes.com/view/a-new-reality-for-psychiatr… -
PsychiatryLive
@Psychiatry_Live
The new ASAM youth criteria are redefining substance use disorder care. Our latest Q&A explores this update. www.psychiatrictimes.com/view/new-adolescent-substance-us…
-
PsychiatryLive
@Psychiatry_Live
The April issue of Psychiatric Times is now live! This month, we take closer look at reality TV. Is it reducing stigma or raising risks?
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6/psychtimes/a1615c87f16ddd5dc… -
PsychiatryLive reposted
Friedman Brain Institute
@SinaiBrain
ONLINE NOW! In this interview w/ @PsychTimes, @EmmaGuttman @MSHSDerm & @JMurrough @IcahnDAC discuss their research collaboration linking inflammatory pathways in atopic dermatitis to the pathophysiology of #majordepressivedisorder. Watch Interview Here 👉 psychiatrictimes.com/view/depression-and-inflammatory-ski…
-
PsychiatryLive
@Psychiatry_Live
Deep intracranial frequency stimulation 77.5 Hz high-gamma approach was associated with statistically significant reductions in self-injury behaviors and depressive symptoms in female adolescents with nonsuicidal self-injury, according to a new study. www.psychiatrictimes.com/view/deep-intracranial-frequency…
-
PsychiatryLive
@Psychiatry_Live
Stroke meets CMS chronic-condition criteria, yet therapy reimbursement commonly ends at 2–3 months, despite evidence that function and skills can improve at any time poststroke.
So why aren’t we practicing that type of medicine in chronic strokes? www.psychiatrictimes.com/view/why-arent-we-treating-strok… -
PsychiatryLive
@Psychiatry_Live
The first participants have now been enrolled in a US Department of War-funded phase 2a clinical trial evaluating sublingual dexmedetomidine (BXCL501) for the treatment of acute stress reactions. @BioXcel_Tx www.psychiatrictimes.com/view/first-participants-enrolled…
-
PsychiatryLive reposted
Nicolas Badre
@BadreNicolas
Ultimately, psychiatry is two people in a room trying to better understand the world, and themselves. That requires the honest, caring exchange of ideas.
If you come in with relationship problems, my job isn’t to push you to stay or leave. It’s to help you understand yourself more clearly through it.
Discussion and debate are at the core of what we do, they’re the very process by which we help people understand their lives. Yet modern medicine often does them poorly. So a few colleagues and I created a psychiatry debate competition.
The goal isn’t to declare winners. It’s to model the kind of rigorous, respectful dialogue our field should be built on. The first finals will be held at the APA.
I also wrote an article with some of this year’s participants on the motion: “Should Accrediting Bodies Require AI for Suicide Risk Stratification in Emergency Settings?”
@PsychTimes featured it on their homepage. I’d be grateful if you read it, or better yet, join us at the APA to watch psychiatry residents debate important topics with intelligence and respect. -
PsychiatryLive
@Psychiatry_Live
Early MRS data show AL001 delivers lithium effects across the brain while sparing glutamate, hinting at better tolerability than lithium carbonate. @AlzamendNeuro www.psychiatrictimes.com/view/encouraging-pharmacodynamic…
-
PsychiatryLive
@Psychiatry_Live
🥦 It's time to take a closer look at mood and food. Let's explore new developments coming out of the field of nutritional psychiatry. www.psychiatrictimes.com/view/what-is-the-relationship-be…
-
PsychiatryLive
@Psychiatry_Live
Psychiatrists and mental health clinicians: We want to know your thoughts on the addictive nature of social media📱⬇️
Is social media addictive? -
PsychiatryLive
@Psychiatry_Live
Psychedelics for the treatment of depression: strong interventions that must be handled with the utmost care. www.youtube.com/shorts/PJ0mGZwbzzk
-
PsychiatryLive
@Psychiatry_Live
Oral brexanolone LPCN 1154 for the treatment of postpartum depression failed to meet the primary endpoint in a phase 3 placebo-controlled trial. www.psychiatrictimes.com/view/lpcn-1154-for-postpartum-de…
-
PsychiatryLive
@Psychiatry_Live
Our April theme: Schizophrenia.
If you are interested in being featured in a future Special Report/print issue, submit to our content series! www.psychiatrictimes.com/view/presenting-our-april-2026-t… -
PsychiatryLive
@Psychiatry_Live
Alkermes has announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared with placebo in adults with narcolepsy type 1 and narcolepsy type 2. @Alkermes
www.psychiatrictimes.com/view/phase-3-brilliance-studies-… -
PsychiatryLive
@Psychiatry_Live
A panel of experts presented new consensus recommendations focused on the screening, diagnosis, and treatment of tardive dyskinesia among older adults in long-term care settings. www.psychiatrictimes.com/view/first-expert-consensus-reco…
-
PsychiatryLive
@Psychiatry_Live
As the month comes to a close, let's take a look at all the recent psychopharmacology updates: www.psychiatrictimes.com/view/march-2026-in-review-update…
-
PsychiatryLive
@Psychiatry_Live
GLP-1 medications may have problematic interactions with eating disorders. Learn more in our latest YouTube short: www.youtube.com/shorts/jnM0gd1RDBI
-
PsychiatryLive
@Psychiatry_Live
Interim results from a phase 2 trial of tazbentetol for treatment of schizophrenia showed trends of improving positive and negative symptoms in patients via synaptic regeneration. @Spinogenix_Inc www.psychiatrictimes.com/view/tazbentetol-for-schizophren…
-
PsychiatryLive
@Psychiatry_Live
The ASAM has announced new youth substance use disorder criteria, promoting early intervention, family-focused care, integrated mental health, and updated levels of treatment. www.psychiatrictimes.com/view/asam-announces-new-standard…
-
PsychiatryLive reposted
Dr Yasuhiro Kotera
@YasuKotera
New in @PsychTimes. Culture as Wind: Adapting Recovery&Shared Decision-Making Across Cultures
Same recovery/SDM approach can be used well in one context, but less smoothly in another. Culture shapes what good care looks like. Quick “wind-check” can help
www.psychiatrictimes.com/view/culture-as-wind-adapting-re… -
PsychiatryLive
@Psychiatry_Live
Proactive ICU psychiatry reduces delirium, length of stay, and readmissions while advancing equity and value-based critical care. www.psychiatrictimes.com/view/racing-toward-the-fire-proa…
-
PsychiatryLive
@Psychiatry_Live
LB Pharmaceuticals has initiated the pivotal phase 3 NOVA-2 trial evaluating the efficacy and safety of LB-102 as a treatment for schizophrenia. @lb_pharma www.psychiatrictimes.com/view/new-pivotal-phase-3-trial-l…
-
PsychiatryLive
@Psychiatry_Live
Resort thrillers like HBO's "The White Lotus" glamorize hotel killings, but data reveals a quieter risk: planned suicides by local guests are much more common—and there are warning signs clinicians can spot. www.psychiatrictimes.com/view/hotel-homicide-hotel-suicid…
-
PsychiatryLive
@Psychiatry_Live
Grief and depression symptoms overlap clinically, but the context for understanding of the symptoms and pursuant management decisions make a world of difference. www.psychiatrictimes.com/view/what-constitutes-too-sad-ps…
-
PsychiatryLive
@Psychiatry_Live
🚨 Last chance for early bird savings 🚨
Join us at the SoCal Psych Conference, July 10–11 for expert insights & clinical updates in mental health.
⏳ Early bird ends March 31 — don’t miss out.
🔗 Register now: registration.gotoper.com/scpsych-26/home
#psychiatry #psychcme -
PsychiatryLive
@Psychiatry_Live
The @ASCPorg has released a consensus statement containing recommendations for the deprescribing of psychotropic medication. Learn more here: www.psychiatrictimes.com/view/deprescribing-recommendatio…
-
PsychiatryLive
@Psychiatry_Live
📚 Need something to read this weekend? The entire March issue of Psychiatric Times is now live on our website. Read it here: www.psychiatrictimes.com/journals/psychiatric-times/volum…
-
PsychiatryLive
@Psychiatry_Live
According to new data, BPL-003, mebufotenin benzoate nasal spray, showed reduced depressive symptoms and sustained response rates in patients with moderate to severe treatment-resistant depression. www.psychiatrictimes.com/view/bpl-003-nasal-spray-shows-q…
-
PsychiatryLive
@Psychiatry_Live
How are psychedelics are transforming the face of psychiatry as we know it? Guy Goodwin, MD, the chief medical officer at @COMPASSPathway, provided us with his thoughts: www.psychiatrictimes.com/view/dispelling-myths-about-psyc…
-
PsychiatryLive
@Psychiatry_Live
📝 Get your submissions in by March 31, 2026!
Submit to our writing contest on use of the PRiSM instrument for the opportunity to win publication in Psychiatric Times and a $500 prize. Guidelines here: www.psychiatrictimes.com/view/call-for-papers-on-use-of-t… -
PsychiatryLive
@Psychiatry_Live
Catatonia management typically involves 3 domains: targeting the syndrome of catatonia, addressing associated conditions or contributory substances, and preventing medical and functional complications.
www.psychiatrictimes.com/view/catatonia-where-we-are-and-… -
PsychiatryLive
@Psychiatry_Live
PTSD may not present in a prototypical manner and may become further exacerbated within different ethnic groups or communities that experience sustained violence and trauma, thus increasing the risk of underdiagnosis or misdiagnosis. www.psychiatrictimes.com/view/multilayered-trauma-one-pts…
-
PsychiatryLive reposted
Kevin Kunzmann
@NotADoctorKevin
New episode of #thehealthbeat!
I dive into the recently proposed changes to the DSM with Leah Kuntz of @PsychTimes, featuring expert perspective and excerpts from their latest cover story.
Watch the episode and subscribe to the show here: youtu.be/G26inWDTDzk -
PsychiatryLive reposted
Helus Pharma
@Helus_Pharma
No adjunctive pharmacologic treatment for generalized anxiety disorder (GAD) has ever been approved, and no new monotherapy has been approved in almost two decades.
@PsychTimes highlights our topline data for HLP004, an investigational therapy that was evaluated in a Phase 2 signal detection study in patients with GAD.
➡️ Read the article: shorturl.at/dny9w
📺 Watch our webcast: lnkd.in/esCJDpuB
$HELP -
PsychiatryLive
@Psychiatry_Live
New study findings suggest that 6 months of dialectical behavioral therapy are superior to SSRI treatment in reducing suicidal thoughts and behaviors and nonsuicidal self-injury in individuals with borderline personality disorder. www.psychiatrictimes.com/view/comparing-ssri-treatment-an…
-
PsychiatryLive
@Psychiatry_Live
Our March theme: Hormones & Psychiatry.
If you are interested in being featured in a future Special Report/print issue, submit to our content series! www.psychiatrictimes.com/view/presenting-our-march-2026-t… -
PsychiatryLive
@Psychiatry_Live
Early bird pricing for SoCal Psych is now available.
Join colleagues from across the region for two days of timely clinical insights, expert-led discussions, and practical takeaways you can bring back to your practice.
Register now: registration.gotoper.com/scpsych-26/home -
PsychiatryLive reposted
Awais Aftab
@awaisaftab
In the March cover story for Psychiatric Times (@PsychTimes ), I provide an overview of the proposed changes to the future DSM, accompanied by some personal commentary and suggestions of my own.
My suggestions revolve around the following points:
· Diagnostic Formulation Needs to Be Linked to Treatment
· The Missing Domain: Psychological Factors and Personality Traits
· DSM’s Notion of Dimensionality Is Underdeveloped
· Major Categories Should Not Become the New “Unspecified”
· The Definition of Disorder (and the Proposed Name Change)
· Indicate the Degree of Empirical Validation for Specific Diagnoses
· Explain Why Diagnostic Thresholds Are What They Are
· Include HiTOP in the DSM Appendix -
PsychiatryLive
@Psychiatry_Live
The March issue of Psychiatric Times is now live! This month, we take closer look at the future DSM and changes from previous editions.
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6/psychtimes/0be40de8906170b74… -
PsychiatryLive
@Psychiatry_Live
Weight bias can obscure eating disorders in all body sizes. This National Eating Disorder Awareness Week, learn more about evolving epidemiology, diagnostic challenges, and the importance of universal screening for eating disorders. www.psychiatrictimes.com/view/recognizing-eating-disorder…
-
PsychiatryLive
@Psychiatry_Live
"Relapse is an expected feature of illness, not a moral failure."
Learn more on why repeat psychiatric admissions persist and what care teams can do to break the cycle: www.psychiatrictimes.com/view/frequent-flyer-is-a-systemi… -
PsychiatryLive
@Psychiatry_Live
The "baby goose bonding theory" suggests MDMA reopens social plasticity, fostering trust and emotional openness, which are crucial for trauma integration and the reduction of PTSD symptoms. www.psychiatrictimes.com/view/breaking-trauma-mechanisms-…
-
PsychiatryLive
@Psychiatry_Live
During National Eating Disorder Awareness Week, we’re highlighting findings clinicians should be aware of, including the potential link between acne and eating disorder risk.
Read more: www.psychiatrictimes.com/view/acne-might-increase-eating-… -
PsychiatryLive
@Psychiatry_Live
The FDA has accepted the NDA for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of adults with schizophrenia. @tevapharm www.psychiatrictimes.com/view/nda-accepted-olanzapine-ext…
-
PsychiatryLive
@Psychiatry_Live
Psychedelic therapies surge in trials, but safety varies by substance—learn key benefits, risks, and why psychiatric history raises complications in our latest Special Report article: www.psychiatrictimes.com/view/adverse-events-and-psychede…
-
PsychiatryLive
@Psychiatry_Live
Mitigating the psychosocial, social, and physical harms of climate change requires not only addressing global temperature changes but confronting the longstanding social inequities that magnify its effects.
PsychiatryLive
@Psychiatry_Live
Read more in our latest Tales From the Clinic article: www.psychiatrictimes.com/view/forced-uprooting-effects-of…
-
PsychiatryLive
@Psychiatry_Live
Reality TV shows therapy and mental health diagnoses as entertainment—raising stigma, misinformation, and suicide concerns. Here's what psychiatrists and mental health clinicians need to know: www.psychiatrictimes.com/view/keeping-up-with-the-ketamin…
-
PsychiatryLive
@Psychiatry_Live
These researchers are currently evaluating the hypothesis that reducing stress and depression during pregnancy can also minimize cardiovascular health for the mother and her child. Learn more here: www.psychiatrictimes.com/view/depression-surrounding-preg…
-
PsychiatryLive
@Psychiatry_Live
Our February cover stories explore both sides of the discussion on antidepressant withdrawal. Read both stories in our interactive digital issue: indd.adobe.com/view/5e75daed-86f0-43ab-8dc3-eaa07d53856b
PsychiatryLive
@Psychiatry_Live
According to Nicolas Badre, David Cohen, and Camila Strassle, antidepressant withdrawal is more common and severe than previously acknowledged: www.psychiatrictimes.com/view/exiting-antidepressants-a-n…
PsychiatryLive
@Psychiatry_Live
According to Ronald Pies and Jonathan F. Henssler, antidepressant discontinuation can be averted by slow, careful, individualized tapering, and by avoiding short half-life agents: www.psychiatrictimes.com/view/antidepressant-withdrawal-s…
-
PsychiatryLive
@Psychiatry_Live
💤 The FDA has accepted a New Drug Application and granted Priority Review for Takeda's oveporexton for the treatment of narcolepsy type 1. www.psychiatrictimes.com/view/nda-accepted-and-priority-r…
-
PsychiatryLive
@Psychiatry_Live
💊The interactive February digital issue of Psychiatric Times is now live! This month, our exclusively-online issue puts a spotlight on antidepressant withdrawal.
Explore the issue now and follow along as articles are shared throughout the month. indd.adobe.com/view/5e75daed-86f0-43ab-8dc3-eaa07d53856b -
PsychiatryLive
@Psychiatry_Live
Women with both depression and anxiety demonstrated an approximately 78% increased risk of developing long COVID compared with women without these conditions. Learn more in this video: www.psychiatrictimes.com/view/depression-and-long-covid-o…
-
PsychiatryLive
@Psychiatry_Live
New data shows negative allosteric modulator targeting metabotropic glutamate receptor 7 may be transformative in treating anxiety and fear-related disorders such as PTSD. www.psychiatrictimes.com/view/data-supports-potential-of-…
-
PsychiatryLive
@Psychiatry_Live
According to an update from nonprofit @Active_Minds, there is now a push to place information about #988 on student ID cards for the very first time. Learn more about this news here: www.psychiatrictimes.com/view/a-new-era-of-mental-health-…
-
PsychiatryLive reposted
GW Integrative Medicine
@GWIntegrative
What we're reading: "Changes in Gut Microbiome May Be Connected to Alzheimer Disease and Mild Cognitive Impairment" from @PsychTimes, which interviewed @GWSMHS faculty @PhD_Leigh Frame and Alison Warren about their gut-brain-dementia connection research. www.psychiatrictimes.com/view/changes-in-gut-microbiome-m…
-
PsychiatryLive
@Psychiatry_Live
Our February theme: Bipolar Disorder.
If you are interested in being featured in a future print issue, submit to our content series! www.psychiatrictimes.com/view/presenting-our-february-202… -
PsychiatryLive
@Psychiatry_Live
Psychiatric and cardiovascular conditions frequently intersect. This #americanheartmonth, we highlight the importance of integrated assessment and management across specialties.
-
PsychiatryLive
@Psychiatry_Live
This #blackhistorymonth, we recognize the contributions of Black clinicians, researchers, and advocates—and reaffirm the importance of equity in mental health care.
-
PsychiatryLive
@Psychiatry_Live
ADHD symptoms may extend beyond inattention and impulsivity. Explore how executive dysfunction and emotional dysregulation affect patients and why addressing these challenges remains essential for improving outcomes. Read More: www.psychiatrictimes.com/view/recognizing-gaps-in-treatme… #sponsored
-
PsychiatryLive
@Psychiatry_Live
🚨Are you ready for a new DSM? The @APApsychiatric has released plans for a new edition of the DSM, one that aims to address the shortcomings and critiques of previous editions.
Learn more here: www.psychiatrictimes.com/view/a-new-and-improved-dsm-the-… -
PsychiatryLive
@Psychiatry_Live
The FDA has accepted for priority review @OtsukaUS's New Drug Application for centanafadine, an investigational, once-daily extended-release capsule for the treatment of ADHD in children, adolescents, and adults. www.psychiatrictimes.com/view/fda-accepts-nda-for-priorit…
-
PsychiatryLive
@Psychiatry_Live
A newly-initiated phase 2 study from @neurocrine will assess the safety, efficacy, and tolerability of NBI-1065890 in adults with tardive dyskinesia. www.psychiatrictimes.com/view/phase-2-study-initiated-for…
-
PsychiatryLive
@Psychiatry_Live
New phase 2 trial initiated: @lb_pharma has announced a study evaluating the efficacy and safety of LB-102 in patients with bipolar depression. www.psychiatrictimes.com/view/phase-2-trial-initiated-lb-…
-
PsychiatryLive
@Psychiatry_Live
Lifestyle psychiatry offers an evidence-based, low-risk, and cost-effective third pillar of care alongside psychotherapy and medication for major depressive disorder. Here's how lifestyle strategies can be integrated within a stepped care model. www.psychiatrictimes.com/view/lifestyle-psychiatry-for-su…
-
PsychiatryLive
@Psychiatry_Live
Nutrition discussions can offer valuable insight into patients’ emotional lives, identities, and daily routines. Eating behaviors often mirror underlying feelings, revealing patterns of avoidance, control, neglect, or care. www.psychiatrictimes.com/view/integrating-nutritional-gui…
-
PsychiatryLive
@Psychiatry_Live
For patients with schizophrenia spectrum disorders, even small amounts of physical activity (ie, less than 150 minutes of moderate to vigorous physical activity) may confer benefits. www.psychiatrictimes.com/view/physical-activity-as-a-trea…
-
PsychiatryLive
@Psychiatry_Live
❄️ Need some winter reading? The entire January issue of Psychiatric Times is now live on our website. Read it here: www.psychiatrictimes.com/journals/psychiatric-times/vol-4…
-
PsychiatryLive
@Psychiatry_Live
💰✂️On late Tuesday January 13, the government cut off approximately $2 billion in federal grant money for national mental health and addiction programs. Then, in a rapid reversal, they restored the money on Wednesday night. www.psychiatrictimes.com/view/mental-health-grants-cut-th…
-
PsychiatryLive
@Psychiatry_Live
💊@BioXcel_Tx has submitted a supplemental New Drug Application to the FDA for dexmedetomidine (Igalmi) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the outpatient setting. www.psychiatrictimes.com/view/snda-submission-igalmi-for-…
-
PsychiatryLive
@Psychiatry_Live
A new analysis of phase 3 data has found that lumateperone (Caplyta), in combination with an antidepressant, showed significantly greater remission rates in adults with major depressive disorder than placebo plus an antidepressant at 6 weeks. #acnp
www.psychiatrictimes.com/view/new-phase-3-data-analysis-l… -
PsychiatryLive
@Psychiatry_Live
The first patient has been dosed in @axsome's FORWARD phase 3 trial of esreboxetine (AXS-14) for the management of fibromyalgia. www.psychiatrictimes.com/view/first-patient-dose-in-phase…
-
PsychiatryLive
@Psychiatry_Live
🤖🧠 AI in health care offers precision in diagnosis and treatment, but raises ethical concerns regarding privacy and transparency. Let's demystify the mechanism behind the magic. www.psychiatrictimes.com/view/demystifying-artificial-int…
-
PsychiatryLive
@Psychiatry_Live
🚨💉The FDA has requested that drug application holders remove information regarding the risk of suicidal ideation and behavior from the labeling of GLP-1 RA medications, including liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound). www.psychiatrictimes.com/view/fda-issues-removal-of-suici…
-
PsychiatryLive
@Psychiatry_Live
🧠⚡ The FDA has approved @RelivionMG's ProlivRx, the first prescription, physician-directed, at-home brain neuromodulation therapy as an adjunctive treatment for adults with MDD. www.psychiatrictimes.com/view/fda-approves-prolivrx-first…
-
PsychiatryLive
@Psychiatry_Live
An independent Data Safety Monitoring Board review of the ongoing phase 3 clinical trial evaluating LPCN 1154 for the rapid relief treatment of postpartum depression recommended that the trial continue as planned with no modifications. www.psychiatrictimes.com/view/progress-report-second-inte…
-
PsychiatryLive
@Psychiatry_Live
Psychosis and epilepsy have a controversial and convoluted history.
Learn more about the most effective treatment strategies for affected patients. www.psychiatrictimes.com/view/it-s-not-normal-a-discussio… -
PsychiatryLive
@Psychiatry_Live
Elite athletes experience high rates of sleep disturbances, often requiring interventions beyond standard sleep hygiene.
Check out our latest CME article here: www.psychiatrictimes.com/view/acute-sleep-medications-for… -
PsychiatryLive
@Psychiatry_Live
New data: Explore clinical vocal and speech biomarker data from the RECOVER phase 3 clinical trial and the therapeutic potential of brilaroxazine for the treatment of schizophrenia. www.psychiatrictimes.com/view/new-phase-3-clinical-vocal-…
-
PsychiatryLive
@Psychiatry_Live
In case you missed it: The FDA has accepted the Investigational New Drug Application for @COMPASSPathway's COMP360 in the treatment of patients with PTSD. www.psychiatrictimes.com/view/fda-accepts-investigational…
-
PsychiatryLive
@Psychiatry_Live
The FDA has granted Breakthrough Therapy designation to Alkermes’ alixorexton for the treatment of narcolepsy type 1. www.psychiatrictimes.com/view/fda-grants-breakthrough-the…
-
PsychiatryLive
@Psychiatry_Live
Our January 2026 theme: Consultation Liaison Psychiatry.
If you are interested in being featured in a future Special Report/print issue, submit to our content series! www.psychiatrictimes.com/view/presenting-our-january-2026… -
PsychiatryLive
@Psychiatry_Live
The January 2026 issue of Psychiatric Times is now live! This month, we take closer look at what might be a new era of treatment for schizophrenia.
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6/psychtimes/4015687fd0420c434… -
PsychiatryLive
@Psychiatry_Live
🚨The FDA has granted Fast Track designation to ML-007C-MA, an investigational novel M1/M4 muscarinic agonist, for the treatment of hallucinations and delusions associated with Alzheimer disease psychosis. www.psychiatrictimes.com/view/fast-track-designation-gran…
-
PsychiatryLive
@Psychiatry_Live
BHV-7000 for the treatment of major depressive disorder failed to meet the primary endpoint in a phase 2 proof-of-concept study. www.psychiatrictimes.com/view/phase-2-proof-of-concept-st…
-
PsychiatryLive
@Psychiatry_Live
As the new year begins, we recognize the clinicians and professionals dedicated to advancing mental health care every day. Wishing you clarity, growth, and well-being in the year ahead. Happy New Year 💙✨
-
PsychiatryLive
@Psychiatry_Live
🌈Explore use of the innovative PRiSM diagnostic tool, bridging categorical and dimensional approaches to enhance psychiatric diagnosis and treatment. Then submit your experiences for the chance to win publication and $500! www.psychiatrictimes.com/view/bridging-the-categorical-di…
-
PsychiatryLive
@Psychiatry_Live
Earn CME credit before 2025 ends! Check out our latest CME here: www.psychiatrictimes.com/view/through-the-peaks-and-valle…
-
PsychiatryLive
@Psychiatry_Live
As we reflect on the year, we’re grateful for the compassion and commitment of the mental health community. Wishing you comfort, connection, and well-being this holiday season. Happy holidays. ❄️💙
-
PsychiatryLive
@Psychiatry_Live
Mirtazapine and duloxetine show significant efficacy in reducing negative symptoms of schizophrenia when used with antipsychotics. www.psychiatrictimes.com/view/antidepressants-assessed-fo…
-
PsychiatryLive
@Psychiatry_Live
Athletes face psychiatric disorders at rates comparable to the general population, with treatment options limited by WADA restrictions. Explore how transcranial magnetic stimulation enhances athletic performance and mental health. www.psychiatrictimes.com/view/transcranial-magnetic-stimu…
-
PsychiatryLive
@Psychiatry_Live
Analysis Insights: Learn how to critically analyze randomized controlled trials to ensure trustworthy results and improve clinical decision-making in mental health care. www.psychiatrictimes.com/view/analyzing-a-randomized-cont…
-
PsychiatryLive
@Psychiatry_Live
Explore the transformative impact of lifestyle psychiatry on mental health, emphasizing exercise, nutrition, and connectedness for improved well-being in our latest Special Report. www.psychiatrictimes.com/view/continuing-conversations-in…
-
PsychiatryLive
@Psychiatry_Live
Learn more about the important aspects of therapeutic drug monitoring of clozapine. Join expert Jonathan M. Meyer, MD, DLFAPA as he reviews TDM’s evidence‑based rationale, explores rapid‑testing technologies, and focuses on improving patient outcomes: www.psychiatrictimes.com/insights/exploring-therapeutic-d…
-
PsychiatryLive
@Psychiatry_Live
Psychiatric Times 2025 Wrapped is here.
From must-read articles to expert insights and conversations shaping mental health care—here’s a look at what resonated most with our audience this year.
Thank you for reading, watching, and learning with us 💙 -
PsychiatryLive
@Psychiatry_Live
The @afspnational has launched Clinical Approach to Preventing Suicide: An Introduction (CAPS), a 90-minute presentation that provides an overview of how to identify patients at risk for suicide, brief interventions, and treatment options. Read more here: www.psychiatrictimes.com/view/caps-a-new-program-to-suppo…
-
PsychiatryLive
@Psychiatry_Live
🚨NDA Submission: @tevapharm has submitted an NDA to the FDA for extended-release injectable olanzapine for the treatment of schizophrenia in adults. www.psychiatrictimes.com/view/nda-submission-olanzapine-e…
-
PsychiatryLive
@Psychiatry_Live
According to new positive phase 2 data, @ASX_IHL's PSX-001, a psilocybin-assisted psychotherapy treatment for generalized anxiety disorder, showed statistically significant and clinically meaningful improvements in patients with moderate to severe anxiety. www.psychiatrictimes.com/view/psychedelic-psx-001-for-gen…
-
PsychiatryLive
@Psychiatry_Live
❄️ The December issue of Psychiatric Times is now live! This month, we take closer look at the IV lorazepam shortage and the concept of psychopathology.
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6/psychtimes/380554b5a2e6ecc1b… -
PsychiatryLive
@Psychiatry_Live
Today is #givingtuesday2025 🫶
Check out this curated list of places where you can make a difference in psychiatry with your donations. www.psychiatrictimes.com/view/this-giving-tuesday-give-ba… -
PsychiatryLive
@Psychiatry_Live
Our December theme: 2025 Wrap Up.
What did you learn in 2025? What was the most important psychiatric advancement in 2025? Do you have practice tips to offer your fellow mental health clinicians? Share with us! www.psychiatrictimes.com/view/presenting-our-december-the… -
PsychiatryLive
@Psychiatry_Live
This season, we give thanks for the mental health professionals, researchers, and advocates who work tirelessly to support wellness and healing. 🦃💙
Wishing you peace and connection this Thanksgiving. -
PsychiatryLive
@Psychiatry_Live
Need CME credit? This holiday weekend, check out our latest CME article on the assessment and management of suicide risk in bipolar disorder: www.psychiatrictimes.com/view/through-the-peaks-and-valle…
-
PsychiatryLive
@Psychiatry_Live
Jail diversion programs reduce recidivism, improve health outcomes, and are cost-effective compared with traditional incarceration. www.psychiatrictimes.com/view/breaking-the-cycle-jail-div…
-
PsychiatryLive
@Psychiatry_Live
Free clozapine education modules for prescribers.
Focused. Practical. Expert-led.
Get answers to “When do I start?” and “How do I adjust?”
Featuring expert, Megan Ehret, PharmD, MS, BCPP, FAAPP
Sign up for updates ⬇️
🔗 sczaction.org/clozapine-curriculum/?hss_channel=tw-21098119
#clozapine #psychiatry -
PsychiatryLive
@Psychiatry_Live
The FDA has granted a label expansion for the deep transcranial magnetic stimulation system that makes the treatment available as an adjunct therapy for adolescents aged 15 to 21 years who have major depressive disorder. www.psychiatrictimes.com/view/fda-clears-deep-transcrania…
-
PsychiatryLive
@Psychiatry_Live
Placebo treatments can yield clinically meaningful improvements across psychiatric disorders. A new study found the strongest effects in depression and anxiety, and the weakest effects seen in schizophrenia and OCD. www.psychiatrictimes.com/view/placebo-response-rates-vary…
-
PsychiatryLive
@Psychiatry_Live
In the Vibrance-2 study, once-daily alixorexton met the dual primary endpoints, demonstrating statistically significant and clinically meaningful improvements from baseline compared with placebo at week 8. www.psychiatrictimes.com/view/alixorexton-for-treatment-o…
-
PsychiatryLive
@Psychiatry_Live
Mentalization-based treatment for narcissism recommends a step-by-step trajectory of interventions, organized around the different types of mentalizing. Learn more in one of our November cover stories: www.psychiatrictimes.com/view/mentalization-based-treatme…
-
PsychiatryLive
@Psychiatry_Live
On #veteransday, we honor those who have served—and recognize the ongoing importance of supporting veterans’ mental health.
Together, we can continue advancing understanding, treatment, and care for those who have sacrificed for us all.
#mentalhealthawareness #psychiatry -
PsychiatryLive
@Psychiatry_Live
New positive phase 2b open-label extension study results from @ataibeckley for BPL-003 showed sustained antidepressant effects in patients with treatment-resistant depression after redosing. www.psychiatrictimes.com/view/bpl-003-positive-phase-2b-o…
-
PsychiatryLive
@Psychiatry_Live
📢 CALL FOR PAPERS: Submit articles, 1000 to 1800 words in length, on use of the PRiSM instrument in research or clinical practice by January 31, 2026. See full guidelines here: www.psychiatrictimes.com/view/call-for-papers-on-use-of-t…
-
PsychiatryLive
@Psychiatry_Live
What increases the risk for ADHD?
Panelists examine the genetic, environmental, and socioeconomic factors that shape ADHD risk and what clinicians need to know. Watch now: www.psychiatrictimes.com/clinical-case-collective/navigat… -
PsychiatryLive
@Psychiatry_Live
The FDA has approved lumateprone (Caplyta) as an adjunctive therapy for the treatment of adults with major depressive disorder. @JNJNews www.psychiatrictimes.com/view/fda-approves-caplyta-for-ad…
-
PsychiatryLive
@Psychiatry_Live
The Stuttering Treatment and Research Society (STARS) is advancing neuroscience-based research to reshape how we understand and treat stuttering—reducing stigma and improving access to care through collaboration in psychiatry, neurology, and speech-language pathology.
-
PsychiatryLive
@Psychiatry_Live
🚨New supplemental NDA submitted to the FDA: dextromethorphan-bupropion (AXS-05) for the treatment of Alzheimer disease agitation. www.psychiatrictimes.com/view/snda-submitted-for-axs-05-f…
-
PsychiatryLive
@Psychiatry_Live
Our November theme: Best Practices.
If you are interested in potentially being featured in our print issue, submit to our content series! www.psychiatrictimes.com/view/presenting-our-november-the… -
PsychiatryLive
@Psychiatry_Live
🎃 Happy Halloween! Explore the psychological meanings behind Halloween symbols, from ghosts to jack-o'-lanterns. www.psychiatrictimes.com/view/halloween-symbols-and-their…
-
PsychiatryLive
@Psychiatry_Live
🚨FDA Update: Successful FDA feedback meeting for @nutriband and the abuse deterrent fentanyl patch for pain management in patients with opiate tolerance who require daily and constant long term opiate treatment. www.psychiatrictimes.com/view/positive-fda-meeting-for-ab…
-
PsychiatryLive
@Psychiatry_Live
Today is #worldstrokeday.
Understanding what lies ahead in the road to stroke recovery can help patients and their families prepare for the challenges they will face. Learn more here: www.psychiatrictimes.com/view/beyond-survival-understandi… -
PsychiatryLive
@Psychiatry_Live
According to new positive phase 3 results, CTx-1301 for the treatment of pediatric ADHD delivered rapid onset of effect and sustained efficacy through the evening hours. www.psychiatrictimes.com/view/positive-phase-3-results-ct…
-
PsychiatryLive
@Psychiatry_Live
Catatonia can present with overlapping symptoms of other neuropsychiatric conditions, complicating diagnosis and treatment, especially in critical care settings. www.psychiatrictimes.com/view/a-critical-catch-catatonia-…
-
PsychiatryLive
@Psychiatry_Live
🗞️Need weekend reading? The entire October issue of Psychiatric Times is now live on our website. Read it here: www.psychiatrictimes.com/journals/psychiatric-times/vol-4…
-
PsychiatryLive
@Psychiatry_Live
Creative patients often experience loneliness, which can be both a challenge and a source of inspiration. How can you as a clinician help them reframe the meaning of their experience in terms of solitude? www.psychiatrictimes.com/view/loneliness-meet-solitude
-
PsychiatryLive
@Psychiatry_Live
A recent study reveals that the choice of initial antipsychotic significantly impacts long-term weight gain over 5 years. www.psychiatrictimes.com/view/can-the-initial-antipsychot…
-
PsychiatryLive
@Psychiatry_Live
Insomnia in older adults is linked to accelerated aging and various medical conditions, with nearly 50% reporting sleep issues and 20% meeting insomnia disorder criteria. www.psychiatrictimes.com/view/insomnia-in-older-adults-a-…
-
PsychiatryLive
@Psychiatry_Live
Learn more about the historical and clinical features commonly used clinically to distinguish dementia from intoxication/withdrawal syndromes and to differentiate among the most common dementia syndromes. www.psychiatrictimes.com/view/precision-diagnosis-the-new…
-
PsychiatryLive
@Psychiatry_Live
Pediatricians are on the front lines of ADHD care.
Hear experts discuss their essential role—and the challenges they face—in diagnosis and long-term management. Tune in to the full discussion here: www.psychiatrictimes.com/clinical-case-collective/navigat… -
PsychiatryLive
@Psychiatry_Live
New analysis reveals that the 40 mg dose of once-daily Ingrezza capsules experienced clinically meaningful improvements in tardive dyskinesia symptoms. www.psychiatrictimes.com/view/new-post-hoc-analysis-ingre…
-
PsychiatryLive
@Psychiatry_Live
According to Jennifer L. Payne, MD, women are being subtly and not so subtly encouraged to ignore their own needs in favor of having a pregnancy that is not exposed to any medications, leading to worse physical and mental health outcomes. www.psychiatrictimes.com/view/treating-mental-illness-dur…
-
PsychiatryLive
@Psychiatry_Live
New research reveals that benzodiazepines and antipsychotics increase mortality risk in hospice patients with Alzheimer disease and dementia. www.psychiatrictimes.com/view/increased-risk-of-death-in-…
-
PsychiatryLive
@Psychiatry_Live
The FDA has accepted for review the New Drug Application for dexmethylphenidate (CTx-1301), Cingulate’s lead candidate for the treatment of ADHD in children and adults. www.psychiatrictimes.com/view/fda-accepts-nda-for-ctx-130…
-
PsychiatryLive reposted
MUSC Department of Psychiatry & Behavioral Science @MUSCpsychiatry
We are proud to share that Dr. Julia Rodes, a fourth-year psychiatry resident at MUSC, was featured in @PsychTimes to discuss integrative approaches to chronic pain, advocacy, and her personal journey as a clinician living with chronic pain.
Watch here: www.psychiatrictimes.com//view/chronic-pain-and-personal-… -
PsychiatryLive
@Psychiatry_Live
Women are diagnosed with ADHD approximately 5 years later than men, despite symptoms appearing at the same age, according to new research. www.psychiatrictimes.com/view/women-are-diagnosed-with-ad…
-
PsychiatryLive
@Psychiatry_Live
Mental health care changes lives—and so do the clinicians behind it. 💚🌍
On #worldmentalhealthday, we’re reminded that progress in psychiatry means progress for every patient, family, and community.
#mentalhealthawareness #mentalhealth -
PsychiatryLive
@Psychiatry_Live
Investigators have discovered a new nanotechnological device for the treatment and prevention of neuropsychiatric and neurodegenerative diseases: lithium-loaded gold nanoparticles in the form of a nasal spray that delivers treatment directly to the brain. www.psychiatrictimes.com/view/lithium-loaded-gold-nanopar…
-
PsychiatryLive
@Psychiatry_Live
The October issue of Psychiatric Times is now live! This month, we take closer look at the new INTEGRATE guidelines for the treatment of schizophrenia.
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6/psychtimes/2d3f23bc5f744c394… -
PsychiatryLive
@Psychiatry_Live
🌟Our website has a brand new look! Check out the elevated design, easier navigation, and new Shorts feature—with quick, digestible insights for busy psychiatric clinicians. We are so proud to offer this digital experience as part of our 40th anniversary! www.psychiatrictimes.com
-
PsychiatryLive
@Psychiatry_Live
The newly published International Guidelines for Algorithmic Treatment (INTEGRATE) represent an international effort to standardize schizophrenia care. How do they differ from typical practice? Learn more here: www.psychiatrictimes.com/view/closing-the-gap-in-schizoph…
-
PsychiatryLive
@Psychiatry_Live
A new study reveals the Reversal of Cognitive Decline program significantly reduces depression in patients with cognitive impairment, enhancing both mood and cognitive health. www.psychiatrictimes.com/view/reduced-depression-in-patie…
-
PsychiatryLive
@Psychiatry_Live
Movement disorders are categorized into hyperkinetic and bradykinetic based on their clinical presentation, but distinct clinical entities often have features of both.
🧠 Check out our latest CME article to learn more: www.psychiatrictimes.com/view/movement-disorders-in-psych… -
PsychiatryLive
@Psychiatry_Live
Reproductive psychiatrist Sarah Oreck, MD, MS challenges the claims linking acetaminophen use in pregnancy to autism and ADHD. www.psychiatrictimes.com/view/acetaminophen-use-during-pr…
-
PsychiatryLive
@Psychiatry_Live
Cognitive function is uniquely important in late-life depression, with at least 50% of patients experiencing decline. www.psychiatrictimes.com/view/addressing-cognition-in-lat…
-
PsychiatryLive
@Psychiatry_Live
🚨 BREAKING NEWS: The FDA has granted Fast Track Designation to BMS-986446, a potential best-in-class anti-microtubule binding region-tau antibody in phase 2 development for the treatment of early #alzheimer disease.
Read more here: www.psychiatrictimes.com/view/bms-986446-granted-fast-tra… -
PsychiatryLive
@Psychiatry_Live
Our October theme: Lifestyle Psychiatry.
If you are interested in being featured in a future Special Report/print issue, submit to our content series! www.psychiatrictimes.com/view/presenting-our-october-them… -
PsychiatryLive
@Psychiatry_Live
The ongoing pivotal phase 3 clinical trial evaluating oral brexanolone (LPCN 1154) for the treatment of postpartum depression is on track, with one-third of planned participants randomly assigned. @LipocineInc www.psychiatrictimes.com/view/progress-update-lpcn-1154-f…
-
PsychiatryLive
@Psychiatry_Live
According to new phase 3 data, seltorexant showed comparable efficacy to quetiapine XR as an adjunctive treatment for major depressive disorder with insomnia symptoms. Andrew J. Cutler, MD, shares his thoughts on the latest data: www.psychiatrictimes.com/view/insights-on-seltorexant-as-…
-
PsychiatryLive
@Psychiatry_Live
An ADHD diagnosis can be both challenging and clarifying. It can impact family dynamics, daily life, and long-term outcomes, from school performance to driving safety. Watch the expert-led conversation: www.psychiatrictimes.com/clinical-case-collective/navigat…
-
PsychiatryLive
@Psychiatry_Live
In this phase 2 MINDFuL trial, XPro demonstrated consistent positive trends across cognitive, neuropsychiatric, and biological endpoints in patients with early Alzheimer disease with inflammation, despite not meeting the trial's primary endpoint. www.psychiatrictimes.com/view/xpro1595-in-early-alzheimer…
-
PsychiatryLive
@Psychiatry_Live
Polypharmacy and potentially inappropriate medication use is associated with adverse drug events, increased health care use, and greater health care costs. These risks are increased for adults 65 years and older. www.psychiatrictimes.com/view/deprescribing-in-older-adul…
-
PsychiatryLive
@Psychiatry_Live
Hetlioz showed significant improvement in sleep latency in a phase 3 study for insomnia from @vandapharma, with effects persisting throughout the study duration. www.psychiatrictimes.com/view/phase-3-results-hetlioz-imp…
-
PsychiatryLive
@Psychiatry_Live
New topline results for SYT-510, a first-in-class inhibitor that modulates a newly identified drug target in the endocannabinoid system that helps restore healthy brain functions. Read more here: www.psychiatrictimes.com/view/syt-510-first-in-class-inhi…
-
PsychiatryLive
@Psychiatry_Live
Apathy, defined as a quantitative reduction in goal-directed activity compared with a patient’s previous functioning, is highly prevalent and pervasive in patients with cognitive impairment. www.psychiatrictimes.com/view/time-to-care-about-apathy-a…
-
PsychiatryLive
@Psychiatry_Live
Neuroplastic symptoms: real, physical symptoms (ie, not to be confused with malingering or factitious symptoms) caused by neuroplasticity in the brain rather than damage, disease, or dysfunction in the body. Learn more in our latest Special Report article: www.psychiatrictimes.com/view/new-hope-for-older-adults-w…
-
PsychiatryLive
@Psychiatry_Live
The FDA has granted an expansion of the currently cleared treatment protocols for @BrainsWay deep transcranial magnetic stimulation to include accelerated protocol for patients with major depressive disorder and comorbid symptoms of anxiety. www.psychiatrictimes.com/view/fda-clears-accelerated-prot…
-
PsychiatryLive
@Psychiatry_Live
In the second installment of his new video series, "Brain Trust: Conversations in Psychopharmacology," Joseph Goldberg sits down with Roger McIntyre to discuss the "truly transformative" power of GLP-1s in psychiatry.
Watch the whole video here: www.psychiatrictimes.com/view/a-better-understanding-of-g… -
PsychiatryLive
@Psychiatry_Live
Today, we remember the tragic events of September 11, 2001. Beyond the immeasurable loss, many continue to carry the psychological impact of that day. As we honor the lives lost, let us also recognize the importance of supporting mental health in the face of trauma. #neverforget
-
PsychiatryLive
@Psychiatry_Live
Today on #worldsuicidepreventionday, we honor those affected and work to reduce stigma 💙 Explore our articles on suicide prevention and mental health resources. If you’re struggling, call or text 988 for the Suicide & Crisis Lifeline.
🕊️You are not alone. -
PsychiatryLive
@Psychiatry_Live
In recognition of #worldsuicidepreventionday, we sat down with @cmoutierMD of @afspnational to discuss changing the narrative on suicide prevention. How can we best prevent suicides and support patients? Read more here: www.psychiatrictimes.com/view/changing-the-narrative-on-s…
-
PsychiatryLive
@Psychiatry_Live
Today is #worldsuicidepreventionday. Media training is essential for psychiatrists to counteract misinformation and enhance suicide prevention efforts, shares @DrMirhom.
www.psychiatrictimes.com/view/is-media-training-suicide-p… -
PsychiatryLive
@Psychiatry_Live
Theta-band responses, especially theta-band inter-trial coherence, effectively differentiate patients with schizophrenia from healthy controls, validating their use as biomarkers for cognitive impairment. @AltoNeuro www.psychiatrictimes.com/view/theta-band-responses-the-ee…
-
PsychiatryLive
@Psychiatry_Live
The FDA has approved @AmnealPharma risperidone extended-release injectable suspension, an atypical antipsychotic for treatment of schizophrenia and maintenance of bipolar 1 disorder. www.psychiatrictimes.com/view/fda-approves-risperidone-ex…
-
PsychiatryLive
@Psychiatry_Live
New data from clinical trials RELIEF and RESILIENT shows that Tonmya for the treatment of fibromyalgia provided significant pain reduction and has favorable tolerability. Learn more here: www.psychiatrictimes.com/view/new-clinical-data-on-tonmya…
-
PsychiatryLive
@Psychiatry_Live
Diagnosing ADHD isn’t always straightforward. Hear how experts tackle key challenges, like ruling out other conditions and using tools such as the Vanderbilt and Conners scales to guide evaluation. Watch the episode: www.psychiatrictimes.com/view/challenges-in-diagnosing-ad…
-
PsychiatryLive
@Psychiatry_Live
The September issue of Psychiatric Times is now live! This month, we examine the impact of cannabis use on older adults.
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6/psychtimes/a90be77e5d755b041… -
PsychiatryLive
@Psychiatry_Live
Neuphoria Therapeutics today announced the achievement of target enrollment of the AFFIRM-1 phase 3 trial that will evaluate the lead candidate BNC-210 as a first-in-class, acute, as-needed, fast-acting treatment for social anxiety disorder. www.psychiatrictimes.com/view/target-enrollment-completed…
-
PsychiatryLive
@Psychiatry_Live
The FDA has accepted a New Drug Application for cytisinicline for smoking cessation in adults. @achievelifesci www.psychiatrictimes.com/view/fda-accepts-new-drug-applic…
-
PsychiatryLive
@Psychiatry_Live
Our September theme: Diagnosis Dilemmas.
If you are interested in being featured in a future Special Report/print issue, submit to our content series! www.psychiatrictimes.com/view/presenting-our-september-th… -
PsychiatryLive
@Psychiatry_Live
The @APApsychiatric has published the updated comprehensive "Practice Guideline for the Prevention and Treatment of Delirium," which provides evidence-based recommendations to improve the detection, prevention, and treatment of delirium. www.psychiatrictimes.com/view/apa-publishes-comprehensive…
-
PsychiatryLive
@Psychiatry_Live
In case you missed the news, the FDA has approved the lecanemab (Leqembi) self-administered injection for maintenance treatment of Alzheimer disease in patients with mild cognitive impairment or mild dementia.
Read more here: www.psychiatrictimes.com/view/fda-approves-leqembi-for-at… -
PsychiatryLive
@Psychiatry_Live
This Labor Day, we recognize the tireless work of mental health professionals supporting patient well-being 🧠💚. Thank you for all you do. #laborday
-
PsychiatryLive
@Psychiatry_Live
Explore MDD strategies in our Clinical Consult series. #ad For psychiatrists, NPs, and advanced practice clinicians. Watch here: www.psychiatrictimes.com/clinical-consult/understanding-t… #psychiatrictimes #clinicalconsult #majordepressivedisorder
-
PsychiatryLive
@Psychiatry_Live
A new mobile app has been shown to reduce suicidal behavior among high-risk psychiatric inpatients: OTX-202 reduced the recurrence of post-discharge suicide attempts by 58.3% for patients with a prior suicide attempt. www.psychiatrictimes.com/view/new-digital-intervention-fo…
-
PsychiatryLive
@Psychiatry_Live
Cognitive symptoms often precede formal schizophrenia diagnosis. Early identification and intervention, including cognitive remediation and lifestyle changes, are crucial for improving outcomes. www.psychiatrictimes.com/view/assessing-cognitive-dysfunc…
-
PsychiatryLive
@Psychiatry_Live
Experts break down the diagnostic thresholds and explore why inattentive presentations, especially in girls and high-achieving students, are often overlooked. Learn more about accurate identification and evolving insights into ADHD with this series: www.psychiatrictimes.com/clinical-case-collective/navigat…
-
PsychiatryLive
@Psychiatry_Live
Joy Baker, Elizabeth Johnson, APRN, Dr. Alison Reminick & Dr. Kelly Devine Arch share how to boost clinical awareness of postpartum depression, improve diagnosis & treatment, and support patient self-advocacy.
Watch here: www.psychiatrictimes.com/peer-exchange/clinical-recogniti… -
PsychiatryLive
@Psychiatry_Live
BioXcel Therapeutics today announced that the SERENITY At-Home pivotal phase 3 trial evaluating the safety of BXCL501, an acute treatment for agitation associated with bipolar disorders or schizophrenia in the at-home setting, met its primary endpoint. www.psychiatrictimes.com/view/primary-endpoint-of-phase-3…
-
PsychiatryLive
@Psychiatry_Live
The entire August issue of Psychiatric Times—exploring the management obesity and metabolic dysfunction in schizophrenia, issues in diversity, spirituality and psychiatry, and more—is now live on our website. Read it here: www.psychiatrictimes.com/journals/psychiatric-times/vol-4…
-
PsychiatryLive
@Psychiatry_Live
New positive phase 2 data on PSX-001, a psilocybin-assisted psychotherapy treatment for generalized anxiety disorder: Participants treated with PSX-001 achieved statistically significant and clinically meaningful improvements across every key endpoint. www.psychiatrictimes.com/view/positive-phase-2-results-ps…
-
PsychiatryLive
@Psychiatry_Live
Leqembi for the treatment of Alzheimer disease has been launched in Austria on August 25, 2025, and will be launched in Germany on September 1, 2025—the first launches in the European Union. www.psychiatrictimes.com/view/leqembi-for-alzheimer-disea…
-
PsychiatryLive
@Psychiatry_Live
Neuropsychiatric symptoms often precede motor symptoms in Huntington disease, requiring early identification and management by psychiatric clinicians. www.psychiatrictimes.com/view/huntington-disease-recogniz…
-
PsychiatryLive
@Psychiatry_Live
What should the FDA expert panel on SSRIs and pregnancy have discussed? Experts weigh in on this subject in our latest video series: www.psychiatrictimes.com/view/getting-to-the-truth-about-…
-
PsychiatryLive
@Psychiatry_Live
Antidepressant treatment for late-life depression may improve cognitive domains such as memory, learning, and processing speed, with improvements potentially linked to reductions in depressive symptoms. www.psychiatrictimes.com/view/cognitive-effects-of-antide…
-
PsychiatryLive
@Psychiatry_Live
Nearly half of catatonia patients relapse within 2 years. Recent research underscores the importance of early maintenance treatment and suggests antipsychotics may protect against catatonia relapse. www.psychiatrictimes.com/view/risk-factors-for-catatonia-…
-
PsychiatryLive
@Psychiatry_Live
One clinician shares her thoughts on SSRIs in pregnancy: "No physician disputes the importance of carefully weighing risks when prescribing any medications in pregnancy. But these decisions must be based on science—not fear, stigma, or ideology."
www.psychiatrictimes.com/view/maternal-health-is-fetal-he… -
PsychiatryLive
@Psychiatry_Live
The FDA has granted Fast Track designation to pemvidutide for the treatment of alcohol use disorder. www.psychiatrictimes.com/view/fda-grants-fast-track-desig…
-
PsychiatryLive
@Psychiatry_Live
AI chatbots pose significant mental health risks, often exacerbating issues like suicide, self-harm, and delusions. Learn more from @AllenFrancesMD. www.psychiatrictimes.com/view/preliminary-report-on-chatb…
-
PsychiatryLive
@Psychiatry_Live
BXCL501 for the treatment of agitation associated with bipolar disorders or schizophrenia received positive pre-sNDA meeting comments from the FDA. @BioXcel_Tx www.psychiatrictimes.com/view/bxcl501-for-agitation-assoc…
-
PsychiatryLive
@Psychiatry_Live
In his brand new video series, "Brain Trust: Conversations in Psychopharmacology," Joseph Goldberg, MD, sits down with Marlene Freeman, MD, to discuss the treatment of depression, SSRIs, and pregnancy.
Watch the whole video here: www.psychiatrictimes.com/view/getting-to-the-truth-about-… -
PsychiatryLive
@Psychiatry_Live
Major Depressive Disorder (#mdd) affects everyone differently. Leslie
Citrome, MD, shares insights on symptoms, TESD, and speed of
processing in MDD. Watch now: www.psychiatrictimes.com/expert-perspectives/navigating-t…
PAID CONTENT FROM TAKEDA PHARMACEUTICALS. -
PsychiatryLive
@Psychiatry_Live
The FDA has approved ketamine product KETARx from @Pharmather_Inc for the management of surgical pain. www.psychiatrictimes.com/view/fda-approves-ketarx-for-man…
-
PsychiatryLive
@Psychiatry_Live
The FDA has granted Fast Track designation to NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression. www.psychiatrictimes.com/view/fda-fast-track-designation-…
-
PsychiatryLive
@Psychiatry_Live
The FDA has granted a Type C Meeting for Aversa fentanyl, which has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. www.psychiatrictimes.com/view/fda-grants-type-c-meeting-f…
-
PsychiatryLive
@Psychiatry_Live
CT-155, an investigational prescription digital therapeutic, reduced negative symptoms in schizophrenia when combined with standard antipsychotic therapy. www.psychiatrictimes.com/view/investigational-prescriptio…
-
PsychiatryLive
@Psychiatry_Live
Adial Pharmaceuticals today announced the completion of a successful end of phase 2 meeting with the FDA, in which the FDA provided input into the AD04 phase 3 adaptive design clinical trial and the overall clinical program. @AdialPharma www.psychiatrictimes.com/view/end-of-phase-2-meeting-with…
-
PsychiatryLive
@Psychiatry_Live
In this expert-led discussion, panelists explore the case of a 10-year-old boy with combined presentation ADHD. Learn how symptoms manifest across settings, why family history matters, and what to watch for in diagnosis and care. www.psychiatrictimes.com/clinical-case-collective/navigat…
-
PsychiatryLive
@Psychiatry_Live
The Benzodiazepine Wars: Are benzodiazepines good or bad? Which side are you on?
Join the discussion in the latest "Affirming Psychiatry" column: www.psychiatrictimes.com/view/will-the-benzodiazepine-war… -
PsychiatryLive
@Psychiatry_Live
The August issue of Psychiatric Times is now live! This month, we take closer look at metabolic health for schizophrenia.
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6/psychtimes/08d55964d3d89c943… -
PsychiatryLive reposted
Oxford Academic
@OUPAcademic
Don't miss @psychunseen's preview of 'False' over at @PsychTimes : oxford.ly/4oapavj
-
PsychiatryLive
@Psychiatry_Live
Our August theme: ADHD.
If you are interested in being featured in a future Special Report/print issue, submit to our content series! www.psychiatrictimes.com/view/presenting-our-august-theme… -
PsychiatryLive
@Psychiatry_Live
The entire July issue of Psychiatric Times—exploring GLP-1 receptor agonists, borderline personality disorder, the renewed interest in psychotherapy, and more—is now live on our website. Read it here: www.psychiatrictimes.com/journals/psychiatric-times/vol-4…
-
PsychiatryLive
@Psychiatry_Live
The FDA has cleared the IND application for Ketamir-2, a promising oral treatment for neuropathic pain, which has shown superior efficacy and safety in preclinical studies. www.psychiatrictimes.com/view/fda-clearance-of-ind-for-ke…
-
PsychiatryLive reposted
Mount Sinai Psychiatry
@MountSinaiPsych
Tom Hildebrandt, PsyD, explains how hormonal differences influence the development of bulimia nervosa and binge eating disorder, revealing potential biomarkers and treatment strategies. via @PsychTimes
www.psychiatrictimes.com/view/sex-hormones-as-biomarkers-… -
PsychiatryLive
@Psychiatry_Live
Cingulate secures a $4.3 million PDUFA fee waiver from the FDA for its innovative ADHD treatment, CTx-1301. @CingulateInc www.psychiatrictimes.com/view/cingulate-receives-4-3-mill…
-
PsychiatryLive
@Psychiatry_Live
Valproic acid is effective for epilepsy and bipolar disorder but poses significant teratogenic risks during pregnancy, including major congenital malformations and neurodevelopmental disorders. www.psychiatrictimes.com/view/valproic-acid-during-pregna…
-
PsychiatryLive
@Psychiatry_Live
What cascade of factors can lead to a "difficult" or treatment-resistant patient? Integrating psychodynamic skills with biomedical approaches can improve outcomes for these patients. www.psychiatrictimes.com/view/psychodynamic-therapy-and-t…
-
PsychiatryLive
@Psychiatry_Live
Need CME Credit? Learn more about best practices in prescribing monoamine oxidase inhibitors for the treatment of major depressive disorder in this month's CME article! www.psychiatrictimes.com/view/successfully-prescribing-ma…
-
PsychiatryLive
@Psychiatry_Live
According to positive topline results from the LunAIRo study, participants treated with AD109, the first oral pill for obstructive sleep apnea, saw clinically meaningful and statistically significant reductions in airway obstruction at 26 weeks. www.psychiatrictimes.com/view/positive-topline-results-fr…
-
PsychiatryLive
@Psychiatry_Live
New positive phase 2 results from @Alkermes show that treatment with alixorexton led to statistically significant and dose-dependent improvements in sleep latency among patients with narcolepsy type 1. www.psychiatrictimes.com/view/positive-phase-2-data-alixo…
-
PsychiatryLive
@Psychiatry_Live
BioXcel Therapeutics has submitted a pre-supplemental New Drug Application meeting package to the FDA for Igalmi in support of a label expansion for outpatient use for the acute treatment of agitation associated with bipolar disorders or schizophrenia. www.psychiatrictimes.com/view/potential-label-expansion-f…
-
PsychiatryLive
@Psychiatry_Live
The FDA advisory committee is currently meeting to discuss the sNDA for brexpiprazole (Rexulti) tablets in combination with sertraline for the treatment of adults with PTSD. Psychiatric Times will provide all the latest updates: www.psychiatrictimes.com/topics/drug-watch
Post not available here, view on X
PsychiatryLive
@Psychiatry_Live
"Is study 61 enough to overcome study 72? We are here today because these are difficult questions."
PsychiatryLive
@Psychiatry_Live
The FDA Advisory Committee has voted against recommending brexpiprazole plus sertraline for PTSD. www.psychiatrictimes.com/view/fda-advisory-committee-vote…
-
PsychiatryLive
@Psychiatry_Live
There is no one-size-fits-all approach to treating Major Depressive
Disorder (#mdd). Watch now as Leslie Citrome, MD, delves into
Treatment-Emergent Sexual Dysfunction (TESD): www.psychiatrictimes.com/expert-perspectives/navigating-t…
PAID CONTENT FROM TAKEDA PHARMACEUTICALS. -
PsychiatryLive
@Psychiatry_Live
Seaport Therapeutics just announced that the first patient has been dosed in the phase 2b BUOY-1 study of GlyphAllo in major depressive disorder with or without anxious distress. If successful, GlyphAllo could be a first-in-class treatment. www.psychiatrictimes.com/view/first-patient-dosed-in-phas…
-
PsychiatryLive
@Psychiatry_Live
Serum drug levels offer essential insights into medication efficacy and patient responsiveness. Learn more in this month's editorial. www.psychiatrictimes.com/view/using-serum-drug-levels
-
PsychiatryLive
@Psychiatry_Live
The FDA has granted Breakthrough Therapy designation to Transcend Therapeutics for their compound TSND-201 (methylone) for the treatment of PTSD. www.psychiatrictimes.com/view/tsnd-201-receives-breakthro…
-
PsychiatryLive
@Psychiatry_Live
Johnson & Johnson has submitted an sNDA to the FDA based upon long-term data evaluating the safety and efficacy of lumateperone (Caplyta) for the prevention of relapse in schizophrenia. www.psychiatrictimes.com/view/snda-submitted-lumateperone…
-
PsychiatryLive
@Psychiatry_Live
Check out all the updates in the psychiatric treatment pipeline from 2025 Quarter 2! www.psychiatrictimes.com/view/the-psychiatric-pipeline-in…
-
PsychiatryLive
@Psychiatry_Live
The July issue of Psychiatric Times is now live! This month, we take closer look at GLP-1 receptor agonists for the treatment of mental disorders.
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6/psychtimes/c3b09480141aa4241… -
PsychiatryLive
@Psychiatry_Live
Wishing you a safe and reflective Fourth of July! ❤️🤍💙
As we honor resilience and freedom today, we’re also reminded of the importance of protecting mental health: for ourselves, our patients, and our communities.
#fourthofjuly #independenceday -
PsychiatryLive
@Psychiatry_Live
Happy July 4th! 🇺🇸 As we celebrate the nation's birthday, let's remember the values that unite us and stand together to improve mental health care for all.
-
PsychiatryLive
@Psychiatry_Live
According to new research, ketamine can be safely used in patients with active eating disorders, even with severe malnutrition, in a controlled environment. www.psychiatrictimes.com/view/ketamine-safe-for-the-treat…
-
PsychiatryLive
@Psychiatry_Live
What constitutes a sleep disorder? Our Sleep Special Report authors developed an account of what constitutes a sleep disorder based on the harmful dysfunction analysis. www.psychiatrictimes.com/view/what-is-a-sleep-disorder-a-…
-
PsychiatryLive
@Psychiatry_Live
Our July theme: Geriatric Psychiatry.
If you are interested in being featured in a future Special Report/print issue, submit to our content series!
www.psychiatrictimes.com/view/presenting-our-july-theme-g… -
PsychiatryLive
@Psychiatry_Live
According to positive topline phase 2b clinical trial results, BPL-003 demonstrated rapid, robust, and durable antidepressant effects in patients with treatment-resistant depression with just a single dose. @atai_life @BeckleyPsytech
www.psychiatrictimes.com/view/positive-results-from-the-p… -
PsychiatryLive
@Psychiatry_Live
The FDA today announced it is revising the label of all extended-release stimulants indicated to treat ADHD to warn about the risk of weight loss and other adverse effects in patients younger than 6 years of age. www.psychiatrictimes.com/view/fda-requires-new-label-warn…
-
PsychiatryLive
@Psychiatry_Live
India observes National Doctor's Day on July 1, 2025. This year, doctors are asking for reform—not flowers—in the wake of escalating burnout and violence. www.psychiatrictimes.com/view/spare-me-the-bouquets-the-g…
-
PsychiatryLive
@Psychiatry_Live
Check out this month’s developments in the psychiatric treatment pipeline! www.psychiatrictimes.com/view/june-in-review-updates-on-t…
-
PsychiatryLive
@Psychiatry_Live
Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how postpartum depression affects 1 in 7 new mothers, yet it often goes undiagnosed and undertreated. Explore the custom video series here: www.psychiatrictimes.com/clinical-case-collective/postpar…
-
PsychiatryLive
@Psychiatry_Live
Gain valuable knowledge from leading experts on optimizing bipolar disorder care through advanced therapies. Watch here: www.psychiatrictimes.com/clinical-consult/the-role-of-lon…
-
PsychiatryLive
@Psychiatry_Live
The intersection of sex and psychiatry: an important topic for patient well-being that is often avoided due to stigma. www.psychiatrictimes.com/view/sex-and-psychiatry-the-sizz…
-
PsychiatryLive
@Psychiatry_Live
CBT-I is the recommended first-line treatment for insomnia, but access is limited due to a shortage of trained clinicians. www.psychiatrictimes.com/view/promoting-insomnia-manageme…
-
PsychiatryLive
@Psychiatry_Live
Leslie Citrome, MD, reviews clinical data on speed of processing in
patients with Major Depressive Disorder (#mdd). Watch now. www.psychiatrictimes.com/expert-perspectives/navigating-t…
PAID CONTENT FROM TAKEDA PHARMACEUTICALS. -
PsychiatryLive
@Psychiatry_Live
Don’t miss the opportunity to dive into the treatment of major depressive disorder with our insightful discussion on atypical antipsychotics. #ad Watch here: www.psychiatrictimes.com/view/atypical-antipsychotics-for…
-
PsychiatryLive
@Psychiatry_Live
The entire June issue of Psychiatric Times—exploring the future of psychiatry, sleep disorders, tardive dyskinesia, and more—is now live on our website. Read it here: www.psychiatrictimes.com/journals/psychiatric-times/vol-4…
-
PsychiatryLive
@Psychiatry_Live
Psychiatric symptoms often coexist with sleep disorders, creating diagnostic and therapeutic complexities. Understanding these psychiatric manifestations is crucial for clinicians to manage both sleep disorders and psychiatric conditions effectively. www.psychiatrictimes.com/view/beyond-the-night-unraveling…
-
PsychiatryLive
@Psychiatry_Live
From screening tools to FDA-approved therapies such as zuranolone, discover how to manage postpartum depression with expert guidance and real-world case studies. Explore the full Case-Based Psych Perspective series: www.psychiatrictimes.com/case-based-psych-perspectives/po…
-
PsychiatryLive
@Psychiatry_Live
Mistreatment, including microaggressions, can lead to increased hopelessness, isolation, and career regret among medical trainees. www.psychiatrictimes.com/view/walking-the-line-navigating…
-
PsychiatryLive
@Psychiatry_Live
NRx Pharmaceuticals, Inc. is pursuing FDA approval for NRX-100, a preservative-free ketamine, via the new Commissioner’s National Priority Voucher pathway, which expedites review for public health priority drugs. @NRxPharma
www.psychiatrictimes.com/view/nrx-pharmaceuticals-applies… -
PsychiatryLive
@Psychiatry_Live
On July 17, 2025, the 988 National Suicide & Crisis Lifeline will stop providing tailored support options to LGBTQ+ youth and young adults. www.psychiatrictimes.com/view/loss-of-988-hotline-service…
-
PsychiatryLive
@Psychiatry_Live
A study found that children diagnosed with ADHD have a 10-fold increase in the incidence of developing bipolar disorder when compared with matched children without ADHD. The comorbidity of ADHD and bipolar disorder may involve overlapping genetics. www.psychiatrictimes.com/view/adhd-with-bipolar-disorder-…
-
PsychiatryLive
@Psychiatry_Live
Ecopipam for Tourette syndrome was found to be safe and effective in a 12-month, open-label extension of a phase 2b study. The 1.8 mg/kg/day dose reduced tic severity and improved quality of life in children and adolescents with Tourette syndrome. www.psychiatrictimes.com/view/new-positive-12-month-exten…
-
PsychiatryLive
@Psychiatry_Live
Tamir Aldad, MD, MBA, knew we needed to create a system that answers the immediate demand for mental health care and puts individuals ahead of bureaucracy. @tamiraldad
Read his story about creating an urgent care for mental health here: www.psychiatrictimes.com/view/from-psychiatrist-to-pionee… -
PsychiatryLive
@Psychiatry_Live
The FDA has officially eliminated the clozapine REMS, and all REMS operations have ceased. In the wake of this decision, the @sczaction has announced the development of a set of clinical courses designed to provide guidance for clozapine prescribing. www.psychiatrictimes.com/view/fda-officially-eliminates-c…
-
PsychiatryLive
@Psychiatry_Live
Effective psychopharmacology education requires engaging learners emotionally and intellectually, using storytelling and metaphor. Learn more from experts Stephen M. Stahl, MD, PhD, DSc (Hon), and Joseph F. Goldberg, MD. www.psychiatrictimes.com/view/how-do-psychiatry-residents…
-
PsychiatryLive
@Psychiatry_Live
Agencies and news sources have reported and compiled a list of more than 350 words that have been flagged per directives and guidance issued by the federal government. See the top banned words related to mental health here: www.psychiatrictimes.com/view/facts-over-fiction-the-curr…
-
PsychiatryLive
@Psychiatry_Live
Discover essential insights for diagnosing and treating child mental health issues in the "DSM-5-TR Casebook and Treatment Guide for Child Mental Health," a vital resource for clinicians written by Peter S. Jensen, MD, and Cathryn A. Galanter, MD. www.psychiatrictimes.com/view/a-guide-for-child-mental-he…
-
PsychiatryLive
@Psychiatry_Live
Women face significant challenges in getting diagnosed with ADHD. Ann Childress, MD, and @BusyPhilipps share their thoughts in our latest video discussion: www.psychiatrictimes.com/view/women-with-adhd-the-differe…
-
PsychiatryLive
@Psychiatry_Live
The anti-psychiatry movement is experiencing a resurgence, challenging the legitimacy of psychiatric practices and treatments. Education and advocacy are crucial for psychiatrists to counter misinformation and maintain public trust in mental health care. www.psychiatrictimes.com/view/make-america-healthy-again-…
-
PsychiatryLive
@Psychiatry_Live
The June issue of Psychiatric Times is now live! This month, we take a closer look at the path forward for psychiatry amidst a slew of changes.
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6/psychtimes/01d19d9f0b8c68cb8… -
PsychiatryLive
@Psychiatry_Live
Ghosting is prevalent in online dating. Does it cause emotional harm and long-term mental health impacts? www.psychiatrictimes.com/view/more-connected-than-ever-be…
-
PsychiatryLive
@Psychiatry_Live
Early adversity, including abuse and neglect, significantly increases the risk of developing psychosis spectrum symptoms, with a dose-dependent relationship observed. www.psychiatrictimes.com/view/the-enduring-impact-of-earl…
-
PsychiatryLive
@Psychiatry_Live
Schizophrenia is characterized by dysfunction across multiple functional domains. These functions are supported by specific circuits in the brain, which are heavily modulated by the transmitter dopamine. www.psychiatrictimes.com/view/from-a-dysfunctional-neurom…
-
PsychiatryLive
@Psychiatry_Live
Early intervention for psychosis shows promise in altering the outlook for individuals with schizophrenia spectrum disorder. www.psychiatrictimes.com/view/coordinated-specialty-care-…
-
PsychiatryLive
@Psychiatry_Live
MAOIs remain a valuable treatment option for specific patients, with careful risk management. Learn more in our May CME: www.psychiatrictimes.com/view/understanding-and-overcomin…
-
PsychiatryLive
@Psychiatry_Live
Discover how LAI antipsychotics can improve adherence and outcomes for patients with bipolar I disorder. Learn more now: www.psychiatrictimes.com/clinical-consult/the-role-of-lon…
-
PsychiatryLive
@Psychiatry_Live
Learn about the latest in digital therapeutics for depression, focusing on how the EFMT targets cognitive and emotional dysfunction in patients with major depressive disorder. Watch now: www.psychiatrictimes.com/between-the-lines/a-randomized-c…
-
PsychiatryLive
@Psychiatry_Live
Need something to read this weekend? The entire May issue of Psychiatric Times is now live on our website. Read it here: www.psychiatrictimes.com/journals/psychiatric-times/vol-4…
-
PsychiatryLive
@Psychiatry_Live
According to a poster presentation at the 2025 ASCP Annual Meeting, dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists. www.psychiatrictimes.com/view/treatment-comparison-somnol…
-
PsychiatryLive
@Psychiatry_Live
Long-term open-label treatment with adjunctive cariprazine was associated with improvements in anhedonia for up to 26 weeks. www.psychiatrictimes.com/view/new-data-cariprazine-adjunc…
-
PsychiatryLive
@Psychiatry_Live
New data from the ASCP Annual Meeting: NBI-1117568, the first and only investigational oral muscarinic M4 selective orthosteric agonist in development for schizophrenia, showed a significant improvement in symptoms and overall severity. www.psychiatrictimes.com/view/positive-phase-2-results-on…
-
PsychiatryLive
@Psychiatry_Live
Don’t miss the opportunity to dive into the treatment of major depressive disorder with our insightful discussion on atypical antipsychotics. #ad Watch here: www.psychiatrictimes.com/view/atypical-antipsychotics-for…
-
PsychiatryLive reposted
Mena Mirhom, MD, FAPA
@DrMirhom
So glad I got to sit with my friends at @PsychTimes to discuss the importance of #mentalhealth & media!
www.psychiatrictimes.com/view/promoting-mental-health-thr… -
PsychiatryLive
@Psychiatry_Live
This Memorial Day, we honor those that have sacrificed to defend our freedoms.
-
PsychiatryLive reposted
Alto Neuroscience
@AltoNeuro
Our latest work is featured in @PsychTimes showcasing new data presented at #sobp2025. Check out the video interview series to learn more about the biological and clinical insights that support Alto’s #precisionpsychiatry pipeline.
Part 2 here: www.psychiatrictimes.com/view/biomarker-mechanism-for-alt… -
PsychiatryLive
@Psychiatry_Live
New analyses reveal valbenazine (Ingrezza) significantly enhances quality of life and functional outcomes for patients with tardive dyskinesia, supporting its long-term efficacy. www.psychiatrictimes.com/view/new-ingrezza-data-demonstra…
-
PsychiatryLive
@Psychiatry_Live
Recent research reveals that intravenous haloperidol and ziprasidone are safe for treating delirium in patients that are critically ill, showing minimal impact on QTc intervals. www.psychiatrictimes.com/view/antipsychotics-and-the-qtc-…
-
PsychiatryLive
@Psychiatry_Live
Combination therapy of transcranial magnetic stimulation and ketamine could enhance brain perfusion and neuroplasticity. www.psychiatrictimes.com/view/whats-perfusion-got-to-do-w…
-
PsychiatryLive
@Psychiatry_Live
Newron Pharmaceuticals today announced the approval of the ENIGMA-TRS phase 3 development program evaluating evenamide as an add-on therapy to current antipsychotics in patients with treatment-resistant schizophrenia. www.psychiatrictimes.com/view/phase-3-development-plan-fo…
-
PsychiatryLive reposted
Jesus Ramirez-Bermudez
@JRBneuropsiq
I published a review on @awaisaftab's Conversations on Critical Psychiatry.
1/14 🧵💭
The book offers a detailed examination of the philosophical, scientific, sociocultural, and ethical controversies in psychiatry and mental health.
www.psychiatrictimes.com/view/critical-pluralism-in-psych… @PsychTimes -
PsychiatryLive
@Psychiatry_Live
May is American Stroke Month. About 1 in 4 adults over the age of 25 will experience a stroke in their lifetime.
Learn how to recognize the signs here: www.psychiatrictimes.com/view/recognizing-stroke-why-know… -
PsychiatryLive
@Psychiatry_Live
A recent story from the New York Times, “Have We Been Thinking About A.D.H.D. All Wrong?”, has provoked a vigorous response from psychiatrists and other mental health advocates. Let's unpack the critical thinking around ADHD diagnoses and treatment. www.psychiatrictimes.com/view/the-new-york-times-moves-th…
-
PsychiatryLive
@Psychiatry_Live
A strong therapeutic alliance is essential for effective treatment outcomes. Learn more in our May editorial: www.psychiatrictimes.com/view/the-therapeutic-alliance?hs…
-
PsychiatryLive
@Psychiatry_Live
Happy National Nurses Week! www.psychiatrictimes.com/view/national-nurses-week-2025-c…
-
PsychiatryLive
@Psychiatry_Live
It's time to reclaim the term deprescribing, a critical practice in medicine that emphasizes thoughtful medication management and patient-centered care for optimal health outcomes. www.psychiatrictimes.com/view/deprescribing-does-the-term…
-
PsychiatryLive
@Psychiatry_Live
The May issue of Psychiatric Times is now live! This month, we take closer look at how to reclaim the term deprescribing and the possibility of dementia prevention.
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6/psychtimes/71e65dd48f44c4940… -
PsychiatryLive
@Psychiatry_Live
Our May theme focuses on the important practice of psychotherapy. How often do you use psychotherapy in your practice? How should practitioners approach conversations about psychotherapy vs pharmacotherapy? www.psychiatrictimes.com/view/presenting-our-may-theme-ps…
-
PsychiatryLive
@Psychiatry_Live
Curious about LAIs for schizophrenia? The latest installment of this Expert Perspectives series delves into what providers need to know about this treatment option. #ad www.psychiatrictimes.com/view/the-benefits-of-long-acting…
-
PsychiatryLive
@Psychiatry_Live
Take a look at this month’s developments in the psychiatric treatment pipeline. www.psychiatrictimes.com/view/april-in-review-updates-on-…
-
PsychiatryLive
@Psychiatry_Live
Looking for reading material? The entire April issue of Psychiatric Times is now live on our website! Read it here: www.psychiatrictimes.com/journals/psychiatric-times/vol-4…
-
PsychiatryLive
@Psychiatry_Live
In a first-of-its-kind study from @Boehringer, @CumulusNeuro, and @UniofOxford, the novel NeuLogiq neuroassessment platform will be used to quantify brain activity, mood, and behavior at home in individuals with borderline personality disorder. www.psychiatrictimes.com/view/first-of-its-kind-study-usi…
-
PsychiatryLive
@Psychiatry_Live
Emotional regulation, positive psychology, adaptive coping, optimism, and spirituality are effective strategies to strengthen resilience in patients with traumatic brain injuries. www.psychiatrictimes.com/view/resilience-and-renewal-enha…
-
PsychiatryLive
@Psychiatry_Live
Parkinson disease prevalence is increasing. Neuropsychiatric symptoms are common but often underrecognized, impacting disease progression and patient outcomes. In our latest CME article, learn more about how to assess and treat them. www.psychiatrictimes.com/view/depression-apathy-and-anxie…
-
PsychiatryLive
@Psychiatry_Live
Enhance your understanding of major depressive disorder and its
treatment options via this expert panel discussion on adjunctive therapies
and antipsychotics. #ad Watch here: www.psychiatrictimes.com/view/atypical-antipsychotics-for… -
PsychiatryLive
@Psychiatry_Live
On July 30, 2024, officials cut the ribbon on UK HealthCare’s Emergency Psychiatric Assessment, Treatment, and Healing (EmPATH) unit, ushering in a new chapter in behavioral health care. Since that day, EmPATH has helped more than 2700 individuals. www.psychiatrictimes.com/view/first-emergency-psychiatric…
-
PsychiatryLive
@Psychiatry_Live
Discover innovative treatment strategies with expert insights on long-acting injectables to enhance your practice today. Watch now: www.psychiatrictimes.com/clinical-consult/the-role-of-lon…
-
PsychiatryLive
@Psychiatry_Live
Emergency psychiatry faces several unique legal and ethical issues. Review key practice points in our latest Special Report article: www.psychiatrictimes.com/view/legal-and-ethical-issues-in…
-
PsychiatryLive
@Psychiatry_Live
Transneural Therapeutics just announced its launch. Transneural aims to transform the treatment of neuropsychiatric and neurodegenerative diseases with novel neuroplastogens. www.psychiatrictimes.com/view/transneural-therapeutics-a-…
-
PsychiatryLive
@Psychiatry_Live
Patients with intellectual and developmental disabilities present to the emergency department at nearly double the rate of those without intellectual and developmental disabilities, facing unique challenges and increased wait times. www.psychiatrictimes.com/view/the-waiting-game-treating-p…
-
PsychiatryLive
@Psychiatry_Live
New results show that Cobenfy as an adjunctive treatment to atypical antipsychotics did not show a statistically significant difference compared with placebo in adults with inadequately controlled symptoms of schizophrenia. www.psychiatrictimes.com/view/cobenfy-as-add-on-treatment…
-
PsychiatryLive
@Psychiatry_Live
Emergency psychiatry is gaining recognition, with 2025 shaping up to be one of the most consequential years ever for this burgeoning subspecialty. www.psychiatrictimes.com/view/2025-is-a-landmark-year-for…
-
PsychiatryLive
@Psychiatry_Live
Yesterday, @CybinInc announced a strategic partnership with @OsmindHQ. Together, they will aim to bring innovative mental health treatments to patients in need. www.psychiatrictimes.com/view/cybin-announces-partnership…
-
PsychiatryLive
@Psychiatry_Live
Happy Earth Day! 🌎
Climate change exacerbates heat exposure, posing significant risks to mental health, especially for patients with psychiatric disorders due to physiological vulnerabilities and medication effects. www.psychiatrictimes.com/view/climate-change-and-heat-rel… -
PsychiatryLive
@Psychiatry_Live
Effective care for postpartum depression begins with better diagnosis and treatment. Watch this informative Clinical Case Collective episode for expert insights on treating PPD: www.psychiatrictimes.com/view/treatment-approach-for-a-mo…
-
PsychiatryLive
@Psychiatry_Live
MindMed recently announced that the first patient has been dosed in its phase 3 Emerge study evaluating MM120 ODT for treatment of major depressive disorder. MM120 ODT is a proprietary, pharmaceutically optimized form of LSD. www.psychiatrictimes.com/view/mindmed-begins-phase-3-emer…
-
PsychiatryLive
@Psychiatry_Live
Prodromal symptoms of schizophrenia include cognitive deficits, mood changes, and subthreshold psychotic symptoms, often preceding full psychosis by weeks to years. www.psychiatrictimes.com/view/the-slow-road-to-psychosis
-
PsychiatryLive
@Psychiatry_Live
Effective care for postpartum depression begins with better diagnosis and treatment. Explore the Clinical Case Collective series here: www.psychiatrictimes.com/clinical-case-collective/postpar…
-
PsychiatryLive
@Psychiatry_Live
Discontinuation of long-term benzodiazepine therapy may increase mortality and adverse outcomes, contrary to the belief that reducing use decreases harm. www.psychiatrictimes.com/view/benzodiazepine-discontinuat…
-
PsychiatryLive
@Psychiatry_Live
Pharmacists can play a crucial role in supporting treatment adherence, contributing to the prevention of medication errors, and addressing real-world barriers to care for patients with schizophrenia. www.psychiatrictimes.com/view/treating-schizophrenia-brin…
-
PsychiatryLive
@Psychiatry_Live
It's Black Maternal Health Week! Our Sports Psychiatry Section Editor highlights Black maternal health disparities using stories from elite athlete moms. www.psychiatrictimes.com/view/from-victory-to-vulnerabili…
-
PsychiatryLive
@Psychiatry_Live
Self-harm affects at least 14 million people worldwide annually. Treatment for self-harm varies significantly by region and is often inaccessible. www.psychiatrictimes.com/view/the-lancet-commission-tackl…
-
PsychiatryLive
@Psychiatry_Live
How can psychiatrists and mental health professionals advocate for parental leave? Learn more in the new video series, "Psyched Perspectives" by @tapkidmd! www.psychiatrictimes.com/view/parental-leave-and-psychiat…
-
PsychiatryLive
@Psychiatry_Live
The number of female defendants convicted of violent offenses has grown by 30% compared with 12% among male defendants since 1990. www.psychiatrictimes.com/view/female-offenders-patterns-r…
-
PsychiatryLive
@Psychiatry_Live
Pregnancy can worsen psychiatric disorders, with peripartum psychosis being a psychiatric emergency due to self-harm risks and adverse obstetric outcomes.Induction of labor may be necessary when psychosis impairs decision-making capacity. www.psychiatrictimes.com/view/examining-a-case-of-acute-l…
-
PsychiatryLive
@Psychiatry_Live
The diagnostic criteria and terminologies for cognitive disorders continue to evolve. A good cognitive screen should have high sensitivity for identifying cognitive impairment. www.psychiatrictimes.com/view/diagnostic-considerations-i…
-
PsychiatryLive
@Psychiatry_Live
Are you ready to put the Psychopathology Refracted into 7 Modalities (PRiSM) Scale into practice? Learn more about this psychiatric diagnostic instrument, codeveloped by @MarkLRuffalo and Ronald W. Pies, here: www.psychiatrictimes.com/view/use-of-the-prism-diagnostic…
-
PsychiatryLive
@Psychiatry_Live
According to recent research, mental health clinicians are most concerned about patients’ quality of life as well as medications issues like adherence and switching. www.psychiatrictimes.com/view/online-survey-reveals-clini…
-
PsychiatryLive
@Psychiatry_Live
Catch the second installment of this informative Expert Perspectives series discussing common challenges with schizophrenia management and how providers can help. #ad www.psychiatrictimes.com/view/the-impact-of-nonadherence-…
-
PsychiatryLive
@Psychiatry_Live
We asked our readers if psychiatry is doing enough to address federal doubt of the field. Over 70% said no. www.psychiatrictimes.com/view/poll-results-is-psychiatry-…
-
PsychiatryLive
@Psychiatry_Live
Psychiatry is, at its heart, a pragmatic discipline. These 3 stories offer a lesson in humility to the field. @BadreNicolas www.psychiatrictimes.com/view/tales-of-overconfidence-3-s…
-
PsychiatryLive reposted
CNS
@neuroskills
Acquired brain injuries (ABI) are complex and require individualized treatment to address unique causes, effects, and comorbidities. www.psychiatrictimes.com/view/challenges-in-treating-acqu…
@PsychTimes
#neuroskills #braininjury #neurorehab #tbi -
PsychiatryLive
@Psychiatry_Live
Although many patients with major depressive disorder experience an improvement in antidepressant side effects with time, not everyone’s side effects improve. In fact, some patients' side effects get worse.
Learn more about how to optimize treatment: www.psychiatrictimes.com/view/no-your-patients-are-not-wr… -
PsychiatryLive reposted
Nicolas Badre
@BadreNicolas
Tales of Overconfidence: 3 Stories to Refine Psychiatry
My take on @LauraDelano 's book: Many reviews have debated facts about psychiatry or psychotropic medications, but too few considered what psychiatry can learn from it.
Her story "challenges the field to reflect on our skill at recognizing when treatments and labels persist beyond their therapeutic point."
I see her story as opposite to Osheroff's, whose hospitalization pushed psychiatry into the biological era, and related Calahan's, who reminded us to consider non-psychiatric medical causes. These three stories exemplify "lessons in humility."
I hope my article is seen as constructive, aiming to improve the field. Link below. -
PsychiatryLive
@Psychiatry_Live
Evidence shows that over 70% of patients who respond to SSRI treatment continue to experience significant cognitive impairments, even when their mood symptoms have improved. www.psychiatrictimes.com/view/when-the-fog-doesnt-lift-ta…
-
PsychiatryLive
@Psychiatry_Live
Evidence has been growing to support the prevalence of long-term complications of COVID-19 beyond the acute phase of the infection. Post-acute sequelae of COVID-19 occurs in about 10% to 20% of individuals. www.psychiatrictimes.com/view/post-acute-sequelae-of-covi…
-
PsychiatryLive
@Psychiatry_Live
Trontinemab, utilizing Brainshuttle technology, showed significant amyloid plaque reduction in Alzheimer's patients, prompting a phase 3 study. www.psychiatrictimes.com/view/positive-interim-results-on…
-
PsychiatryLive
@Psychiatry_Live
Patients with treatment resistant late-life depression are more likely to respond to antidepressants when sleep is sufficient or has improved. www.psychiatrictimes.com/view/improving-sleep-to-treat-re…
-
PsychiatryLive reposted
Dinah Miller, M.D. @shrinkrapdinah
Some people are worriers, how wonderful it must be never to worry! Seems like there is a lot of it going around. My thoughts on @PsychTimes
www.psychiatrictimes.com/view/the-worried-and-the-well -
PsychiatryLive
@Psychiatry_Live
The April issue of Psychiatric Times is now live! This month, we take closer look at patterns, risk, and assessment of female forensic psychiatry patients.
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6/psychtimes/f5d1f7302d1bc651b… -
PsychiatryLive reposted
Heather Burrell Ward, MD
@hbwardMD
Thank you @PsychTimes for the opportunity to share my work! @VUMCPsych
PsychiatryLive
@Psychiatry_Live
The prevalence of tobacco use in schizophrenia is over 60%—3 times that of the general population. www.psychiatrictimes.com/view/in-schizophrenia-nicotine-e…
-
PsychiatryLive
@Psychiatry_Live
In case you missed it: Check out new data from NOVA1, a phase 2 clinical trial of LB-102 in patients with acutely exacerbated schizophrenia. www.psychiatrictimes.com/view/additional-positive-data-on…
-
PsychiatryLive
@Psychiatry_Live
Cognitive control is essential for emotion regulation, with disruptions linked to psychiatric disorders. www.psychiatrictimes.com/view/emotion-and-cognitive-contr…
-
PsychiatryLive
@Psychiatry_Live
Video games have become vital for LGBTQIA+ representation and community-building, especially during the COVID-19 pandemic. www.psychiatrictimes.com/view/leveling-up-together-nurtur…
-
PsychiatryLive
@Psychiatry_Live
The prevalence of tobacco use in schizophrenia is over 60%—3 times that of the general population. www.psychiatrictimes.com/view/in-schizophrenia-nicotine-e…
-
PsychiatryLive
@Psychiatry_Live
It is important for clinicians to recognize that sex- and gender-based cognitive differences may impact the presentation and course of psychiatric conditions. www.psychiatrictimes.com/view/are-there-sex-differences-i…
-
PsychiatryLive
@Psychiatry_Live
Our April theme: Sleep.
If you are interested in being featured in a future Special Report/print issue, submit to our content series! www.psychiatrictimes.com/view/presenting-our-april-theme-… -
PsychiatryLive
@Psychiatry_Live
Earn CME Credit!
Learn more about the common neuropsychiatric sequelae of post-acute sequelae of COVID-19, the underlying neurobiological mechanisms, and evidence-based treatments and interventions in our March CME article. www.psychiatrictimes.com/view/post-acute-sequelae-of-covi… -
PsychiatryLive
@Psychiatry_Live
LB Pharmaceuticals shared additional positive data from NOVA1 exploring LB-102 in patients with acutely exacerbated schizophrenia. John M. Kane, MD, the principal investigator of NOVA1, shared exclusive insights with Psychiatric Times: www.psychiatrictimes.com/view/lb-102-for-the-treatment-of…
-
PsychiatryLive
@Psychiatry_Live
Today is #worldbipolarday. For the latest clinical pearls, treatment updates, and best practices, see our Bipolar Disorder section here: www.psychiatrictimes.com/topics/bipolar
-
PsychiatryLive
@Psychiatry_Live
Cognitive symptoms affect between 85% and 94% of patients with major depressive disorder. Despite this prevalence, cognitive dysfunction often remains undertreated and inadequately addressed in routine clinical practice. www.psychiatrictimes.com/view/when-the-fog-doesnt-lift-ta…
-
PsychiatryLive
@Psychiatry_Live
Need something to read this weekend? The entire March issue of Psychiatric Times is now live on our website! Read it here: www.psychiatrictimes.com/journals/psychiatric-times/vol-4…
-
PsychiatryLive
@Psychiatry_Live
Have you heard of cinematherapy? There is a new program centered on addiction in film that is now used in recovery centers and clinics across the US and Canada. Learn more here: www.psychiatrictimes.com/view/recovery-movie-meetups
-
PsychiatryLive
@Psychiatry_Live
Gain expert insights from this informative video series on adjunctive treatment of major depressive disorder using atypical antipsychotics. #ad
Watch here: www.psychiatrictimes.com/view/atypical-antipsychotics-for… -
PsychiatryLive
@Psychiatry_Live
Alzamend announced its plans to initiate a highly anticipated phase 2 clinical study of AL001, a novel lithium-delivery system for the treatment of patients with major depressive disorder, in late 2025. www.psychiatrictimes.com/view/phase-2-clinical-trial-of-a…
-
PsychiatryLive
@Psychiatry_Live
Based on a new study, ketamine may be preferred among outpatients and for those with “moderately severe or severe” depression, whereas ECT may be preferred among inpatients and those with “very severe” depression. www.psychiatrictimes.com/view/clinical-features-associate…
-
PsychiatryLive
@Psychiatry_Live
In a large joint statement, leading psychiatric organizations pushed back against concerns that could lead to misinformation and reduced access to evidence-based treatments.
In your opinion, is psychiatry doing enough to address federal doubt of the field? -
PsychiatryLive
@Psychiatry_Live
Premenstrual dysphoric disorder is a severe and debilitating form of premenstrual syndrome that affects women between ovulation and the start of menstruation. www.psychiatrictimes.com/view/the-debilitating-impact-of-…
-
PsychiatryLive
@Psychiatry_Live
March is Brain Injury Awareness Month 🧠
Learn more about how we can address challenges that arise in treating individuals with acquired brain injury. www.psychiatrictimes.com/view/challenges-in-treating-acqu… -
PsychiatryLive
@Psychiatry_Live
Joint statements from leading psychiatric organizations voice concern about impact on patient care from executive orders and budget cuts. www.psychiatrictimes.com/view/psychiatric-organizations-r…
-
PsychiatryLive
@Psychiatry_Live
Join Melanie Barrett, MD; Anita Clayton, MD; and Carmen Kosicek, MSN, PMHNP-BC, as they explore maternal mental health challenges, effective diagnostic approaches, and evidence-based treatments. Explore the series here: www.psychiatrictimes.com/clinical-case-collective/postpar…
-
PsychiatryLive
@Psychiatry_Live
Legislative and legal realities at the state and federal levels are difficult to navigate even for seasoned practitioners, and are beyond the knowledge of most patients and their families. www.psychiatrictimes.com/view/difficulties-with-insurance…
-
PsychiatryLive
@Psychiatry_Live
New data from the long-term, open-label KINECT 4 study demonstrated remission of tardive dyskinesia among most patients treated with once-daily Ingrezza capsules, with approximately 59.2% of participants who completed the study achieving remission. www.psychiatrictimes.com/view/new-48-week-remission-data-…
-
PsychiatryLive
@Psychiatry_Live
Get insights from experts on treating severe postpartum depression with rapid-acting therapies. Explore the informative Case-Based Psych Perspectives video series here: www.psychiatrictimes.com/case-based-psych-perspectives/po…
-
PsychiatryLive
@Psychiatry_Live
Anti-psychiatry’s animus toward psychiatric medication has both ancient and modern parallels. www.psychiatrictimes.com/view/the-ongoing-movement-agains…
-
PsychiatryLive
@Psychiatry_Live
Postpartum psychosis occurs in about 1 to 2 per thousand new mothers. In this personal story, Meghan Cliffel shares her experience with postpartum psychosis, and why psychiatrists need to be able to recognize and diagnose this condition. www.psychiatrictimes.com/view/tragic-or-treated-why-we-ca…
-
PsychiatryLive
@Psychiatry_Live
Welcome to the age of the internet... and the anxious generation it has spawned. www.psychiatrictimes.com/view/the-anxious-generation
-
PsychiatryLive
@Psychiatry_Live
Which DSM-5 diagnosis accurately reflects the complexity of early childhood adversity on neurodevelopment: PTSD? Complex PTSD? Why does it matter? www.psychiatrictimes.com/view/why-developmental-trauma-di…
-
PsychiatryLive
@Psychiatry_Live
Routine screening for tardive dyskinesia is important for people who have taken antipsychotics. Learn more about this involuntary movement disorder from two advanced practice providers. #ad #tardivedyskinesia Learn more: www.psychiatrictimes.com/view/empowering-advanced-practic…
-
PsychiatryLive
@Psychiatry_Live
Muscarinic receptors offer a promising alternative target in schizophrenia treatment. www.psychiatrictimes.com/view/how-the-study-of-muscarinic…
-
PsychiatryLive
@Psychiatry_Live
The missing person case of Gabby Petito transfixed the nation in the fall of 2021 and has remained in the public eye with a recent Netflix documentary. Psychiatry has a lot to learn from this case about "Missing White Woman Syndrome." www.psychiatrictimes.com/view/missing-white-woman-syndrom…
-
PsychiatryLive
@Psychiatry_Live
It's National Drug and Alcohol Facts Week! Check out this selection of recent research concerning adolescents and substance use disorder: www.psychiatrictimes.com/view/adolescent-substance-use-re…
-
PsychiatryLive
@Psychiatry_Live
Join us on LinkedIn for a brand new newsletter, "Dialogues in Psychiatry"! www.linkedin.com/build-relation/newsletter-follow?entityU…
-
PsychiatryLive
@Psychiatry_Live
Learn how to optimize MDD outcomes and bridge treatment gaps with actionable strategies. Watch today: www.psychiatrictimes.com/clinical-case-collective/expandi…
-
PsychiatryLive
@Psychiatry_Live
Learn how LAIs offer an alternative treatment option for patients living with bipolar I disorder or schizophrenia. #ad
www.psychiatrictimes.com/view/offering-long-acting-inject…
INTENDED FOR US HEALTHCARE PROFESSIONAL AUDIENCES ONLY
© 2024 Otsuka America Pharmaceutical, Inc.
October 2024 23US24EUP0024 -
PsychiatryLive
@Psychiatry_Live
Struggling with postpartum depression can leave a mother feeling alone and unsupported. Experts share seven key recommendations for effective treatment and support. www.psychiatrictimes.com/view/experts-share-top-7-recomme…
-
PsychiatryLive
@Psychiatry_Live
In an increasingly connected world, safeguarding professional boundaries is more critical than ever. Mena Mirhom, MD, FAPA shares some strategies to maintain ethics and professionalism online. psychiatrictimes.com/view/protecting-professional-boundar…
-
PsychiatryLive
@Psychiatry_Live
A huge thank you to Axsome Therapeutics for sponsoring Real Psychiatry 2025! We’re proud to partner with you in advancing the field of psychiatry.
-
PsychiatryLive
@Psychiatry_Live
Through resilience and remembrance, hope finds its rhythm. Dance/movement therapy has been used to connect children to their world after experiencing trauma. www.psychiatrictimes.com/view/we-will-remember-dancing-a-…
-
PsychiatryLive
@Psychiatry_Live
How does media bias shape public perception of missing persons? Learn more about "Missing White Woman Syndrome" and its implications for psychiatry and societal bias. www.psychiatrictimes.com/view/missing-white-woman-syndrom…
-
PsychiatryLive
@Psychiatry_Live
We couldn’t do it without you! A heartfelt thank you to Bristol Myers Squibb for their support of Real Psychiatry 2025 and the psychiatric community.
-
PsychiatryLive
@Psychiatry_Live
A Phase 1 trial has begun for NBI-1140675, a next-generation VMAT2 inhibitor targeting neurological and neuropsychiatric conditions. Here's what we know: www.psychiatrictimes.com/view/phase-1-study-initiated-nbi…
-
PsychiatryLive
@Psychiatry_Live
Managing catatonia in underserved areas is a critical challenge. This case report from Grace Lehnerdt in rural South Africa highlights the complexities and approaches to treatment.
www.psychiatrictimes.com/view/managing-catatonia-a-case-r… -
PsychiatryLive
@Psychiatry_Live
Recent studies on muscarinic receptors have led to the development of Cobenfy, the first new antipsychotic drug in decades. @NKhutaija discusses how the study is changing schizophrenia treatment. www.psychiatrictimes.com/view/how-the-study-of-muscarinic…
-
PsychiatryLive
@Psychiatry_Live
A huge thank you to Sage Therapeutics | Biogen for your support of Real Psychiatry 2025! Your partnership fuels impactful education and collaboration in our field.
-
PsychiatryLive
@Psychiatry_Live
A new phase 1 clinical trial is underway, exploring the safety and efficacy of a novel stem cell therapy for Parkinson's disease. This approach utilizes patients' own reprogrammed cells to potentially restore lost dopamine function. www.psychiatrictimes.com/view/phase-1-clinical-trial-laun…
-
PsychiatryLive
@Psychiatry_Live
Emerging research indicates that psilocybin-assisted therapy may offer significant relief for frontline COVID-19 clinicians experiencing depression, PTSD, and burnout. Kenneth J. Bender, PharmD, MA, discusses the findings. www.psychiatrictimes.com/view/psilocybin-benefits-clinici…
-
PsychiatryLive
@Psychiatry_Live
Explore our new Expert Perspectives series that sheds light on the complex world of schizophrenia and the treatments making a difference. #ad www.psychiatrictimes.com/view/overview-of-schizophrenia-a…
-
PsychiatryLive
@Psychiatry_Live
We’re grateful to Boehringer Ingelheim for their generous sponsorship of Real Psychiatry 2025. Together, we’re shaping the future of psychiatry.
-
PsychiatryLive
@Psychiatry_Live
A growing body of research suggests that anxiety and depression in young people may be linked to changes in childhood experiences—more screen time, less independence, and fewer real-world interactions. www.psychiatrictimes.com/view/the-anxious-generation
-
PsychiatryLive
@Psychiatry_Live
Tuesday, March 11, marks 5 years since the WHO declared COVID-19 a pandemic. Nidal Moukaddam, MD, PhD, reflects on the lastimg impact of the pandemic on clinicians and society alike. www.psychiatrictimes.com/view/the-5-year-anniversary-of-c…
-
PsychiatryLive
@Psychiatry_Live
Treating postpartum psychosis is urgent—when missed, it can lead to tragic outcomes, but with the right treatment, recovery is possible. www.psychiatrictimes.com/view/tragic-or-treated-why-we-ca…
-
PsychiatryLive
@Psychiatry_Live
Palliative psychiatry and assisted suicide for mental illness—are they the same? Not quite. www.psychiatrictimes.com/view/palliative-psychiatry-and-a…
-
PsychiatryLive
@Psychiatry_Live
Five years after the pandemic was declared, we continue to see its lasting effects—on mental health, healthcare systems, and daily life. What have we learned, and where do we go from here? www.psychiatrictimes.com/view/covid-19-5-years-later
-
PsychiatryLive
@Psychiatry_Live
Misunderstanding arises from equating rising mental illness rates with treatment failure, ignoring external factors like trauma and social isolation. Daniel Morehead, MD, explains a recent "dumb idea" in psychiatry.
www.psychiatrictimes.com/view/psychiatry-a-graveyard-of-d… -
PsychiatryLive
@Psychiatry_Live
A new study examining suicide risk evaluations from the Veterans Health Administration found that suicidal ideation and firearm access are the strongest predictors of veteran suicide risk within 30 days and 1 year. Read more about the study findings:
www.psychiatrictimes.com/view/veteran-suicide-risk-evalua… -
PsychiatryLive
@Psychiatry_Live
BLP-003, currently being evaluated for treatment-resistant depression and alcohol use disorder, announced their global phase 2b clinical trial has completed patient enrollment. Learn more about the study here:
www.psychiatrictimes.com/view/blp-003-for-treatment-resis… -
PsychiatryLive
@Psychiatry_Live
March is a time to honor the achievements of women past and present. Join us in celebrating, learning, and amplifying their voices. Explore content by women at psychiatrictimes.com.
-
PsychiatryLive
@Psychiatry_Live
Female physicians in the U.S. have a 53% higher suicide risk than female nonphysicians, while male physicians have a lower risk than their general population counterparts. Learn more about the new study here:
www.psychiatrictimes.com/view/new-study-finds-female-phys… -
PsychiatryLive
@Psychiatry_Live
René S. Kahn, MD, PhD, is colead on a new study aimed at introducing objective measures in psychiatry. He spoke with Psychiatric Times about the study model, support from the NIMH, and potential challenges.
www.psychiatrictimes.com/view/predictor-study-engages-ai-… -
PsychiatryLive
@Psychiatry_Live
How best can guardians and clinicians alike address an adolescent showing signs of an eating disorder? Margot Rittenhouse, MS, LPCC shared some tips and insights on how best to broach the subject, as well as a new alternative to inpatient treatment.
www.psychiatrictimes.com/view/recognizing-addressing-and-… -
PsychiatryLive
@Psychiatry_Live
5 years ago this month, COVID-19 changed the way many clinicians approach their work. Psychiatric Times brought readers coverage from the beginning of the pandemic to today. Check out out last 5 years of March covers.
www.psychiatrictimes.com/view/psychiatric-times-through-t… -
PsychiatryLive
@Psychiatry_Live
🔥The March issue of Psychiatric Times is now live! This month, we take closer look at posttraumatic growth following disasters.
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6/psychtimes/a8b17dcce1a638fbc… -
PsychiatryLive
@Psychiatry_Live
In this Clinical Conversation, Stephen McLeod-Bryant, MD, president of the Black Psychiatrists of America, shares his thoughts on making a difference for Black communities, the removal of the REMS for clozapine, and more.
www.psychiatrictimes.com/view/learning-how-to-actively-li… -
PsychiatryLive
@Psychiatry_Live
Looking for books to add to your reading list? Edmund S. Higgins, MD, reviewed 2 books popular books related to mental health and the field of Psychiatry. Check them out:
www.psychiatrictimes.com/view/brief-book-reviews-march-2025 -
PsychiatryLive
@Psychiatry_Live
Should clinicians engage with media? @DrMirhom, the new Media & Psychiatry Section Editor of Psychiatric Times, has started a new column to share his expertise. Be sure to check out "Media Mastery With Dr Mena," and read his latest Q&A with us here: www.psychiatrictimes.com/view/psychiatric-times-welcomes-…
-
PsychiatryLive
@Psychiatry_Live
What is going on in the world of adolescent psychiatry? In this Research Roundup, we check out how grandparenting style impacts adolescent mental health, how an internet addiction can impact an adolescent's mental health, and more. www.psychiatrictimes.com/view/adolescent-psychiatry-resea…
-
PsychiatryLive
@Psychiatry_Live
Our March theme: Schizophrenia.
If you are interested in being featured in a future Special Report/print issue, submit to our content series! www.psychiatrictimes.com/view/presenting-our-march-theme-… -
PsychiatryLive
@Psychiatry_Live
As cannabis use rises among older adults, what are the mental health implications? Understanding risks, benefits, and psychiatric considerations is crucial for informed care.
www.psychiatrictimes.com/view/cannabis-use-in-senior-pati… -
PsychiatryLive
@Psychiatry_Live
Celiac disease can cause neurological and psychiatric issues due to nutritional deficiencies, autoimmune antibodies, and gluten's neurotoxicity. Could it be at play on some adolescent mental illnesses? James Greenblatt, MD discusses.
www.psychiatrictimes.com/view/celiac-disease-an-overlooke… -
PsychiatryLive
@Psychiatry_Live
The Psychiatric Times March cover story explores the impact of the recent wildfires via the personal experiences of Dave Baron, DO, MSEd. We have collected some further reading for those wishing to learn more. www.psychiatrictimes.com/view/resources-for-resilience-af…
-
PsychiatryLive
@Psychiatry_Live
Watch Atypical Antipsychotics for Adjunctive Treatment of Major
Depressive Disorder, and gain insights from industry experts on major
depressive disorder, its symptoms, and treatment options. #ad
Watch here: www.psychiatrictimes.com/view/atypical-antipsychotics-for… -
PsychiatryLive
@Psychiatry_Live
Need something to read this weekend? The entire February issue of Psychiatric Times is now live on our website. Read it here: www.psychiatrictimes.com/journals/psychiatric-times/vol-4…
-
PsychiatryLive
@Psychiatry_Live
Is it possible to use social media to cure some phobias? One resident shares how Reddit helped her confront her fear of spiders. www.psychiatrictimes.com/view/an-unexpected-psychiatric-b…
-
PsychiatryLive
@Psychiatry_Live
🌟📰 The February issue of Psychiatric Times is here! This month, explore expert insights on psychiatric diagnosis models, the impact of alcohol on mental health, aggression as a treatment target, and more.
Stay informed—Subscribe now! ⬇️
one.psychiatrictimes.com/subscribe/ -
PsychiatryLive
@Psychiatry_Live
Newly shared top-line data from the phase 4 study, KINECT-PRO, demonstrates clinically meaningful and sustained effects of Ingrezza capsules on the physical, social, and emotional impacts experienced by patients living with tardive dyskinesia. www.psychiatrictimes.com/view/significant-improvements-in…
-
PsychiatryLive
@Psychiatry_Live
Addressing culture in adolescent psychiatry is essential for providing effective and empathetic care. Understanding a young person’s cultural background can shape diagnosis, treatment, and engagement. www.psychiatrictimes.com/view/addressing-culture-in-adole…
-
PsychiatryLive
@Psychiatry_Live
Could social media offer an answer for some phobias? Sharon Packer, MD, unpacks the case of one resident who cured her fears using social media as exposure therapy. www.psychiatrictimes.com/view/arachnophobia
-
PsychiatryLive
@Psychiatry_Live
The FDA has accepted the supplemental New Drug Application for Uzedy extended-release injectable suspension for the maintenance treatment of bipolar I disorder in adults. www.psychiatrictimes.com/view/fda-accepts-snda-for-uzedy-…
-
PsychiatryLive
@Psychiatry_Live
Cannabis use disorder and schizophrenia both peak in prevalence around the same age. Is there a cause-and-effect relationship? www.psychiatrictimes.com/view/what-is-the-link-between-ca…
-
PsychiatryLive
@Psychiatry_Live
Check it out! Psychiatric Times is celebrating its 40th anniversary, and all year long we are taking a look back at the last 5 years in covers. From the Australian bushfires to vaccine mandate anxiety, here's what we covered the last 5 February covers. www.psychiatrictimes.com/view/psychiatric-times-through-t…
-
PsychiatryLive
@Psychiatry_Live
How do insurance companies impact psychiatric care? Consider at the role of insurers as 'Guardians of Necessity' and how they enhance access to mental health treatment while addressing systemic challenges. www.psychiatrictimes.com/view/guardians-of-necessity-how-…
-
PsychiatryLive
@Psychiatry_Live
Managing acute late-pregnancy psychosis presents unique challenges for clinicians. Check out our latest case report, exploring a planned induction of labor in a patient experiencing acute late-pregnancy psychosis. www.psychiatrictimes.com/view/planned-induction-of-labor-…
-
PsychiatryLive
@Psychiatry_Live
Cognitive behavioral therapy (CBT) can be a powerful tool in fostering resilience and empowerment. A conversation between clinicians discusses how CBT can be used to support Black patients in navigating mental health challenges and well-being. www.psychiatrictimes.com/view/using-cbt-to-empower-black-…
-
PsychiatryLive
@Psychiatry_Live
Connecting with young patients is key to effective mental health care. Stephen Mateka D.O. shares strategies to ensure children and adolescents feel heard, seen, and validated in clinical settings. How do you build trust and engagement with young patients? www.psychiatrictimes.com/view/heard-seen-validated-how-be…
-
PsychiatryLive
@Psychiatry_Live
The Southern California Psychiatry Conference is back this July! Register by March 1 to receive early bird pricing and save 30% on registration. Save your spot: event.gotoper.com/event/87c8f05b-debf-4412-a297-3c11f3fb4… #socal #gotoper
-
PsychiatryLive
@Psychiatry_Live
Should psychiatrists engage with the media? Our new column from Mena Mirhom, MD, FAPA explores the benefits, challenges, and responsibilities of mental health professionals in the public eye.
www.psychiatrictimes.com/view/should-psychiatrists-engage… -
PsychiatryLive
@Psychiatry_Live
Discover how PTSD impacts society and care in this Clinical Case Collective series.
Learn more: www.psychiatrictimes.com/clinical-case-collective/optimiz… -
PsychiatryLive
@Psychiatry_Live
Exploring the past, present, and future of mental health in Black communities—what progress has been made, and what challenges remain? Dr. Altha Stewart shares her insights.
www.psychiatrictimes.com/view/on-the-legacy-and-future-of… -
PsychiatryLive
@Psychiatry_Live
Learn how LAIs offer an alternative treatment option for patients living with bipolar I disorder or schizophrenia. #ad
www.psychiatrictimes.com/view/offering-long-acting-inject…
INTENDED FOR US HEALTHCARE PROFESSIONAL AUDIENCES ONLY
© 2024 Otsuka America Pharmaceutical, Inc.
October 2024 23US24EUP0024 -
PsychiatryLive
@Psychiatry_Live
Revolutionize your approach to MDD with actionable insights and digital solutions.
Learn more today: www.psychiatrictimes.com/clinical-case-collective/expandi… -
PsychiatryLive
@Psychiatry_Live
The EMERGENT-5 trial highlights the long-term efficacy & safety of xanomeline and trospium in schizophrenia treatment. Could this be a game-changer for sustained symptom management?
www.psychiatrictimes.com/view/long-term-efficacy-and-safe… -
PsychiatryLive
@Psychiatry_Live
A new patent has been issued for methods to identify patients with substance use-associated genetic markers for treatment with AD04. This could revolutionize personalized addiction therapy and improve treatment outcomes. www.psychiatrictimes.com/view/patent-issued-for-methods-o…
-
PsychiatryLive
@Psychiatry_Live
How does the endocrine system impact major depressive disorder? In this Research Roundup, learn more about how hypothalamic-pituitary-adrenal axis influences the progression of major depressive disorder.
www.psychiatrictimes.com/view/major-depressive-disorder-r… -
PsychiatryLive
@Psychiatry_Live
AXS-05 shows promising efficacy in treating major depressive disorder (MDD) while maintaining a manageable safety profile. Findings from two clinical trials highlight its potential as a novel treatment option. www.psychiatrictimes.com/view/axs-05-demonstrates-efficac…
-
PsychiatryLive
@Psychiatry_Live
How does family history influence postpartum depression diagnosis? Learn more in our expert-led case study.
www.psychiatrictimes.com/case-based-psych-perspectives/po…
#ppd #maternalmentalhealth -
PsychiatryLive
@Psychiatry_Live
Cybin has initiated PARADIGM, a phase 3 program evaluating CYB003, a deuterated psilocybin molecule, as an adjunctive therapy for major depressive disorder. Early trials show promise in symptom improvement and remission rates.
www.psychiatrictimes.com/view/cyb003-for-the-adjunctive-t… -
PsychiatryLive
@Psychiatry_Live
The United States Patent and Trademark Office has issued a patent for Adial Pharmaceuticals’ identification of patients with specific genetic markers linked to substance use disorders and treatment with AD04. www.psychiatrictimes.com/view/patent-issued-for-methods-o…
-
PsychiatryLive
@Psychiatry_Live
Discover clinical and real-world approaches to postpartum depression care in our latest series.
Watch here: www.psychiatrictimes.com/clinical-case-collective/postpar… -
PsychiatryLive
@Psychiatry_Live
Long wait times for mental health care can have serious consequences—but New Hampshire is taking action. www.psychiatrictimes.com/view/delays-in-psychiatric-care-…
-
PsychiatryLive
@Psychiatry_Live
The first patient has been dosed in the second Phase 3 study of MM120, a psychedelic treatment for generalized anxiety disorder. What does this mean for the future of anxiety care? www.psychiatrictimes.com/view/first-patient-dosed-in-seco…
-
PsychiatryLive
@Psychiatry_Live
What if private practice could prioritize both clinicians and patients equally? Layne Gritti DO discusses joining Brittany Albright MD, MPH at her practice, where ethics are at the core of the practice's foundation.
www.psychiatrictimes.com/view/a-love-letter-to-my-workpla… -
PsychiatryLive
@Psychiatry_Live
On game day, dive into the unique psychological challenges athletes face, from performance anxiety to the pressure of competition. Understanding their mental game is just as crucial as their physical training. www.psychiatrictimes.com/view/clinical-pearls-inside-the-…
-
PsychiatryLive
@Psychiatry_Live
We at Psychiatric Times are excited to announce Dr. Wilsa Charles Malveaux, M.D., M.A., F.A.P.A. has joined our team as the Sports Psychiatry Section Editor!🎉 Get to know more about her and her practice here:
www.psychiatrictimes.com/view/wilsa-m-s-charles-malveaux-… -
PsychiatryLive
@Psychiatry_Live
The beginning of 2025 has seen exciting updates in research involving major depressive disorder. Check out 5 of the biggest updates from January and the first few days of February.
www.psychiatrictimes.com/view/major-depressive-disorder-p… -
PsychiatryLive
@Psychiatry_Live
How has public policy changed psychiatry over the last 40 years? Sara Robinson, DNP, RN, PMHNP-BC took some time to discuss 2 policy changes enacted that have impacted the way clinicians practice.
www.psychiatrictimes.com/view/public-policy-in-psychiatry… -
PsychiatryLive
@Psychiatry_Live
The February issue of Psychiatric Times is now live! This month, we take closer look at media excess and its impact on our mental health.
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6/psychtimes/3353f9d3b0d9aa53f… -
PsychiatryLive
@Psychiatry_Live
SSRIs are commonly used to treat depression and anxiety, but they may also increase the risk of bleeding. A new review explores how SSRIs affect platelet function, who may be most at risk, and what precautions should be considered. www.psychiatrictimes.com/view/the-impact-of-selective-ser…
-
PsychiatryLive
@Psychiatry_Live
The 2024 Paris Olympic Games showcased athletes' resilience and adaptability, offering valuable lessons for navigating our uncertain world. Embracing change, maintaining mental well-being, and fostering community can help us all thrive in 2025 and beyond.
www.psychiatrictimes.com/view/adapting-and-thriving-in-20… -
PsychiatryLive
@Psychiatry_Live
A new update from GH research shows promising results in the use of GH001 for treatment-resistant depression. Learn more about phase 2b of the trial: www.psychiatrictimes.com/view/positive-results-in-phase-2…
-
PsychiatryLive reposted
Texas A&M Public Health
@TAMU_SPH
Virtual Reality Meditation offers personalized experiences, enhances symptom relief for anxiety according to @TAMU_SPH research.
www.psychiatrictimes.com/view/virtual-reality-meditation-… via @psychtimes -
PsychiatryLive
@Psychiatry_Live
Our February theme: Emergency Psychiatry. www.psychiatrictimes.com/view/presenting-our-february-the…
-
PsychiatryLive
@Psychiatry_Live
For psychiatric clinicians, the work might not end for them when a session does. The emotions, stories, and challenges can stay. Here is how one clinician 'digests and metabolizes' clinical work.
www.psychiatrictimes.com/view/using-art-to-digest-and-met… -
PsychiatryLive
@Psychiatry_Live
In Montana, where access to mental health care is scarce, one county is stepping up with a Mobile Crisis Response Team—providing rapid, on-the-ground support when it’s needed most. Could more states benefit from a similar program? www.psychiatrictimes.com/view/montana-s-mental-health-cri…
-
PsychiatryLive
@Psychiatry_Live
During our time at Real Psychiatry, we sat down with clinicians working with patients who have ADHD. Here are some of the words of wisdom they offered!
www.psychiatrictimes.com/view/clinical-pearls-factors-whe… -
PsychiatryLive
@Psychiatry_Live
Missed some of our coverage this week? No problem! We wrapped the week in 5 pieces. www.psychiatrictimes.com/view/the-week-in-review-january-…
-
PsychiatryLive
@Psychiatry_Live
Postpartum depression can have long lasting impacts on mother, baby, and family if left untreated. In this Research Roundup, learn more about potential treatments and markers for postpartum depression.
www.psychiatrictimes.com/view/postpartum-depression-resea… -
PsychiatryLive
@Psychiatry_Live
Check it out! Here at Psychiatric Times, we are celebrating our 40th anniversary all year long. This month, take a look back at the last 5 January covers:
www.psychiatrictimes.com/view/psychiatric-times-through-t… -
PsychiatryLive
@Psychiatry_Live
A new study shows that meditation using immersive virtual reality devices provides greater relief from major depressive disorder and generalized anxiety disorder symptoms than meditation alone. www.psychiatrictimes.com/view/virtual-reality-meditation-…
-
PsychiatryLive
@Psychiatry_Live
How should clinicians approach loneliness in elderly patients, and how can technology assist in treatment? Temitope Ogundare shares his thoughts on some of the best approaches to loneliness in older adults.
www.psychiatrictimes.com/view/a-prescription-for-loneline… -
PsychiatryLive
@Psychiatry_Live
Shoutout to Axsome Therapeutics for their partnership in making Real Psychiatry 2025 a success. Your contribution brings valuable resources to psychiatric providers nationwide.
-
PsychiatryLive
@Psychiatry_Live
How do we guide ourselves through grief? Brittany Albright MD, MPH shares her experience and what a patient taught her about doing the work to feel better: "There's no magic pill." www.psychiatrictimes.com/view/no-magic-pill-a-psychiatris…
-
PsychiatryLive
@Psychiatry_Live
Thank you to Bristol Myers Squibb for supporting Real Psychiatry 2025 and helping us empower psychiatric providers with innovative discussions and solutions.
-
PsychiatryLive
@Psychiatry_Live
Polypharmacy in patients with traumatic brain injury (TBI) is often overlooked, especially during acute care, potentially hindering recovery. In this Special Report, learn more about how best to manage polypharmacy in patients with TBI.
www.psychiatrictimes.com/view/best-practices-for-polyphar… -
PsychiatryLive
@Psychiatry_Live
A big thank you to Sage Therapeutics | Biogen for sponsoring Real Psychiatry 2025! Your partnership helps us deliver valuable insights and foster meaningful connections in the psychiatric community.
-
PsychiatryLive
@Psychiatry_Live
Comprehensive medication reconciliation is vital to prevent drug interactions and ensure effective treatment in psychiatric practice. In this Special Report, learn more about medication reconciliation.
www.psychiatrictimes.com/view/its-time-to-reconcile-with-… -
PsychiatryLive
@Psychiatry_Live
Grateful for our sponsor, Boehringer Ingelheim, whose support helped make Real Psychiatry 2025 possible. Together, we’re driving impactful conversations in psychiatry.
-
PsychiatryLive
@Psychiatry_Live
Neurocrine Biosciences just announced the initiation of a phase 3 registrational study to evaluate the efficacy, safety, and tolerability of osavampator, a drug under development as an adjunctive treatment to antidepressants for major depressive disorder. www.psychiatrictimes.com/view/phase-3-study-initiated-osa…
-
PsychiatryLive
@Psychiatry_Live
The FDA has approved an update for the label for Qelbree to include new pharmacodynamic data and lactation data for breastfeeding women with ADHD, which shows the transfer of Qelbree into breastmilk is low. www.psychiatrictimes.com/view/label-update-for-adhd-treat…
-
PsychiatryLive
@Psychiatry_Live
Psychiatric diagnosis is more than just labeling symptoms—it’s a complex, evolving process influenced by science, culture, and individual experiences. Learn how Ronald W. Pies, MD, uses a prism model when diagnosing complex patients.
www.psychiatrictimes.com/view/the-prism-of-psychiatric-di… -
PsychiatryLive
@Psychiatry_Live
What are best practices when it comes to polypharmacy in traumatic brain injury? In this Special Report, Matthew Ashley, MD, JD discusses treatment from the moment the patient enters the emergency department to care long after injury.
www.psychiatrictimes.com/view/best-practices-for-polyphar… -
PsychiatryLive
@Psychiatry_Live
🌟📰 The January Issue of Psychiatric Times Is Here—Celebrating 40 Years! Explore decades of trusted insights, including the latest advancements in mental health care, groundbreaking research, and more.
Subscribe: one.psychiatrictimes.com/subscribe/ -
PsychiatryLive
@Psychiatry_Live
From the myths of the "tortured artist" to the real psychological dynamics at play, Jane B. Sofair, MD, sheds light on how creativity can both challenge and heal the mind.
www.psychiatrictimes.com/view/how-does-psychiatry-interfa… -
PsychiatryLive
@Psychiatry_Live
Need something to read this weekend? The entire January issue of Psychiatric Times, celebrating our 40th anniversary, is now live on our website. Read it here: www.psychiatrictimes.com/journals/psychiatric-times/vol-4…
-
PsychiatryLive
@Psychiatry_Live
Struggling with regret or fear? Cognitive Behavioral Therapy (CBT) can help you stay present and overcome these "two thieves" that steal your peace.
www.psychiatrictimes.com/view/cbt-and-the-2-thieves-regre… -
PsychiatryLive
@Psychiatry_Live
What is it like when clinicians have to adapt dues to limited resources? Grace Lehnerdt shares her experiences working in rural South Africa.
www.psychiatrictimes.com/view/rural-realities-resilience-… -
PsychiatryLive
@Psychiatry_Live
Does the psychiatric approach to treating women need to change? How does feminist thought consider psychiatric treatment? Awais Aftab shares his thoughts on "Out of Her Mind" by Linda Gask, Msc, PhD
www.psychiatrictimes.com/view/out-of-her-mind-how-we-are-… -
PsychiatryLive
@Psychiatry_Live
What are some of the best methodologies to treat patients with alcohol use disorder? In part 2 of our 6-part interview with Joseph Volpicelli MD, PhD, he discusses the treatments he uses with his patients.
www.psychiatrictimes.com/view/treating-alcohol-use-disord… -
PsychiatryLive
@Psychiatry_Live
Explore Atypical Antipsychotics for Adjunctive Treatment of Major Depressive Disorder, in which experts discuss major depressive disorder, its symptoms, and treatment options. #ad
Watch here: www.psychiatrictimes.com/view/atypical-antipsychotics-for… -
PsychiatryLive reposted
Awais Aftab
@awaisaftab
I reviewed Linda Gask’s (@suzypuss )
“Out of Her Mind: How We Are Failing Women’s Mental Health and What Must Change” for @PsychTimes
www.psychiatrictimes.com/view/out-of-her-mind-how-we-are-… -
PsychiatryLive
@Psychiatry_Live
The FDA has approved the Johnson & Johnson supplemental New Drug Application for Spravato, the first and only monotherapy for adults with treatment-resistant depression. www.psychiatrictimes.com/view/esketamine-ciii-nasal-spray…
-
PsychiatryLive
@Psychiatry_Live
What does psychiatry have to learn from Eastern religions? Psychiatric Times Editorial Board Member Renato D. Alarcón, MD, MPH reviews "eastern Religions, Spirituality, and Psychiatry" edited in part by H. Steven Moffic.
www.psychiatrictimes.com/view/eastern-religions-spiritual… -
PsychiatryLive
@Psychiatry_Live
How can personalized care, addressing comorbidities, and focusing on gradual improvement help increase treatment success for alcohol use disorder? We spoke with Joseph Volpicelli, MD, PhD, about how he approaches treating patients experiencing addiction. www.psychiatrictimes.com/view/revolutionizing-addiction-t…
-
PsychiatryLive
@Psychiatry_Live
Learn how LAIs offer an alternative treatment option for patients living with bipolar I disorder or schizophrenia. #ad
www.psychiatrictimes.com/view/offering-long-acting-inject…
INTENDED FOR US HEALTHCARE PROFESSIONAL AUDIENCES ONLY
© 2024 Otsuka America Pharmaceutical, Inc.
October 2024 23US24EUP0024 -
PsychiatryLive
@Psychiatry_Live
Our Editor in Chief has arrived! Don't miss John J. Miller, MD's sessions tomorrow at #realpsychiatry
-
PsychiatryLive
@Psychiatry_Live
Approximately 75% of patients with schizophrenia and 78% of caregivers report that residual negative symptoms are an ongoing concern despite treatment with antipsychotics. www.psychiatrictimes.com/view/breaking-down-barriers-to-q…
-
PsychiatryLive
@Psychiatry_Live
Want a free issue of Psychiatric Times? Stop by our booth in the exhibit hall at #realpsychiatry to grab our latest copies!
-
PsychiatryLive
@Psychiatry_Live
A new study links genetic predispositions for psychiatric disorders to a higher likelihood of divorce. The research sheds new light on the interplay between mental health and relationships.
www.psychiatrictimes.com/view/study-links-divorce-to-gene… -
PsychiatryLive
@Psychiatry_Live
Sports psychiatry is becoming a game-changer in performance and mental health. @drmirhom talks with sports psychiatrist Derek H. Suite, MD, MS, about how the field goes beyond the playing field to shape the future of sports and the well-being of athletes.
www.psychiatrictimes.com/view/beyond-the-sidelines-the-ev… -
PsychiatryLive
@Psychiatry_Live
From new findings on neuromodulatory treatments to potential prevention, here’s a quick roundup of the latest findings on Major Depressive Disorder.
www.psychiatrictimes.com/view/major-depressive-disorder-r… -
PsychiatryLive
@Psychiatry_Live
Explore personalized PTSD treatments in this Clinical Case Collective series.
Watch now: www.psychiatrictimes.com/clinical-case-collective/optimiz… -
PsychiatryLive
@Psychiatry_Live
Leverage digital tools to improve MDD care and outcomes.
Watch here: www.psychiatrictimes.com/clinical-case-collective/expandi… -
PsychiatryLive
@Psychiatry_Live
The lates update in lecanemab’s journey: the FDA has accepted the Biologics License Application for lecanemab-irmb subcutaneous autoinjector for weekly maintenance dosing. www.psychiatrictimes.com/view/fda-accepts-biologics-licen…
-
PsychiatryLive
@Psychiatry_Live
The FDA has granted Breakthrough Device Designation to Spear Bio’s pTau 217 blood test for Alzheimer disease. www.psychiatrictimes.com/view/fda-grants-breakthrough-dev…
-
PsychiatryLive
@Psychiatry_Live
The mental health landscape is evolving, and psychiatric leaders are at the forefront of this transformation. Poorvanshi Alag, MD, and @DrSarahBethWake discuss how today's challenges demand innovation, collaboration, and a forward-thinking mindset.
www.psychiatrictimes.com/view/psychiatric-leadership-in-t… -
PsychiatryLive
@Psychiatry_Live
Bipolar I disorder (BD-I) can be difficult to diagnose and treat due to overlapping symptoms and stigma. What can clinicians utilize to help manage BD-I for better long-term outcomes?
www.psychiatrictimes.com/view/bipolar-disorders-basic-con… -
PsychiatryLive
@Psychiatry_Live
Johnson & Johnson today announced that they will acquire all outstanding shares of Intra-Cellular Therapies, as well as their therapeutic pipeline, including lumateperone. www.psychiatrictimes.com/view/johnson-johnson-acquired-in…
-
PsychiatryLive
@Psychiatry_Live
How do we truly connect with our patients? @pzahid_MD discusses a book about one doctor’s personal journey exploring the quest for empathy, understanding, and humanity in medicine.
www.psychiatrictimes.com/view/how-do-you-feel-one-doctor-… -
PsychiatryLive
@Psychiatry_Live
Join us in congratulating Allan Tasman, MD, Editor in Chief Emeritus of Psychiatric Times, on his recent win of the Hartford HealthCare Institute of Living’s 2024 C. Charles Burlingame award!
www.psychiatrictimes.com/view/allan-tasman-md-receives-aw… -
PsychiatryLive
@Psychiatry_Live
Take a journey to the past, all the way to our first issue in 1985, with our current and former Editors in Chief in this month's cover story: www.psychiatrictimes.com/view/celebrating-40-years-lookin…
-
PsychiatryLive
@Psychiatry_Live
Postpartum depression affects 1 in 7 new mothers.
Learn how to support maternal mental health with expert insights.
www.psychiatrictimes.com/clinical-case-collective/postpar… -
PsychiatryLive
@Psychiatry_Live
How can psychiatric clinicians ensure their practices are accessible to patients with disabilities? Jessica Williams, MD, and @donaldeganMD discuss.
www.psychiatrictimes.com/view/adaptive-psychiatry-a-frame… -
PsychiatryLive
@Psychiatry_Live
Discover the latest in postpartum depression treatment options, including zuranolone, and how these treatments can transform care.
Watch here: www.psychiatrictimes.com/case-based-psych-perspectives/po…
#ppdtreatment #mentalhealthcare -
PsychiatryLive
@Psychiatry_Live
The FDA has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody being investigated for the treatment of patients with early Alzheimer's. www.psychiatrictimes.com/view/fda-grants-fast-track-desig…
-
PsychiatryLive
@Psychiatry_Live
LB Pharmaceuticals just announced positive topline results from a phase 2 dose finding trial evaluating LB-102, a potential first-in-class benzamide antipsychotic, in adult patients with acute schizophrenia. www.psychiatrictimes.com/view/lb-102-sees-positive-phase-…
-
PsychiatryLive
@Psychiatry_Live
In case you missed it, navacaprant for the treatment of major depressive disorder has failed in the phase 3 KOASTAL-1 trial. www.psychiatrictimes.com/view/navacaprant-for-major-depre…
-
PsychiatryLive
@Psychiatry_Live
What does Microsoft's Copilot think about medieval philosophy? Ronald W. Pies, MD, had a conversation with the AI-powered assistant to discuss how 'real' psychiatric disorders like schizophrenia are. Read it here:
www.psychiatrictimes.com/view/how-real-are-psychiatric-di… -
PsychiatryLive
@Psychiatry_Live
Want to be featured in an upcoming Special Report? Submit to our themed content series! www.psychiatrictimes.com/view/presenting-our-january-them…
-
PsychiatryLive
@Psychiatry_Live
The January issue of Psychiatric Times is now live! This month, we kick off the celebration of our 40th anniversary!
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6/psychtimes/9d62861712c3f17ed… -
PsychiatryLive reposted
Dinah Miller, M.D. @shrinkrapdinah
The final wrap-up on my journal of learning to do Ketamine Assisted Psychotherapy. A year into it and here is what't I've come to:www.psychiatrictimes.com/view/lessons-learned-a-wrap-up-o…. @PsychTimes
-
PsychiatryLive
@Psychiatry_Live
We’re celebrating 40 years as the Voice of Psychiatry! Since 1985, Psychiatric Times has been amplifying conversations that matter to psychiatric clinicians.
Here’s to 40 years of learning, growing, and innovating together! -
PsychiatryLive reposted
Alto Neuroscience
@AltoNeuro
Our CEO, @AmitEtkin, spoke with @PsychTimes about our #acnp2024 presentations, including advances in #neuroimaging & the link between ALTO-300's MOA & its #eeg #biomarker in patients with #majordepressivedisorder. Watch the full interview here: www.psychiatrictimes.com/view/alto-neuroscience-presents-…
-
PsychiatryLive
@Psychiatry_Live
If you're looking for something to read, all 12 issues of Psychiatric Times from 2024 are available to peruse online! www.psychiatrictimes.com/journals/psychiatric-times
-
PsychiatryLive
@Psychiatry_Live
If you're looking to earn CME credit over your holiday break, we've got a present for you! www.psychiatrictimes.com/view/the-gift-of-cme-credit
-
PsychiatryLive
@Psychiatry_Live
That's a wrap on 2024! May this festive season bring you joy, health, and cherished moments with your loved ones. Our team looks forward to serving you in the coming year and contributing to your future success!
-
PsychiatryLive
@Psychiatry_Live
Tell us a little bit about how you're handling the holidays here: www.psychiatrictimes.com/view/poll-how-are-you-handling-t…
-
PsychiatryLive
@Psychiatry_Live
Your holiday reading just dropped! The entire December issue of Psychiatric Times is now live on our website. Read it here: www.psychiatrictimes.com/journals/psychiatric-times/vol-4…
-
PsychiatryLive
@Psychiatry_Live
Empower your clinical decisions with expert guidance on MDD care.
Start watching today: www.psychiatrictimes.com/clinical-case-collective/expandi… -
PsychiatryLive
@Psychiatry_Live
New positive topline results from an open-label phase 2a study of IV psilocin benzoate in patients with major depressive disorder showed that the treatment delivers rapid, lasting antidepressant effects for up to 3 months following a single dose. www.psychiatrictimes.com/view/iv-psilocin-benzoate-for-ma…
-
PsychiatryLive
@Psychiatry_Live
Would you like to be featured in an upcoming print issue? Submit an article on child & adolescent psychiatry! www.psychiatrictimes.com/view/submission-call-child-adole…
-
PsychiatryLive
@Psychiatry_Live
A study across four states found ERPOs can save one life for every 13 orders issued, despite not being 100% effective. Read more about ERPOs in our special report:
www.psychiatrictimes.com/view/study-finds-erpos-can-preve… -
PsychiatryLive
@Psychiatry_Live
In some cases of child murder by the mother, psychiatrists may have a critical role in prevention. Learn more here:
www.psychiatrictimes.com/view/mothers-and-child-murder-ho… -
PsychiatryLive
@Psychiatry_Live
What can you expect if you are attending the 2024 American College of Neuropsychopharmacology? Read more here and let us know what you would like to see covered! @ACNPorg
Are you attending the meeting? Let us know what you think!
www.psychiatrictimes.com/view/previewing-acnp-annual-meeting -
PsychiatryLive
@Psychiatry_Live
Explore practical tools for PTSD diagnosis and management in this Clinical Case Collective series.
Learn more: www.psychiatrictimes.com/clinical-case-collective/optimiz… -
PsychiatryLive
@Psychiatry_Live
In a new study from Stanford, Ibogaine has been found to reduce mood disorder and PTSD symptoms, as well as reducing alcohol consumption in patients with alcohol use disorder.
www.psychiatrictimes.com/view/ibogaine-found-to-reduce-mo… -
PsychiatryLive
@Psychiatry_Live
What if biomarkers could tell you whether or not a depression treatment would work before a patient started? We spoke with Rudolf Uher MUDr, PhD on a new study from Dalhousie University:
www.psychiatrictimes.com/view/curating-depression-treatme… -
PsychiatryLive
@Psychiatry_Live
As #theerastour comes to a close, H. Steven Moffic, MD, reflects on the impacts #taylorswift has had on the young women and girls who have come into his practice.
www.psychiatrictimes.com/view/gratitude-for-taylor-swift -
PsychiatryLive
@Psychiatry_Live
A study presented at @ACNPorg examined a rapid-acting antidepressant's safety and tolerability when used as adjunctive therapy for adults with MDD. We spoke to Himanshu Upadhyaya,MBBS, MBA, about the findings: www.psychiatrictimes.com/view/spn-820-rapid-acting-antide…
-
PsychiatryLive
@Psychiatry_Live
The limited utility of biomarkers in differentiating between clinical cases and controls is the focus of research being done by Arthur Caye, MD. We caught up with him at @ACNPorg
PhDwww.psychiatrictimes.com/view/innovative-biomarker-resear… -
PsychiatryLive
@Psychiatry_Live
We caught up with @therealRYC at the 63rd meeting of @ACNPorg where he discussed his research leveraging machine learning to aid in assessing cognitive deficits. Watch our interview here:
www.psychiatrictimes.com/view/cognitive-impairment-in-sch… -
PsychiatryLive
@Psychiatry_Live
“It’s surprising that a single gene could even imitate anything about schizophrenia,” said Psychiatric Times Editorial Board member Thomas R. Kosten, MD, when we ccaught up with him at @ACNPorg. Watch:
www.psychiatrictimes.com/view/exploring-genetic-models-in… -
PsychiatryLive
@Psychiatry_Live
In an exclusive video interview with Psychiatric Times, Romina Mizrahi, MD, and M. Belen Blasco, MD, discuss the clinical relevance of their findings on synaptic dysfunction in psychosis they presented at @ACNPorg
www.psychiatrictimes.com/view/synaptic-dysfunction-in-psy… -
PsychiatryLive
@Psychiatry_Live
So much is happening at the 63rd annual meeting of @ACNPorg right now! Check out some of the research highlights with Psychiatric Times Editorial Board member Thomas R. Kosten, MD. www.psychiatrictimes.com/view/acnp-research-highlights-wi…
-
PsychiatryLive
@Psychiatry_Live
Optimize MDD outcomes by integrating advanced digital solutions into your practice.
Discover how today: www.psychiatrictimes.com/clinical-case-collective/expandi… -
PsychiatryLive
@Psychiatry_Live
"The big argument goes something like this: More and more people in our society get mental health treatment, and yet rates of mental illness continue to go up." Read more about a big misconception in psychiatry here:
www.psychiatrictimes.com/view/the-dumbest-idea-in-mental-… -
PsychiatryLive
@Psychiatry_Live
Excited for a busy day at the 63rd Annual Meeting of the @ACNPorg filled with panel discussions, posters, and interviews - including a surprise Psychiatric Times guest!
-
PsychiatryLive
@Psychiatry_Live
Check out this case example exploring the spectrum of mixed states. www.psychiatrictimes.com/view/coping-with-diagnostic-unce…
-
PsychiatryLive
@Psychiatry_Live
The December issue of Psychiatric Times is now live! This month, we cover the ethics of psychiatric hospitalization and more.
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6/psychtimes/b032fd56ba4e189ea… -
PsychiatryLive
@Psychiatry_Live
Give the gift of psychiatry: If you're looking to buy books as gifts this year, we've got you covered. www.psychiatrictimes.com/view/gift-guide-for-psychiatric-…
-
PsychiatryLive
@Psychiatry_Live
Intra-Cellular Therapies has submitted an sNDA for lumateperone for the treatment of major depressive disorder in adults as adjunctive therapy to antidepressants. www.psychiatrictimes.com/view/snda-submitted-lumateperone…
-
PsychiatryLive
@Psychiatry_Live
Some of the things we do in the name of mental health will one day seem bizarre and barbaric to those who come after us… But what's the dumbest idea in psychiatry? www.psychiatrictimes.com/view/the-dumbest-idea-in-mental-…
-
PsychiatryLive
@Psychiatry_Live
What did you learn this year in your psychiatric practice? What do you want to share with your fellow clinicians? What populations are currently underserved and how can we help?
Submit to our December theme! www.psychiatrictimes.com/view/presenting-our-december-the… -
PsychiatryLive
@Psychiatry_Live
The use of validated and scalable risk prediction tools can potentially improve mental health outcomes in forensic patients. www.psychiatrictimes.com/view/violence-risk-assessment-us…
-
PsychiatryLive
@Psychiatry_Live
Happy Thanksgiving from the Psychiatric Times family to yours!
-
PsychiatryLive
@Psychiatry_Live
📰 The November issue of Psychiatric Times features insights on youth inpatient care for eating disorders, lithium’s antisuicidal effects, violence risk tools, and more. Explore the articles designed to inform and inspire clinicians.
Subscribe now: one.psychiatrictimes.com/subscribe/ -
PsychiatryLive reposted
Columbia Psychiatry
@ColumbiaPsych
“I think I have ADHD, doc. I saw this TikTok…” @DrMirhom writes in @PsychTimes about the need for psychiatrists to better navigate such conversations with patients and to put their own voices into the public education sphere to combat misinformation. www.psychiatrictimes.com/view/mind-the-media-teaching-psy…
-
PsychiatryLive
@Psychiatry_Live
In the phase 3 ENCORE trial, AXS-12 reduced the frequency of cataplexy attacks as compared with placebo at week 3 of the double-blind period. www.psychiatrictimes.com/view/narcolepsy-treatment-axs-12…
-
PsychiatryLive
@Psychiatry_Live
Conspiracy theories can lead individuals to engage in criminal and violent behaviors. It is necessary for psychiatrists treating or forensically evaluating individuals with conspiracy theories to be able to correctly identify different forms of belief. www.psychiatrictimes.com/view/understanding-and-evaluatin…
-
PsychiatryLive
@Psychiatry_Live
The Center for Medicare and Medicaid Services recently recognized brain injury as a chronic health condition. Learn more here: www.psychiatrictimes.com/view/brain-injury-is-a-chronic-h…
-
PsychiatryLive
@Psychiatry_Live
Need CME credit? Learn more about the hospital management of pediatric patients with severe malnutrition related to eating disorders, including the utilization of a multidisciplinary care team and structured psychoeducation materials for families. www.psychiatrictimes.com/view/multidisciplinary-inpatient…
-
PsychiatryLive
@Psychiatry_Live
Malingering, also known as the intentional feigning of symptoms for a secondary gain, is an ever-present entity in the realm of forensic and correctional facilities. Learn more in our latest Special Report article! www.psychiatrictimes.com/view/malingering-in-the-forensic…
-
PsychiatryLive
@Psychiatry_Live
Weekend reading: The entire November issue of Psychiatric Times is now live on our website! Read it here: www.psychiatrictimes.com/journals/psychiatric-times/vol-4…
-
PsychiatryLive
@Psychiatry_Live
How can you best discuss long-acting injectable options with your patients living with schizophrenia? www.psychiatrictimes.com/view/long-acting-injectables-and…
-
PsychiatryLive reposted
Mena Mirhom, MD, FAPA
@DrMirhom
Happy #movember , this Men’s health month- we can consider the ways to discuss mental health with men & why our language matters.
More in the latest @PsychTimes article!
@APApsychiatric
www.psychiatrictimes.com/view/our-capes-are-killing-us-ho… -
PsychiatryLive reposted
Seena Fazel
@seenafazel
We’ve written a short summary of our recent research on risk assessment in mental health for @PsychTimes. Also provides a wider overview of violence risk assessment in forensic and general mental health settings. www.psychiatrictimes.com/view/violence-risk-assessment-us…
-
PsychiatryLive
@Psychiatry_Live
Your patient just offered you a gift. What do you do?
Check out these guidelines: www.psychiatrictimes.com/view/help-my-patient-gave-me-a-g… -
PsychiatryLive reposted
Khutaija Noor @NKhutaija
Excited to share that my article is published!
Beyond Dopamine: Muscarinic Solutions Bring New Hope for Schizophrenia www.psychiatrictimes.com/view/beyond-dopamine-muscarinic-… via @@psychtimes -
PsychiatryLive
@Psychiatry_Live
A systematic review and meta-analysis showed moderate-quality evidence supporting lithium’s ability to lower mortality rates. www.psychiatrictimes.com/view/exploring-the-antisuicidal-…
-
PsychiatryLive
@Psychiatry_Live
Trauma-informed care, incorporating safety, trust, and collaboration, is crucial for effective treatment and recovery in individuals with psychosis. Check out clinical pearls in treatment in our latest Special Report article here: www.psychiatrictimes.com/view/opening-pandoras-box-the-im…
-
PsychiatryLive
@Psychiatry_Live
If you are a psychiatrist, psychiatric NP/PA, psychologist, psychiatric social worker, or master’s level therapist and you have ever lactated while working in these fields, OR you are currently planning lactation, fill out this survey. www.psychiatrictimes.com/view/challenges-to-breastfeeding…
-
PsychiatryLive
@Psychiatry_Live
There is an accumulating body of evidence that metformin may have benefits in aging beyond its effect on glycemic control. Learn about the latest updates here. www.psychiatrictimes.com/view/happy-accidents-repurposing…
-
PsychiatryLive
@Psychiatry_Live
How can we ensure an accountable, effective, and limited conservatorship system? Here are some actionable concepts. www.psychiatrictimes.com/view/abdicated-authority-how-we-…
-
PsychiatryLive
@Psychiatry_Live
Transform how you manage MDD with expert-driven digital tools.
Learn more now: www.psychiatrictimes.com/clinical-case-collective/expandi… -
PsychiatryLive
@Psychiatry_Live
Happy National Nurse Practitioner Week! We are proud to partner with NPs to help improve mental health outcomes.
This week, check out 5 self-care tips from our Nurse Practitioner Liaison: www.psychiatrictimes.com/view/5-important-self-care-tips-… -
PsychiatryLive
@Psychiatry_Live
Having a happy intimate partner might lift your mood and help you manage stress, especially as you age, says new research. www.sciencedaily.com/releases/2024/10/241022153820.htm
-
PsychiatryLive
@Psychiatry_Live
Perinatal loss is prevalent, with significant psychiatric sequelae, including grief, depression, and anxiety disorders, necessitating careful psychiatric evaluation and management. www.psychiatrictimes.com/view/navigating-perinatal-loss
-
PsychiatryLive
@Psychiatry_Live
The FDA has granted clearance to the Horizon Inspire transcranial magnetic stimulation system to treat major depressive disorder, obsessive-compulsive disorder, and anxious depression. www.psychiatrictimes.com/view/newly-fda-cleared-tms-for-m…
-
PsychiatryLive
@Psychiatry_Live
Treatment of aggression is currently constrained within treatment of the associated disorder. However, there are sufficient data to suggest that it is reasonable to view aggression itself as a potential target for treatment. www.psychiatrictimes.com/view/time-to-think-of-aggression…
-
PsychiatryLive
@Psychiatry_Live
According to new research, CBT for insomnia significantly reduces postpartum depression symptoms by improving mood and alleviating insomnia throughout treatment. www.sciencedaily.com/releases/2024/10/241031151713.htm
-
PsychiatryLive
@Psychiatry_Live
Emraclidine once-daily, oral monotherapy treatment for adults with schizophrenia experiencing acute psychotic symptoms, failed to meet the primary endpoints in the 2 phase 2 EMPOWER trials. www.psychiatrictimes.com/view/emraclidine-for-schizophren…
-
PsychiatryLive
@Psychiatry_Live
Research suggests cohabiting couples may have a lower risk of depression than single individuals who live alone. www.theguardian.com/lifeandstyle/2024/nov/04/moving-in-wi…
-
PsychiatryLive
@Psychiatry_Live
ADHD in adults is underdiagnosed, often masked by comorbid conditions, leading to significant psychosocial impairments.
Here are 7 considerations for clinicians looking to diagnose a potential case of adult ADHD. www.psychiatrictimes.com/view/adhd-overlooked-cause-of-pe… -
PsychiatryLive reposted
Nolan Williams
@NolanRyWilliams
Incredibly rewarding to see SAINT therapy demonstrate promise for reducing depressive symptoms of bipolar 1 disorder in an open label, feasibility and safety trial. Congratulations to lead author, Kevin Li, M.D. at Johns Hopkins. Read more in @PsychTimes:
www.psychiatrictimes.com/view/saint-itbs-protocol-shows-p… -
PsychiatryLive
@Psychiatry_Live
Join us tonight at 7:00 PM ET for a free CME live stream on schizophrenia. This one-hour session covers emerging treatments, focusing on therapies for negative symptoms and cognitive deficits. Don’t miss it! Tune in here: gotoper.com/psychsum
-
PsychiatryLive
@Psychiatry_Live
How can you, as psychiatric clinicians, help your patients identify and navigate the aftermath of the election? www.psychiatrictimes.com/view/processing-post-election-re…
-
PsychiatryLive
@Psychiatry_Live
According to new research, CBT for insomnia significantly reduces postpartum depression symptoms by improving mood and alleviating sleep issues throughout treatment. www.sciencedaily.com/releases/2024/10/241031151713.htm
-
PsychiatryLive reposted
Nicolas Badre
@BadreNicolas
Abdicated Authority: How We Fail Conservatees
My latest article for @PsychTimes about conservatorship
www.psychiatrictimes.com/view/abdicated-authority-how-we-…
🧵 -
PsychiatryLive
@Psychiatry_Live
According to data from the EMERGENT-4 and EMERGENT-5 trials, treatment with xanomeline/trospium led to significant improvements in PANSS and CGI-S scores over 52 weeks, indicating sustained efficacy. www.psychiatrictimes.com/view/posters-share-positive-data…
-
PsychiatryLive
@Psychiatry_Live
New positive results demonstrate the efficacy and safety of lumateperone 42 mg for the prevention of relapse in adult patients with schizophrenia. www.psychiatrictimes.com/view/positive-phase-3-results-ev…
-
PsychiatryLive
@Psychiatry_Live
According to new research, there may be a significant link between depression and body temperature. www.ndtv.com/science/study-reveals-possible-link-between-…
-
PsychiatryLive
@Psychiatry_Live
The SAINT protocol rapidly reduced depressive symptoms in bipolar I disorder, achieving 60% remission within a month post-treatment without adverse cognitive or manic effects, according to a new study. www.psychiatrictimes.com/view/saint-itbs-protocol-shows-p…
-
PsychiatryLive
@Psychiatry_Live
Flying anxiety? Portland airport is using llamas and alpacas for stress relief at its terminals. www.businessinsider.com/portland-airport-uses-llamas-for-…
-
PsychiatryLive
@Psychiatry_Live
Let's analyze the different ethical considerations when it comes to mandated psychiatric treatment. www.psychiatrictimes.com/view/ethical-considerations-of-i…
-
PsychiatryLive
@Psychiatry_Live
A majority of Americans report feeling stressed by the presidential election. Here's how to alleviate some anxiety. www.cbsnews.com/news/election-2024-stress-anxiety-tips-ex…
-
PsychiatryLive
@Psychiatry_Live
The November issue of Psychiatric Times is now live! This month, we cover partnership and cooperation between mental health clinicians and law enforcement.
Download the issue now and follow along as articles are shared throughout the month. cdn.sanity.io/files/0vv8moc6/psychtimes/e10ffe3e89a70766a… -
PsychiatryLive
@Psychiatry_Live
Our November theme: Clinical Case Studies! www.psychiatrictimes.com/view/presenting-our-november-the…
-
PsychiatryLive reposted
Vot-ER
@Vot_ER_org
🚨 5 DAYS TO ELECTION DAY: Did you know that only 50% of young voters made it to the polls in 2020? @PsychTimes highlights how healthcare providers can help change that. Read the full article here: www.psychiatrictimes.com/view/empowering-minds-shaping-fu…
#civichealth #gotv #electionday #earlyvoting #voter -
PsychiatryLive
@Psychiatry_Live
Trauma labor, rooted in systemic issues, burdens health care professionals, exacerbating burnout and distress. www.psychiatrictimes.com/view/beyond-emotional-labor-expl…
-
PsychiatryLive
@Psychiatry_Live
Early intervention in psychosis is vital for enhancing recovery outcomes and reducing stigma. www.psychiatrictimes.com/view/bridging-gaps-the-symbiosis…
-
PsychiatryLive
@Psychiatry_Live
Need CME credit? Learn more about the efficacy and tolerability of brexpiprazole for the treatment of agitation among individuals with Alzheimer disease dementia. www.psychiatrictimes.com/view/evaluating-brexpiprazole-fo…
-
PsychiatryLive
@Psychiatry_Live
Malnutrition, particularly zinc deficiency, plays a critical role in anorexia nervosa, affecting neurochemistry and mental health. www.psychiatrictimes.com/view/think-zinc-micronutrient-su…
-
PsychiatryLive
@Psychiatry_Live
A new study shows that rTMS has moderate therapeutic effects on OCD severity. www.psychiatrictimes.com/view/tms-for-the-treatment-of-ocd
-
PsychiatryLive reposted
Dinah Miller, M.D. @shrinkrapdinah
My review of Blind Spots by Marty Makary, MD in @PsychTimes www.psychiatrictimes.com/view/is-medical-research-one-mor…
-
PsychiatryLive
@Psychiatry_Live
The October issue of Psychiatric Times is out! Explore confidentiality dilemmas in psychiatric care, from HIPAA’s impact on decision-making to balancing patient safety and privacy.
Subscribe now to stay informed: one.psychiatrictimes.com/subscribe/ -
PsychiatryLive
@Psychiatry_Live
Deficiency in vitamin D is linked to increased risk of depression, ADHD, anxiety, and suicide, with supplementation showing potential benefits. www.psychiatrictimes.com/view/mental-health-in-the-sun-th…
-
PsychiatryLive reposted
Henry, PhD
@HeyArtez
Late post, but check out our article in @PsychTimes about future directions in treating prolonged grief disorder and the importance of incorporating cultural adaptations in light of COVID-19. Thanks to Dani Spencer-Laitt @ Boston U for leading this!
www.psychiatrictimes.com/view/treating-prolonged-grief-di… -
PsychiatryLive reposted
nccPA Health Fdn @nccPAHealthFdn
#icymi: The nccPA Health Foundation established a strategic alliance partnership w/ @PsychTimes. Read more in @NCCPAcert news: nccpacc.us.newsweaver.com/nccpa-news/bmrbl1754t615hxi92kx…
#pasdothat #pasformentalhealth #mentalillness #mentalillnessawareness #anxiety #depression #suicideprevention #everypaisapsychpa -
PsychiatryLive
@Psychiatry_Live
Before acting on something sensational, you can take a breath, stop, and say, “If true…" www.psychiatrictimes.com/view/if-true
-
PsychiatryLive
@Psychiatry_Live
Happy Wednesday! The entire October issue of Psychiatric Times is now live on our website! Read it here: www.psychiatrictimes.com/journals/psychiatric-times/vol-4…
-
PsychiatryLive
@Psychiatry_Live
The first episode of schizophrenia is a critical period of illness. Learn more about how to manage it in our October Special Report. www.psychiatrictimes.com/view/first-episode-schizophrenia…
-
PsychiatryLive reposted
Autumn House Press
@AutumnHousePrs
Richard Berlin, MD, shares the poem "Owls" by AHP's Liza Katz Duncan, author of Given, which received the Autumn House Press Rising Writer Award and the Laurel Prize for Best International First Collection.
www.psychiatrictimes.com/view/owls-poem via @@psychtimes -
PsychiatryLive
@Psychiatry_Live
Cobenfy: Here are 3 things to be excited about and 3 things to keep an eye on, according to Michael Asbach, DMSc, PA-C, Psych-CAQ. www.psychiatrictimes.com/view/cobenfy-3-things-to-be-exci…
-
PsychiatryLive
@Psychiatry_Live
Adjunctive rTMS for antidepressant nonresponders? Researchers performed a randomized comparison with current antidepressant treatment approaches. www.psychiatrictimes.com/view/rtms-for-antidepressant-non…
-
PsychiatryLive
@Psychiatry_Live
Postpartum psychosis is a rare psychiatric emergency with an incidence of 0.89 to 2.6 per 1000 births, requiring prompt identification and treatment. www.psychiatrictimes.com/view/postpartum-psychosis-compli…
-
PsychiatryLive
@Psychiatry_Live
Pharmacokinetic analysis shows comparable properties when switching from once-monthly RBP-7000 to Uzedy after 4 weeks. Learn more about the data shared at the 37th Annual ECNP Congress here. www.psychiatrictimes.com/view/uzedy-reducing-the-risk-of-…
-
PsychiatryLive
@Psychiatry_Live
Low-dose lithium can act like a bridge between medications and integrative approaches, supporting well-being with reduced adverse effects. Check out some of the positive research on this treatment. www.psychiatrictimes.com/view/low-dose-lithium-a-new-fron…
-
PsychiatryLive
@Psychiatry_Live
Lorcaserin, a serotonin 5-HT2C agonist, was studied for efficacy in treating cocaine use disorder but failed to demonstrate significant results. www.psychiatrictimes.com/view/a-randomized-controlled-tri…
-
PsychiatryLive
@Psychiatry_Live
TEV-‘749 is an investigational once-monthly subcutaneous long-acting injectable that steadily releases olanzapine—the most prescribed second generation antipsychotic for schizophrenia in the US. Learn more about the most recent data: www.psychiatrictimes.com/view/tev-749-an-option-to-serve-…
-
PsychiatryLive
@Psychiatry_Live
Much progress has been made in developing evidence-based nonpharmacological treatment for trauma. www.psychiatrictimes.com/view/complex-ptsd-a-necessary-ds…
-
PsychiatryLive reposted
American Psychiatric Association
@APApsychiatric
Celebrating the resilience and rich cultures of Indigenous peoples’ today and every day. #indigenouspeoplesday
-
PsychiatryLive
@Psychiatry_Live
Is forcing a school shooter to donate his brain to scientific study unethical? www.psychiatrictimes.com/view/the-ethics-of-a-donated-bra…
-
PsychiatryLive reposted
Mena Mirhom, MD, FAPA
@DrMirhom
“When I got injured, what I leaned on the heaviest was my faith and my therapist.” a former NBA player told me.
Thank you @PsychTimes for publishing this. Our work at @AthletesForHope explores this partnership more!
www.psychiatrictimes.com/view/mind-and-soul-of-the-athlete -
PsychiatryLive reposted
nccPA Health Fdn @nccPAHealthFdn
The nccPA Health Foundation is announcing our new #partnership with @PsychTimes, an opportunity to highlight the role of #certifiedpas to expanding access to mental health care: www.psychiatrictimes.com/sap-partner/nccpa-health-foundation
#pasformentalhealth #mentalillness #everypaisapsychpa
Psychiatric Times -
PsychiatryLive reposted
Vincenzo Di Nicola @PhiloShrink
For my 25th column in Psychiatric Times, John Farnsworth, PhD, sociologist and psychotherapist from New Zealand, interviewed me about social psychiatry
www.psychiatrictimes.com/view/how-to-connect-things-a-rel… via @@psychtimes -
PsychiatryLive
@Psychiatry_Live
The CDC just released the Morbidity and Mortality Weekly Report, which highlights issues around adult ADHD prevalence, diagnosis, and treatment.
Explore the most recent data with Greg Mattingly, the president of @APSARD.
www.psychiatrictimes.com/view/insights-into-the-new-cdc-d…
PsychiatryLive
@Psychiatry_Live
Upcoming APSARD guidelines will aim to standardize adult ADHD care in the US, improving patient outcomes. www.psychiatrictimes.com/view/new-cdc-data-highlights-the…
-
PsychiatryLive
@Psychiatry_Live
Today is #worldmentalhealthday, a celebration of mental health education, awareness, and advocacy against stigma. This year's theme is "Mental Health at Work."
What do you do to improve your mental health while working? -
PsychiatryLive
@Psychiatry_Live
The FDA has granted Fast Track designation to Denovo Biopharma LLC’s DB104 (liafensine) for patients with treatment-resistant depression. www.psychiatrictimes.com/view/fast-track-designation-gran…
-
PsychiatryLive
@Psychiatry_Live
A growing body of research documents the effectiveness of CBT for racially diverse populations, including Black Americans. Learn more from a conversation between @drjudithbeck and Janeé M. Steele, PhD. www.psychiatrictimes.com/view/a-conversation-about-black-…
-
PsychiatryLive reposted
Dinah Miller, M.D. @shrinkrapdinah
The next entry in my Ketamine Assisted psychotherapy journal is posted on @PsychTimes . My first experience doing KAP in a small group:
www.psychiatrictimes.com/view/doing-it-together-ketamine-… #kap #psychelics -
PsychiatryLive reposted
Spinogenix @Spinogenix_Inc
This feature in @PsychTimes highlights our progress advancing #spg302 as the first synaptic regenerative therapy for #schizophrenia, now in Phase 2 #clinicaltrials. By targeting #synapse loss, we are redefining how we treat this condition. Read more: www.psychiatrictimes.com/view/first-synaptic-regenerative…
-
PsychiatryLive
@Psychiatry_Live
Clinicians can ensure high-quality care by remaining informed about legal and ethical considerations in navigating patient privacy dilemmas. Learn more about HIPAA Privacy Rule issues in our October cover story! www.psychiatrictimes.com/view/confidentiality-dilemmas-hi…
-
PsychiatryLive
@Psychiatry_Live
Do you want to be featured in our online series and potentially in print for an upcoming Special Report? Check out our October theme: Psychiatric Best Practices! www.psychiatrictimes.com/view/presenting-our-october-them…
-
PsychiatryLive
@Psychiatry_Live
The October issue of Psychiatric Times is now live! This month, we address ethical issues concerning the HIPAA Privacy Rule and the Goldwater Rule.
Download the issue now and follow along as articles are shared throughout the month.
cdn.sanity.io/files/0vv8moc6/psychtimes/458685cfeac69909b… -
PsychiatryLive
@Psychiatry_Live
Teen pregnancy is often viewed through a very negative lens. This book seeks to reduce that stigma. www.psychiatrictimes.com/view/adolescent-pregnancy-and-pa…
-
PsychiatryLive
@Psychiatry_Live
"Galaxy Gas": Learn more about the latest viral substance abuse trend. www.psychiatrictimes.com/view/galaxy-gas-the-dangerous-vi…
-
PsychiatryLive
@Psychiatry_Live
Reports of suicidality with GLP-1RA antiobesity medication are supported by analysis of WHO data, but no association is found in large population cohort study or analysis of clinical trials. www.psychiatrictimes.com/view/specter-of-suicidality-with…
-
PsychiatryLive
@Psychiatry_Live
Mental health clinicians can help empower patients via tools like diet, including the MIND Diet. @DrMirhom shares more on lifestyle and mental health.
www.psychiatrictimes.com/view/mind-diet-and-patient-empow… -
PsychiatryLive
@Psychiatry_Live
Does reduced blood monitoring impact the detection of hematological abnormalities in clozapine-treated patients? Researchers performed a chart review study from the COVID-10 pandemic. www.psychiatrictimes.com/view/reduced-blood-monitoring-an…
-
PsychiatryLive
@Psychiatry_Live
Multiple sites are now enrolling participants in a phase 2 clinical trial to evaluate SPG302, the first synaptic regenerative therapy for schizophrenia. Peter Vanderklish, PhD, CSO at @Spinogenix_Inc shared more about this new potential treatment option. www.psychiatrictimes.com/view/first-synaptic-regenerative…
-
PsychiatryLive
@Psychiatry_Live
How prepared are clinicians to discuss the agent with patients and consider its use in regular practice? www.psychiatrictimes.com/view/poll-do-you-feel-prepared-t…
-
PsychiatryLive reposted
Mena Mirhom, MD, FAPA
@DrMirhom
Thank you @PsychTimes for publishing my piece and diet and patient empowerment!
Lifestyle, an @APApsychiatric theme is a great opportunity to have candid, relatable conversations with our patients and empower them to take control of their own health!
www.psychiatrictimes.com/view/mind-diet-and-patient-empow… -
PsychiatryLive
@Psychiatry_Live
🔔 Stay ahead in psychiatry with the September issue of Psychiatric Times. Each issue is packed with valuable information from top psychiatrists, ensuring you have the most current and relevant knowledge.
Subscribe to never miss an update here: one.psychiatrictimes.com/subscribe/ -
PsychiatryLive
@Psychiatry_Live
What happens when your career, which usually brings you joy and gratitude, paradoxically becomes a source of great stress? www.psychiatrictimes.com/view/the-happiness-paradox-of-th…
-
PsychiatryLive
@Psychiatry_Live
The context and timing of symptoms is critical for a timely and accurate bipolar diagnosis. Learn more in the latest Clinician's Corner column! www.psychiatrictimes.com/view/to-be-or-not-to-be-understa…
-
PsychiatryLive
@Psychiatry_Live
The FDA has approved Cobenfy (KarXT), the first new agent with a novel mechanism of action for schizophrenia more than 50 years. www.psychiatrictimes.com/view/fda-approves-cobenfy-for-sc…
-
PsychiatryLive
@Psychiatry_Live
Why are experts excited about KarXT, a novel muscarinic acetylcholine receptor agonist that, if approved, is poised to revolutionize schizophrenia treatment? Learn more in our latest conversation with @neonneurons! www.psychiatrictimes.com/view/much-ado-about-something-ex…
-
PsychiatryLive
@Psychiatry_Live
Individuals with psychiatric disorders frequently have foreshortened lives. Average life expectancies are often a decade or 2 shorter than population averages. www.psychiatrictimes.com/view/end-of-life-care-for-patien…
-
PsychiatryLive
@Psychiatry_Live
Intensive caring offers an empirically informed way of responding to suffering, which can be used to guide clinical practice. Learn more in the September Special Report article by @HMChochinov!
www.psychiatrictimes.com/view/suffering-revisited-tenets-… -
PsychiatryLive
@Psychiatry_Live
Premenstrual dysphoric disorder: a condition that is often underestimated and mistaken for typical premenstrual symptoms or mood swings. www.psychiatrictimes.com/view/this-is-not-me-the-debilita…
-
PsychiatryLive
@Psychiatry_Live
Happy Friday! The entire September issue of Psychiatric Times is now live on our website! Read it here: www.psychiatrictimes.com/journals/psychiatric-times/vol-4…
-
PsychiatryLive
@Psychiatry_Live
The integration of psychopharmacological interventions is a pivotal, yet underutilized strategy for fostering sustainable substance use recovery. www.psychiatrictimes.com/view/how-to-integrate-psychophar…
-
PsychiatryLive
@Psychiatry_Live
ICYMI: Patients with past-month prescription amphetamine use have a greater likelihood of new-onset psychosis or mania than those without past-month use. www.psychiatrictimes.com/view/new-study-shows-high-doses-…
-
PsychiatryLive
@Psychiatry_Live
Agitation is a major issue in emergency centers. Check out the most common life-threatening causes of acute agitation here. www.psychiatrictimes.com/view/agitation-assessment-the-ro…
-
PsychiatryLive
@Psychiatry_Live
The FDA instead issued a CRL for MDMA-assisted psychotherapy for PTSD, requesting an additional phase 3 trial to examine safety and efficacy. What's next for psychedelics? www.psychiatrictimes.com/view/with-mdma-on-hold-whats-nex…
-
PsychiatryLive reposted
Plastic Pollutes
@PlasticPollutes
The Plastics Crisis: A Neuropsychiatric Problem Hidden in Plain Sight #plasticpollutes #breakfreefromplastic www.psychiatrictimes.com/view/the-plastics-crisis-a-neuro… via @psychtimes
-
PsychiatryLive reposted
Awais Aftab
@awaisaftab
My book “Conversations in Critical Psychiatry” (Oxford University Press, 2024) brings together an edited selection of interviews published in the Psychiatric Times (@PsychTimes) from 2019 to 2022, updated with new and previously unpublished material. These interviews explore critical and philosophical perspectives in psychiatry by engaging with prominent commentators within and outside the profession who have made meaningful criticisms of the status quo.
This volume is the culmination of my pre-Substack era intellectual development with regards to critical issues in psychiatry. It includes interviews with many leading scholars such as Allen Frances, Anne Harrington, Paul McHugh, Nassir Ghaemi, Dainius Pūras, Joanna Moncrieff, Jonathan Shedler, Sanneke de Haan, Nev Jones, and Kenneth Kendler, among others.
Interviewees in the volume (ones on Twitter/X) include: @AllenFrancesMD @JonathanShedler @DrRJChapman @SameiHuda @viscidula @joannamoncrieff @nassirghaemi @SamFellowesHPS @K_L_Nielsen @paulsummergrad @DBDouble @stimimi
eBook/Kindle has been published and is available for purchase. The paperback version will be published on September 20, 2024 in the United Kingdom (available for pre-order) and by the end of November 2024 in the United States.
Book information page on my website: www.awaisaftab.com/conversations-in-critical-psychiatry-o…
Features of the book:
* Foreword by Sir Robin Murray
* A detailed introductory chapter, “Psychiatry and the Critical Landscape,” (along with commentary by Sandra Steingard)
* Edited and updated interviews
* Previously unpublished interviews (including mine by @DrGipps & @viscidula )
* Every interview comes with reading recommendations to enhance educational value and facilitate use in teaching
* Relevant materials, such as book reviews, assembled in an appendix -
PsychiatryLive
@Psychiatry_Live
Phase 2 trials suggest extended-release oral ketamine formulations could be an alternative to clinic-administered treatment for resistant depression. www.psychiatrictimes.com/view/slow-release-oral-ketamine-…
-
PsychiatryLive
@Psychiatry_Live
A new study investigated the origin of ataxia in the brain of patients with stroke and found that a significant number of the stroke lesions in the patients were located outside the cerebellum. www.sciencedaily.com/releases/2024/09/240905121003.htm
-
PsychiatryLive
@Psychiatry_Live
“We are growing a whole population of kids who will eventually be adults with anxiety disorders, posttraumatic stress disorder, and lack of trust and fear in the world around them, all which they wouldn’t have had if it were not for the shootings.” www.cnn.com/2024/09/07/us/school-shooting-mental-health-i…
-
PsychiatryLive
@Psychiatry_Live
Grief is a natural response to loss. But what is the best treatment course for prolonged grief disorder? www.psychiatrictimes.com/view/treating-prolonged-grief-di…
-
PsychiatryLive
@Psychiatry_Live
Parents' health worsens alongside kids' mental illnesses. @KFFHealthNews kffhealthnews.org/mental-health/parents-health-spiral-kid…
-
PsychiatryLive
@Psychiatry_Live
More than 40% of students currently enrolled in an undergraduate degree program had considered dropping out in the past 6 months. @CNN www.cnn.com/2023/03/23/health/mental-health-college-dropo…
-
PsychiatryLive
@Psychiatry_Live
A study found that music therapy has positive applications as an alternative treatment for depression in children and adolescents with ADHD. www.psychiatrictimes.com/view/music-therapy-helps-ease-de…
-
PsychiatryLive
@Psychiatry_Live
Did you enjoy Superbowl Sunday? Let's take a look at the mental health implications of yesterday's big game 🏈 www.psychiatrictimes.com/view/a-black-quarterback-leads-h…
-
PsychiatryLive
@Psychiatry_Live
Why can’t humans get along? An expert explores the biological underpinnings of our dualistic thinking. www.psychiatrictimes.com/view/forgive-our-divisiveness
-
PsychiatryLive
@Psychiatry_Live
Depression and schizophrenia spectrum disorders are now among the health conditions that qualify you for a Pfizer vaccine booster shot.
www.huffpost.com/entry/mood-disorder-covid-booster_l_6169… -
PsychiatryLive
@Psychiatry_Live
Benzodiazepines may be contributing to the opioid epidemic.
www.psychiatrictimes.com/view/the-case-for-caution-when-p… -
PsychiatryLive
@Psychiatry_Live
Struggling With Your Mental Health? MTV Entertainment Studios’ Pink Skies Ahead Helps You Feel Less Alone, by @drjessigold via @forbes www.forbes.com/sites/jessicagold/2021/05/06/struggling-wi…
-
PsychiatryLive
@Psychiatry_Live
Better Mental Health Under the Affordable Care Act www.psychiatrictimes.com/view/better-mental-health-under-… #blogscouchincrisis







































































































































































































































































